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SUMMARY
A normal plasma protein that Inhibits complement-
mediated prevention of immune precipitation (PIP) has been
purified from normal human serum by three different
methods- The first method was based on sequential affinity
chromatography on IgG-Sepharose, protein A-Sepharose, and
C o n .A-Sepharose which resulted in the purification of a
protein which was 60 kD on SDS-PAGE, 2 -9S on sucrose
density gradient centrifugation, 58 kD molecular weight on
gel filtration and had a pre-albumin electrophoretic mobility.
The second method which was a modification of the first
method involving the use of protease inhibitors during the
purification procedure, produced a protein which was 60 kD
molecular weight on SDS-PAGE, 19 S on sucrose density
gradient centrifugation, IOOO kD molecular weight by
Sephacryl S-300 gel filtration and had a /'Y' electrophoretic
2 ^
mobility. The third method did not involve an IgG- 
Sepharose affinity chromatography step but consisted of a 
combination of ion-exchange chromatography, gel filtration 
and heparin-Sepharose affinity chromatography with a final 
yield of 3 8% and 3360- fold purification. The final product 
of this purification procedure was a protein which shared 
the same characteristics with that prepared by method 2.
A monospecific antiserum was produced by immunising 
rabbits with the protein purified by the first method. When 
tested in double-diffusion in agarose gel, the antiserum 
gave a reaction of complete identity with all three protein
X I X
preparations. The present data suggest that the high
molecular weight form of the protein is the polymer of the
low molecular weight form.
The purified protein stained positively in the PAS
reaction, was sensitive to neuraminidase and trifluoro-
methylsulphonic anhydride treatment, indicating that it is
a glycoprotein. On account of its molecular weight on SDS-
PAGE (60 kD), it has been called glycoprotein 60 (gp60).
An ELISA procedure was developed using the anti-gp60
antiserum. The assay enabled me to measure gp60 levels in
serum and to study the behaviour of serum gp60 on gel-
filtration chromatography and sucrose density gradient
centrifugation. Serum gp60 was found to be mainly in the
high molecular weight form (19 S, 1000 kD), although a
small proportion was of low molecular weight (2.9 S, 58 kD).
Thus serum gp60 exists mainly as the polymer with a minor
proportion being present as the monomer.
125
In binding studies, [I]-gp60 was shown to bind to
IgG but not to the IgA or IgM isotypes. The binding was
localised to the Fc piece of IgG, and the subclasses IgGl
and IgG3 bound gp60 more effectively than did IgG2 or IgG&.
125
Analysis of the data from the binding of [I]-gp60 to
solid-phase BSA-IgG anti-BSA immune complexes (IC) showed
that the affinity constant of gp60 for IgG was between 6.6 
8 8 9 
xlO and 11.2x10 1/mol for the monomer and 2.3x10 and 
9
5.1x10 1/mol, and a single class of binding site was 
present. Saturation of binding was achieved when one 
molecule of gp60 monomer was bound for every five molecules 
of IgG, or when one molecule of gp60 polymer was bound for 
every 2k molecules of IgG.
X X
Further binding studies revealed that gp60 competed
with Clq, IgM—RF and F(abf) IgG-RF for binding to the Fc
2
piece of IgG.
Purified gp60 produced dose-dependent inhibition of 
PIP and solubilisation. PIP was the more sensitive to the 
effect of gp60. The polymeric form of gp60 inhibited PIP 
and solubilisation more effectively than the monomer.
The mechanism of action of gp60 was studied by adding 
gp60 to normal serum and showing that it produced dose- 
dependent inhibition of IC-mediated activation of the 
classical pathway as shown by reduced formation of the Cls- 
C1 inhibitor complex, reduced consumption of C&a and C2 and 
reduced C&a and C3a generation. These data showed that gp60 
prevents activation of the classical pathway by preventing 
Cl binding to IC. This leads to reduced C3 convertase 
formation and C3 cleavage so that the binding of C3b to IC 
is limited.
Levels of gp60 in rheumatoid arthritis sera correlated 
with their ability to inhibit PIP.
Gp60 which was present in normal serum was shown to 
regulate complement activation as the addition of Fab anti- 
gp60, but not normal rabbit IgG Fab, to sera resulted in 
1) increased levels of haemolytic complement when EA(IgG) 
were used as targets, 2) increased complement activation by 
IC and 3) increased levels of PIP activity. It was 
concluded that in normal serum gp60 regulated complement 
activation.
The identity of gp60 is unknown. It was shown to be 
distinct from the proteins recognised by 57 antisera. So
X X I
far* attempts at amino acid sequencing have failed, and cDNA 
expression libraries are being screened to identify 
positive cDNA clones which can be used for nucleotide 
sequencing.
X X I I
CHAPTER 1 
INTRODUCTION
1
The complement system plays a major role In host 
defence against Infection and in the inflammatory process. 
Since it was discovered, there has been a great increase in 
knowledge which has led to a better understanding of its 
role in health and in the patho-physiological aspects of 
many diseases.
In this introduction, I shall briefly review the 
history of the complement system, nomenclature, 
biochemistry, reaction mechanisms, and the role of 
complement in the elimination of antigen-antibody complexes 
(IC) .
1.1 HISTORICAL ASPECTS
During the last century, it was noted that human serum 
was capable of killing bacteria (Grohmann, 1884). This 
observation was later confirmed by Buchner (1889)* who 
showed that fresh serum was bactericidal and this activity 
was heat-sensitive and lost on dialysis against distilled 
water. Later in the same year, Buchner also demonstrated 
the ability of serum to lyse erythrocytes from another 
species, a process now known as immune haemolysis. 
Therefore, at this time, it was concluded that the lytic 
activity of fresh serum was due to an enzymatic activity, 
which was named alexin.
In 1896 Bordet suggested that this bactericidal 
activity of fresh serum was due to two factors, one heat- 
stable, which was present only in immune serum (now known 
to be antibody), while the other, which was heat-sensitive, 
was present in both immune and non-immune sera. This heat-
labile factor* was called alexin.
Since then, with the advances in medical sciences and 
technology, the complement system has been extensively 
characterized both biochemically and functionally. It is 
now understood that the system consists of more than 25 
self-assembling proteins acting in concert.
Like the other mediator systems that participate in 
the inflammatory process, the coagulation, kinin-forming 
and fibrinolytic systems, the activity of the complement 
system is carefully controlled. At several steps in the 
sequence a zymogen is activated to its proteolytically 
active form which then activates another zymogen to form a 
new protease, which in turn acts on another protein. Thus 
the activation process continues (Ruddy, Gigli & Austin, 
1972).
For many years, it was known that cytolysis was the 
only function of complement. Now there are many functions 
considered to be of equal or greater importance, 
particularly those involved in the mediation of the 
inflammatory response, and those involving complement 
receptors.
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1.2 NOMENCLATURE
Each of the proteins involved in the classical and the 
terminal sequences is denoted by the letter C followed by a 
number e.g. Cl, C/l, C2, C3, C5, C6, C7, C8 and C9 (WHO, 
1968). The alternative pathway components are termed 
factors and each is represented by a letter e.g. Factor B, 
Factor D and properdin (Factor P). These are usually 
abbreviated to B, D and P respectively (WHO 1981)-
The control proteins are referred to by the 
abbreviated forms of their trivial names, e.g Cl inhibitor 
(Cl-INH), CH binding protein (C4-BP) and recently C3b 
inactivator and B1H globulin have been termed factor I and 
H respectively.
The enzymatically active forms of the components have 
a bar over the symbols, e.g Cl, Cls. Cleavage fragments 
are indicated by suffixed lower case letters e.g,Cfta, Cilb, 
Ole and C&d.
The polypeptide subunit chains of each component are 
suffixed with Greek letters, starting with for the 
largest chain, then p  and ^  respectively e.g CHb(* C4 ji 
and C U ^  . Throughout the text the abbreviated symbols
for complement components will be used.
H
1.3 CHEMISTRY AND REACTION MECHANISMS
The complement system can be divided into Tour* groups 
of proteins, the classical pathway, the alternative 
pathway, the terminal sequence and a group of regulatory 
proteins. An outline of the complement system is shown in 
Fig. 1.1
The proteins of the classical pathway [Table 1.1], and 
the alternative pathway [Table 1.2], are responsible for 
the generation of the enzymes which activate C3 and C5 by 
limited proteolysis, while the components of the terminal 
sequence [Table 1.3]* are required for complement-mediated 
cytolysis. Regulatory proteins control the activation and 
turn-over of the complement system. The fluid-phase 
regulatory proteins are shown in Table l.&.
As the subject of this thesis is a study of a plasma 
protein which inhibits classical pathway complement- 
mediated activity, the prevention of immune precipitation 
(PIP), the components and mechanisms of the classical 
pathway activation will be covered in greater depth than 
other aspects of complement activation.
5
Figure.
Schematic diagram for 
complement activation pathways
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1.4 CLASSICAL PATHWAY ACTIVATIOff
The classical pathway consists of three components,
Cl, C4 and C2 which upon activation, form the classical 
pathway C3 activating enzyme (C3 convertase) Cftb2a, the 
formation of which is under the control of three regulatory 
proteins, Cl-inhibitor, C4BP and factor I.
1.5 the Cl MACROMOLECULE
The recognition unit of the classical pathway is the 
Cl macromolecule, which has a molecular weight of 750 kD.
It is a metalloprotein complex consisting of three 
reversibly interacting subunits Clq, Clr and Cls (molar 
ratio 1:2:2 respectively), held together by calcium ions 
(Gigli et al, 1976). It is converted to its enzymatically 
active form by antigen-antibody complexes (IC) or other 
activators.
Clq is a large, collagen-like, structurally complex 
molecule which has a molecular weight of 410 kD (Calcott & 
Muller-Eberhard, 1972). It contains three types of 
polypeptide chain termed A, B and C. From amino acid 
sequence and electron microscopic observations (Reid & 
Porter, 1976), it was found that Clq consists of six A 
chains, six B chains, and six C chains, assembled to form 
triple helices.
A disulphide bond connects each pair of A and B chains 
within a single triple helix, and a second disulphide bond 
connects C chains in adjacent triple helices to form a pair 
of helices and heads. Three such pairs are then assembled 
to form the complete Clq molecule. The collagen-like
6
TA
BL
E 
1.
1 
CL
AS
SI
CA
L 
PA
TH
WA
Y 
PR
OT
EI
NS
I—I
CO ^
Si?
8'? rH -H
O -P •H n 
CQ <
0 0 
O' -P 
0 O 
> 3 
(0 no 0 OrH u
CJ CM
0T5•H 0-P U ,— „
CM 3 CO0 -P XQiC U CO>i*H a '--'
rH 0  Ml
o  .c  -p 00
cm cj cn rH
8
•rH
-P03U
-P
0
OW U O'3 _
n
03
rH
3  4->U X!
0 O'
rH *H
o  0  q  
se is 2
>1
•H 0
CM
CJ
1
-P rH
C CJ U
0
0 0
o 0 0
-p -P -P
0 0
0 > >
TD •H •rH
c •p -P
•H o o
CQ < <
of"
O1rH
CJ
inoo
u
rH
CJ
o
00
oO'
0
rH
CJ
inx cm
os CJ
W  CQ
03 JQ 
CJ CJ
CO
oCO
O
CM
H1
CJ
03 JQ 
CM CM
CJ CJ
O
CM
OO
CM
CJ
1.
2
fd
i—I *rH
o -u•H O
CQ <
X I
CQ
XJ
CO
CJ
MO
IM
CO CN CD
Pi Pd -PO CJ •rH
CJ 10
M u •rH
o o 4-> O CQ
HH <M CJ -H
fd -u CO
'D -p  fd <U
C c q  e >
<d <3 S  > i fd
CP CP 55 n <d•H •rH x : c i—i
J  n . CJ w cj
Xi
3
CO
CJ
CO<1)N
•rH
34JW
<1) 10 
CP -P fd o 
> D fd »n 
0) orH M
cj cu
•H CP
XI U'D
CO CO CO
u u u
<d X! CQ CQ
CN
cn cj
o
in
CN
oco
(d
'o 4J
o  x :
<D cni—I -H
o  o  q  s is 2 CO coCP
in
in
CN
O
CN
CN
X )
CO
CJ CQ PH
CO
(0
■Sft
rH *H O 4-»
■H 9PQ <
<1) CQ 
CT> 4->fd o> a as fg <U O 
rH S-l 
CJ PM
<uTD•rH
44
&
& c•rHfdo x:
a)uo44
B
44
44
f t U C Q
6•rH44
fd
44
44
ca>
u
§44a> _ co u cnO—
d)co
fdJ4
CJ
fd X! 
co co 
CJ CJ
CN
oo
CO
ocn
co
CJ
O
u <44 x
<D O CJ
§
C O XI
c
o c
•H 0 CQ CJ •H •H
X XI 4J X CJ
O in co 44 fd o <
CJ CJ o N 44 g
id 144 •H fd
rH <44 <44 rH rH 144
O O 'D •H >1 O
X! C XI X
CM 44 4-> J3 D g.44
<d u u rji iH fd 44
c fd <d •H O c fd
<3 CM CM CO <  CM
<d jQ in uo 
CJ CJ
CM
in
t"-
moo
in
CJ
g g U g
<44 <44 <44 144
O O O o
44 44 44 44
44 44 44 44
fd fd fd fd
CM CM CM CM
ovo
ooCN
vo
O
CO
ovo o00 oin
CN
COin cn
r—
CJ
ooCJ 04CJ
1.
4 
FU
JI
D-
PH
AS
E 
RE
GD
LA
TO
RY
 
PR
OT
EI
NS
 
OF 
TH
E 
CO
MP
]
0 ^
81#!H  *H 
O 4-> •H O
CQ <
G c
o o
•rH •rH
P p
Pi 0 0
o T3 Xp 0 0
•rH Pi PI
X!
•rH
cn
0 X S’
■s TJ CJ
•rH X! X
1
CO
0 CJ O
w 0
0 Pi Pi
0 o X O
p MM CO MM
o CJ
Pi U 1M
CM O 0 O
P 0 P
0 O TD OC 0 0 0•rl P Pi p
Pi 1 cn L0 o o
cn CJ Q CJ
C
o
•rH
P
•rH
X!•H
•g
•rH
CJ
c
o
•rHP(0
>•H
PU(0c
•rH
c
•rH
s<0
rH
£&
<D CQ
C7>P 0 O 
> 3 <d ro 
0 o
rH V-l
u  CM
cm cj cn
cn cj
o
00
00
o
in
CN
CN
o
in
oo
co
o
in
oo
pi
(di—i
3 -tiU X!
0 cn
rH -H 
0,00 
S  &
o
in
o<j\
oin oooo
oo
co
uOP
•rH
jQ
•rH 
rH "BCJ -H
CM
CQ
a ca
c
•rH
f i
o
Pt
cm
cn
0 
X 'O
(0 0 
u &
sequence of amino acids begins close to the N-terminus and 
continues to about residue 88-90. The remaining 125-135 
residues are folded to form the globular head of Clq.
The role of Clq in serving as the recognition unit of 
Cl mediated binding of the macromolecule to IC, and various 
Cl binding substances is well documented (Muller-Eberhard, 
1975; Loos, 1983; Cooper, 1985)*
Immunoglobulins exhibit specificity in their ability 
to bind Clq. The binding site on IgG lies within the CH2
domain, with IgG3 being the most efficient binder followed
by IgGl and IgG2. IgG& does not bind Clq although its Fc
piece possesses this function (Colomb & Porter, 1975; 
Isenman et al , 1975; Schumaker et al, 1976). IgM also
binds to Clq through the CH3 domain, but IgA. IgD, and IgE 
isotypes do not appear to bind Clq (Ishizaka et al, 1967)-
Monomeric fluid-phase IgG and IgM interact weakly with Clq
6
with an affinity of 1-5 x 10 1/mol, but this affinity is 
increased when the immunoglobulin has been aggregated, or 
is part of an antigen-antibody complex (Wright et al,
1980).
The interaction between Clq and IgG is increased by 
lowering the ionic strength (Burton et al, 1980).
Furthermore, the interaction appears to be highly conserved 
through evolution as human Clq reacts with IgG from 
different species (Alexander & Steiner, 1980).
Clr and Cls are very similar proteins, in terms of 
their amino acid sequence, size, carbohydrate content and 
function. Both are activated by limited proteolytic 
cleavage into two disulphide-linked peptides, with their 
active sites being located close to the C-terminus. In
7
their* active forms each is a serine-protease type enzyme.
This resemblence between Clr and Cls gave rise to the
notion that they may arise by gene duplication (Arlaud &
Gagnon, 1981). Clr exists in nature as a non-covalent
dimer with an apparent molecular weight of 170 kD (Cooper,
1985). Its dimerization is independent of calcium ions,
and it undergoes reversible pH-dependent dissociation into
its monomeric form at pH 5 (Arlaud et al, 1980). Clr
undergoes spontaneous fragmentation into 60 and 35
o
peptides when incubated at 37 C in the presence of EDTA. 
This fragmentation results in Clr activation (Ziccardi & 
Cooper, 1976). The mechanism of Clr activation in vivo is 
not fully understood (Cooper, 1985; Schumaker, Zavodszky & 
Poon, 198 7)* However, it is thought that activation of Clr 
involves one monomeric subcomponent of the dimer cleaving 
the other. Activated Clr, (Clr), then acts on natural 
substrate Cls (Valet & Cooper, 197&; Ziccardi & Cooper, 
1976; Arlaud, Reboul & Colomb, 1977)*
Cls is a single polypeptide chain of 87 kD, which 
undergoes calcium-dependent dimerization. Although Cls is 
very sensitive to proteolytic activation, it does not auto- 
activate. As with Clr, activated Cls (Cls) is composed of 
two disulphide-linked polypeptide chains, the smaller of 
which possesses the serine esterase site which is 
responsible for cleaving C& and C2.
Under physiological conditions, equimolar amounts of 
Clr and Cls undergo calcium-dependent association to form a 
flexible, linear tetramer, with the sequence Cls-Clr-Clr- 
Cls (Tschopp et al, 1980). The tetramer appears to be held
8
together* through Clr-Cls contacts between the N-terminal 
interaction domains, whereas, the C-terminal catalytic 
domains of Cls appears to be located at the ends of the 
tetramer, and the catalytic domains of Clr are in contact 
at the centre of the sequence (Weiss et al, 1986).
9
1.6 THE STRUCTURE AND ACTIVATION OF Cl
It Is well known, that 70% of the Cl sub-components in 
serum are associated in the Cl complex (Ziccardi & Cooper, 
1977)- In the complexed form of Cl, the Cls2-Clr2 tetramer 
is arranged around the collagenous arms of Clq. Final 
agreement on the precise configuration of the tetramer in 
the Cl macromolecule has yet to be achieved. However, one 
of the more popular models suggests that the tetramer is 
wrapped around the Clq cone in such a way that the 
catalytic domains of Cls and Clr are in contact with each 
other within the cone while the Clr-Cls interaction 
(contact) domains are outside the cone (Colomb, Arlaud & 
Viller, 198&; Weiss, Fauser & Engel,1986; Schumaker, 
Zavodszky & Poon, 1987). The pro-enzyme Cl tends to auto- 
activate as shown by Ziccardi (1982) but in the absence of 
a Cl-activator, this spontaneous activation is prevented by 
Cl-inhibitor binding reversibly to the potentially active 
sites of the Clr and Cls tetramer. Upon binding to an 
activator, Clq undergoes a conformational change, which is 
transmitted along the collagen-like stalks to the Clr 
molecule which presumably also undergoes a conformational 
change. This exposes a catalytic site in Clr which cleaves 
the neighbouring Clr molecule. This auto-catalysis results 
in the generation of activated Clr (Clr) which will cleave 
and activate Cls. This process results in reduction of the 
association forces between the Clq and Clr2-Clr2, allowing 
the tetramer to unfold and to extend its Cls catalytic 
domains outside the Clq cone for interaction with Cll and C2 
(Schumaker, Zavodszky & Poon, 1987)*
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Although the precise mechanism of Cl activation by 
immunoglobulins is not fully understood, there is even less 
information available on the mechanism of Cl activation by 
the wide variety of non-immunoglobulin substances including 
lipids, viruses, and parasites which are listed in Table 
1.5. Indeed there are no common biochemical features 
shared between these substances and immunoglobulins.
Although Cl binding is a basic requirement for Cl 
activation (Tschopp, 1982) it is well documented that Cl 
binding to an acceptor surface does not always lead to its 
activation (Cooper & Morrison, 1978; Curd & Cooper, 1978).
1. 7 FORMATION AND STRUCTURE OF THE CLASSICAL PATHWAY C3
CONVERTASE
CH is a 200 kD glycoprotein consisting of three 
disulphide-linked polypeptide chains, 0( (90kD), jE> (80kD), 
and ^  (30kD). The chain possesses an internal thiolester 
(Tack, 198 3) which, upon enzymatic removal of C*la (6 kD) 
from the N-terminus of the chain (Schreiber & Muller- 
Eberhard, 197*0 by Cl or Cls, becomes the metastable 
binding site of nascent C*lb (Muller-Eberhard & Lepow,
1965)- This binding site is unstable, and failure to bind 
to an antigen-antibody complex or other surface within 
milli-seconds results in loss of the binding site, and the 
molecule becomes inactive fluid-phase C*lb. It has been 
suggested that only 1-2% of CUb molecules bind to the 
target, the remainder react with water in the fluid-phase 
to become inactive fluid-phase Cttb. Binding of C*lb 
involves the binding of the thiol group to a hydroxyl or 
amino group on the acceptor molecule to form either ester
11
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or amide bonds respectively (Campbell et al, 1981).
C**b also carries two stable binding sites, one is the 
magnesium-dependent binding site for C2, and the other for 
the C3b/C*J.b receptor (CR1).
C** occurs in the form of two structurally and 
functionally distinct isotypes, C**A and C**B (Carroll et al, 
which are coded by distinct genes which map to the 
class III region of the major histocompatibility complex, 
on the short arm of chromosome 6 (Carroll et al, 198*1). C**A 
has a propensity to react with amino acids to form amide 
bonds, while C*IB tends to bind to hydroxyl groups to form 
ester bonds (Law, Dodds &- Porter, 198**).
C2 is a 110 kD glycoprotein, which is a single chain 
zymogen of the serine esterase family. On activation, C2 is 
cleaved into the N-terminal non-catalytic C2b (**0 kD), and 
the catalytic C-terminal (70 kD) by Cls. Cleavage can 
occur in the presence or absence of C*ib (Gigli & Austin, 
1969). C2 binds to C**b via the C2b fragment, and remains 
bound to C2a by non-covalent bonds following proteolytic 
activation by Cls. (Nagasawa & Stroud, 1977).
The classical pathway C3 convertase is designated
C**b2a. C3 convertase is an unstable enzyme having a very
o
short half-life of 3 minutes at 30 C (Polley & Muller- 
Eberhard, 1968). C2a decays from the complex, which can be 
regenerated by fresh C2 in the presence of Cl or Cls.
£2
C3 is the precursor of many of the biologically active 
fragments that function by association with other 
complement proteins or by binding to cell-surface
12
receptors. It contains nearly ten distinct binding sites.
It is a 190 kD glycoprotein, consisting of two disulphide- 
linked polypeptide chains, 0( chain (118 kD) and ji chain 
(75 kD). Native C3 does not express binding sites for 
physiological ligands and thus does not exhibit biological 
activity. Proteolytic activation and processing are 
required to expose the sites which are concealed within the 
native molecule. Cleavage of the chain by the classical 
or alternative pathway C3 convertases, releases a small 
peptide, C3a (9 kD) from the N-terminus. The remainder of 
the C3 molecule which is termed C3b, contains an internal 
thiolester bond. Following C3b formation, a conformational 
rearrangement occurs in the molecule which enables the 
thiolester to become reactive and form either ester bonds 
(by reactivity with hydroxyl groups) or amide bonds (by 
reacting with amino groups) on the acceptor surface. Thus 
C3b becomes covalently bound to the acceptor surface. If 
binding to the acceptor site does not occur within milli­
seconds, it reacts with water to become inactive fluid- 
phase C3b. It has been calculated that during complement 
activation only 5% of C3b binds covalently to the
target, the remainder becoming the inactive fluid-phase 
product.
Both bound and fluid-phase C3b carry binding sites for 
B, H, P, C5 and CR1. The binding of C3b to the C4b2a 
complex, probably to Cllb results in the formation of the 
classical pathway C5 convertase (Cooper & Muller- 
Eberhard,1970 ), which is the first stage in the terminal 
sequence [ Fig.l].
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1.8 THE ALTERNATIVE PATHWAY
In the early fifties it was noted that many complex 
poly-saccharides such as zymosan or Gram-negative bacterial 
endotoxin were capable of consuming C3 without the
utilization of Cl, CU, or C2 (Pillemer et al, 195*0 - These
observations were confirmed later by the demonstration that 
C3 consumption also occurred upon the addition of these 
polysaccharides to a CU or C2 deficient sera (Frank et al, 
1971; Johnson et al, 1972). They suggested the existence of 
an alternative pathway for complement activation, which was 
independent of Cl activation. In addition to 
polysaccharides, certain immunoglobulins and their F (ab ')
2
fragments (Schur & Becker, 1963)* guinea pig IgGl, and the 
human myeloma proteins IgGft, IgAl and IgA2 (Sandberg et al, 
1971; Sandberg & Osier, 1971; Osier & Sandberg, 1973) were 
shown to activate the alternative pathway of complement. 
Four proteins are involved in the assembly of the 
alternative pathway C3 and C5 convertases, namely C3« B, D,
and P [Fig 1.1], under the control of two fluid-phase
regulatory proteins, factors I and H.
The alternative pathway C3 convertase is formed when 
C3b binds to factor B in the presence of magnesium ions to 
form C3bB, which has weak C3 convertase activity (Medicus, 
Gotze & Muller-Eberhard, 1976). Factor D, a 23.5 kD serine 
protease, then cleaves B with the release of a 30 kD 
fragment Ba which results in the formation of C3bBb, the 
unstable fluid-phase alternative pathway C3 convertase.
This convertase is unstable as Bb decays rapidly from the 
complex. At this stage the enzyme can be regenerated by the
111
addition of fresh B in the presence of D (Fearon et al,
1973)- The enzyme C3bBb is stabilized by the binding of P
to the complex, which results in the retardation of Bb
decay (Fearon & Austen, 1975)- C3bBbP is called the
properdin-stabilised alternative pathway C3 convertase.
The C3b-dependent positive feed-back loop of the
alternative pathway is now established and each newly
generated C3b molecule has the potential to form another
convertase molecule by reacting with B and D [Fig 1.1]. If
uncontrolled, this activation would continue until the
supply of C3 or B was exhausted. The feedback loop is
controlled by two proteins, factor I, a serine protease,
and its cofactor, factor H. Acting in concert, these two
proteins limit convertase formation by degrading C3t>, and
accelerating the decay of the convertase (see below). In
the absence of either of these proteins, uncontrolled
turnover of the alternative pathway occurs (Whaley &
Thompson, 1977)- With such efficient control proteins it
is surprising that the alternative pathway is ever
activated. However, it is now known that initiation of the
alternative pathway occurs continuously by low-grade
hydrolysis of the thiolester bond of C3- The product of
this reaction (C3 H O) has properties like C3b* and is
2
therefore called C3b-like-C3 (Pangburn, 1986) C3 (H O) can
2
bind factor B before being able to bind factor H. Thus a 
low efficiency fluid-phase C3 convertase is formed, which 
cleaves to form C3b which can bind to acceptor sites on 
surfaces in its immediate vicinity. If the C3t> binds to a 
non-activating particle, factor H binds and the C3b becomes 
inactivated by factor I (see 1.12). However, if the C3b
15
binds to an alternative pathway activating surface, it 
becomes relatively resistant to factor H binding and so 
binding of factor B and the formation of the C3 convertase, 
C3bBbP, is favoured. Thus alternative pathway activators 
are really amplifiers of pre-existing low-grade fluid-phase 
turnover, rather than being true activators. As a 
consequence of alternative pathway activation, bacteria are 
opsonised by C3b and the formation of C5 convertase 
prepares them for lysis by the terminal membrane attack 
complex.
For C5 convertase formation to occur, a second molecule 
of C3b must bind to the C3 convertase, probably to the 
first C3b molecule which comprises part of the C3 
convertase (Takata.et al.,1987). The alternative pathway C3 
and C5 convertases cleave C3 and C5 at exactly the same 
sites as their classical pathway counterparts.
16
1.9 THE TERMINAL SEQUENCE
Cell lysis occurs as a result of the classical or 
alternative pathway activation via the formation of the 
membrane attack complex (MAC) (Bhakdi & Tranum-Jensen,
1983)•
1.10 PROTEINS AND STRUCURE OF THE MAC
C5 is a glycoprotein of 210 kD, consisting of two
disulphide-linked polypeptide chains, 130 kD) and (80
kD). C5 is a thermo-labile molecule, as its activity is
o
lost on heating at 56 C for 10 minutes. The Oychain is 
cleaved by the C5 convertase or trypsin with the release of 
12 kD fragment, C5a, from the amino-terminus. C5& is an
anaphylatoxin which also has chemotactic properties. The 
remainder of C5 is called C5b which carries a labile 
binding site for all cell membranes. Binding is promoted 
by the presence of C3b. The binding site is not covalent, 
which distinguishes it from the binding of C&b and C3b 
(Tack, 1980). Loss of the labile binding site follows a 
conformational change in the molecule to form a more stable 
fluid-phase strucure. The functional activity of solid- 
phase C5b decays rapidly, unless it is stabilised by 
binding of C6.
C6 and C7 are very similar proteins, each consisting 
of a single polypeptide chain with molecular weight of 128 
kD and 121 kD respectively. Both are ^-globulins and 
contain some degree of^helical strucure (Podack, Kolb & 
Muller-Eberhard, 1976). As mentioned above, C6 stabilises
the membrane binding site of C5b, and fluid-phase C5b6
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complexes can bind to cells which are distant from the site 
of complement activation. Such cells are susceptible to 
lysis by the subsequent binding of C7. C8 and C9.
(Bystander lysis) (Lachmann & Thompson, 1970). The binding 
of C7 to membrane-bound C5b6 stabilises the binding of the 
complex to the membrane. This is due to the hydrophobicity 
of C7 which becomes inserted into the lipid bilayer 
(Podack, Klob & Muller-Eberhard, 1979)-
C8 is a 150 kD ^ 3-globulin, which consists of three 
polypeptide chains, \ ( 7 7  kD), ^ ( 6 3  kD), an d ^  (1 4 kD) . TheO( 
and chains are held together by disulphide bonds,
whereas the JS chain is linked to them by non-covalent 
forces. The subunit of which C8 binds to C5b in the 
absence of C6 or C7, while the C8 chain is intensely 
hydrophobic and penetrates the lipid bilayer. The 
formation of cell bound C5b-8 causes significant membrane 
damage and low-grade lysis may occur (Stolfi,1968). C8 
possesses a binding site for C9 (Bhakdi & Tranum- 
Jensen,198 2).
C9 is the terminal component of the complement system. 
It is a 79 kD ^3-globulin, which consists of a single 
polypeptide chain (Hadding & Muller-Eberhard, 1969). C9 has 
the tendency to polymerise, particularly when bound to C8. 
This property plays a central role in cell lysis (Tschopp, 
198^).
MAC-polymerised C9 forms cylind rical structures which 
are heterogeneous in size, the inner diameters ranging from 
9-12 nm (Tschopp, 1984). The MAC in its final form 
consists of a hydrophobic outer layer which becomes 
inserted deeply into the membrane lipids, while the
18
hydrophilic core provides a transmembrane channel, which 
allows the passage of ions and water (Mayer, 1972). The 
insertion of large numbers of MACs into cell membranes 
disrupts the membranes by distortion of the lipid bilayers 
leading to leaky-patches, and resulting in cell lysis 
(Esser et al, 1979)-
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1.11 REGULATION OF COMPLEMENT ACTIVATION
The complement system is under the control of two 
groups of regulatory proteins.
1.12. THE FLUID-PHASE REGULATORY PROTEINS
Levy and Lepow (1959).first described a heat-labile, 
non-dialysable substance in human serum which inhibited the 
hydrolytic activity of Cls on synthetic amino acid esters. 
Cl-inhibitor (Cl-inh) is an alpha-2 globulin with an 
approximate molecular weight of 110 kD. The protein is a 
single polypeptide chain, and is thermolabile (Harpel & 
Cooper, 1975)*
Cl-inh forms an equimolar complex with both activated 
Cls and Clr, irreversibly blocking the activities of these 
proteases and preventing activation of Cls by Clr or 
cleavage of Cll and C2 by Cls. The blocking occurs whether 
the subcomponents of Cl are free or incorporated in the Cl 
macromolecular complex. However, Cl-inh does not form a 
stable complex with the precursor forms of these e n z y m es, 
or enzymes which have been inactivated with DFP (Ziccardi & 
Cooper, 1976). Cl-inh also inhibits plasmin, kallikrein, 
activated plasma thromboplastin antecedent, and activated 
Hageman factor (Forbes, Pensky & Ratnoff, 1970; Ratnoff et 
al, 1982).
CtlBP is a 10. OS glycoprotein with an apparent 
molecular weight of 590 kD, consisting of identical 
subunits of 70 kD molecular weight each, linked by 
disulphide bridges. The protein appears to be multivalent, 
with the capacity to bind as many as five or six C&b
20
molecules (Scharfstein et al, 1978).
In the presence of CUBP and factor I, C/lb is cleaved 
at two points in the CX, chain yielding three peptides, while 
the p  and^ chains remaining intact (Fujiti, Gigli & 
Nussensweig, 1978).
One of the chain peptides is C/ld, which is separated 
from the remainder of the molecule during the reaction.
The other two peptides are covalently linked to the p  chain 
and remain part of the C/lc fragment. In the case of C/lb 
bound to IC, C/lc is released into the fluid-phase, 
indicating that the thiolester by which C/lb binds to IC is 
located within the C/ld portion of the 0^ chain.
o
Factor I is a serine esterase which is stable at 56 C 
for four hours. The molecule consists of two disulphide- 
linked chains of 50-55 kD and 38-/12 kD (Fearon, 1977). 
Factor I has no effect on native fluid-phase C3 or C/l, 
However, in the presence of its cofactors^factor H or C/IBP^ 
it will enzymatically degrade C3b and C/lb respectively. 
Although membrane-bound C3b and C/lb are degraded by factor 
I in the absence of cofactor activity, the rate of reaction 
is much reduced (Whaley & Ruddy, 1976; Pangburn & Muller- 
Eberhard, 1983). In the presence of factor H, I cleaves 
the (\ chain of C3b in two closely adjacent sites. The 
resulting molecule, C3bi, has lost its ability to bind B 
and C5 but has acquired the ability to bind to specific 
C3bi receptors (CR3)• C3bi consists of two 0( chain 
fragments (molecular weights of 68kD and Zl3kD) and a small 
fragment (3kD) is released. The two major chain 
fragments remain bound to the intact p  chain by disulphide 
bonds. In serum, C3bi is very slowly converted to a
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fragment termed t>^ 2D and C3c (Medof et al, 1982). ^  2D
(C3dg) consists of C3d and a second fragment, C3g, which 
can be released by trypsinisation (Lachmann, Pangburn & 
Oldroyd, 1982). The serum protease which converts C3bi to 
C3c and C\ 2D has not been identified, but plasmin remains a 
possibility (Chaplin, Monroe & Lachmann, 1982). There is 
evidence that factor I will convert C3bi toO(2D and C3c in 
the presence of its second cofactor CR1 (Medof et al,
198 2). The observation that serum contains small 
quantities of CR1 (Yoon & Fearon, 1985) raises the 
possibility that factor I and serum CR1 are responsible for 
the final degradation of C3bi in serum.
2D (molecular weight llOKD) is the fragment of the 
chain which contains the thiolester of C3b. Thus (X^  2D 
remains covalently linked to C3b acceptors following C3b 
degradation. C3c (molecular weight 1/J-OkD) is released into 
the fluid-phase and has no known biological activity. This 
fragment consists of the intact ^  chain and two chain 
fragments (molecular weight 25kD and &3kD) respectively.
The most important consequences of inactivation of C3b 
by factor I is the loss of the ability of C3b to bind 
factor B or C5- Thus, the formation of the alternative 
pathway amplification C3 convertase, and the classical and
alternative pathway C5 convertases, is inhibited.
o
Factor H is a heat-stable (56 C for 30 min) B l / ^  
glycoprotein containing more than 15% carbohydrate, which 
consists of a single polypeptide chain of 150 kD (Whaley & 
Ruddy, 1976). Factor H is a cofactor which is essential 
for the full expression of the proteolytic activity of
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factor I.
Factor* H binds to C3b (Whaley & Ruddy,1976). The 
binding affinity of factor* H for* C3b is approximately four 
times higher than that of factor B for C3b (Kazatchkine, 
Fearon & Austen, 1979)* Thus, under normal conditions 
regulation of the alternative pathway occurs, as any factor 
B bound to C3b will be displaced by factor H. In addition 
to dissociating factor B from C3b, factor H acts as a 
cofactor for factor I, potentiating the conversion of C3b 
to C3bi which can no longer bind factor B.
The S protein is a 80 kD peptide chain, which is the 
primary MAC inhibitor in serum and functions by competing 
with the membrane binding site on C5t>-7 to prevent membrane 
insertion. (Bhakdi & Tranum-Jensen, 1982). It has also been
shown that the S-protein inhibits C9 polymerisation, 
(Dhalbak & Podack, 1985)- On the other hand, C9 
polymerisation per se has been found to be a mechanism for 
inactivating C9 (Dankert, Shriver & Esser, 1985). Recently 
it was confirmed that the S-protein is identical with the 
serum spreading factor, vitronectin (Jenne & Stanley,
1985).
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1.13 THE MEMBRANE PHASE REGULATORY PROTEINS
Some of the membrane bound regulators have been 
relatively well characterised. Complement receptor 1 
(CR1), decay-accelerating factor (DAF) and glycoprotein 45- 
70 (gp45~70) all bind C3b and C4b and thus are regulators 
of the early components.
CR1 is a single chain membrane glycoprotein with four 
identical allotypes (160 - 250 kD ) which is found on 
erythrocytes, polymorphonuclear leukocytes, monocytes, 
macrophages, B-lymphocytes, a sub-population of T 
lymphocytes, dendritic cells and renal glomerular podocytes 
(Fearon 1979; Medof & Nussenzweig, 1984). CR1 binds C3b 
and serves as a co-factor for factor I in C3bi formation 
and possibly in the subsequent conversion of C3bi to C3c 
and 0>^2D. Furthermore, like factor H, CR1 displaces factor 
Bb from C3bBbP, but in addition CR1 also accelerates the 
decay of C4b2a, by displacing C2a (Seya, Holers & Atkinson, 
1985)- This regulatory effect is seen particularly when 
the convertases are in the fluid-phase, or on neighbouring 
cells. The effect is not so apparent if the convertases 
are bound to the cell membrane where CR1 is also bound.
It has been shown that CR1 and C5 compete for the same 
binding site on C3b (Fishelson, Schreiber & Muller- 
Eberhard, 1985) and it is therefore probable that CR1 also 
participates in the regulation of C5 convertase. In 
addition to these regulatory functions, CR1 serves as a 
cell membrane receptor for C3b-coated ligands (Ross &
Medof, 1985).
DAF is an intrinsic human erythrocyte membrane
24
glycoprotein with a molecular weight of 70 kD (Nicholson- 
Weller et al, 1982). It is found on erythrocytes, 
platelets and all types of leucocytes. It has been found to 
accelerate the decay of the C3 convertases via binding to 
the catalytic subunits Bb and C2a. However, DAF also binds 
to C3b and C4b alone and may thereby prevent the formation 
of C3 convertases (Medof, Kinoshita & Nussenzweig, 198&; 
Fujita et al, 1988). In contrast to CR1, DAF acts mainly on
the membrane where it is located. Thus CR1 and DAF act 
together to protect autologous cells against attack by 
complement.
Gp U 5-70 binds C3b and Cllb alone or in the convertase 
forms, and serves as a co-factor for factor I (Holers et 
al, 1985)* DAF has no cofactor activity whereas CR1,
DAF,and gp&5-70 regulate complement activation on the cell 
membrane at the level of the C3 and C5 convertases.
The homologous restriction factor (HRF) (Schonermark 
et al, 1986; Zalaman, Wood & Muller-Eberhard,1986) is also 
a membrane-bound regulator and serves to control the final 
assembly of the terminal complement complex and therefore 
act at a later stage to protect autologous cells against 
complement mediated lysis. HRF is a single chain plasma 
protein with moleculo-V weight of 80 kD with an internal 
disulphide loop.
HRF, which has been demonstrated on erythrocytes and 
peripheral blood leucocytes, binds to C8 and C9i thereby 
inhibiting the transmembrane channel formation.
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l.ia BIOLOGICAL ACTIVITIES OF THE COMPLEMENT SYSTEM
The complement system playS a key role in the 
inflammatory process, largely by virtue of the properties 
of many of its components or their activation products.
The cytolytic consequences of complement activation first 
drew attention to the existence of the complement system.
It is now known that activation of the complement system 
can cause lysis of nucleated and non-nucleated mammalian 
cells, bacteria, plateletes, mycoplasma and viruses.
Cleavage of C&, C3 or C5 by their respective 
convertases or proteolytic enzymes, yields the 
anaphylatoxins C&a, C3a and C5a respectively. (Chenoweth, 
Cheung & Henderson,1983). C5a being the most potent 
anaphylatoxin and C&a the least. Anaphylatoxins bind to 
receptors on the membranes of mast cells and basophils with 
resulting degranulation. These granules contain, vasoactive 
amines such as histamine, and their release is associated 
with increased vascular permeability.
Smooth muscle contraction is induced by the direct 
action of anaphylatoxins on specific smooth muscle cell 
receptors and is independent of their histamine releasing 
activity (Regal, Eastman & Pickering, 1980). Anaphylatoxin 
inactivator (carboxypeptidase N) removes the N-terminal 
arginine from these molecules. The derivatives which are 
termed C4a des Arg, C3a des Arg, and C5a des Arg 
respectively, have no anaphylatoxic activity (Damerau et 
al, 1980).
C5a, but not C3a or Clla, is chemotactic for 
polymorphonuclear leucocytes or macrophages (Damerau,
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Grunefeld & Vogt, 1978)- The chemotactic activity is 
preserved following degradation of C5a by anaphylatoxin 
inactivator, although in this case C5a des Arg requires a 
serum co-factor to express its full chemotactic activity 
(Perez et al, 1980).
It is well known that complement reacted micro­
organisms or IC are coated with complement activation 
products, mainly C3t>* The presence of CR1 (complement 
receptor type 1) on phagocytic cells promotes phagocytosis 
and killing of micro-organisms (Leigh et al, 1979). and the 
elimination of IC. Other complement receptors are present 
on a variety of cells. CR2 (C3<3 receptor), CR3 (C3bi 
receptor), ClqR (Clq receptor), and the factor H receptor 
have all been identified, and structural and functional 
studies are well underway. Recent evidence supports the 
notion that CR1 and CR2 on lymphocytes may play a 
significant immunoregulatory role (Ross & Medof, 1985;
Weiss et al, 1987; Cooper et al, 1988).
A peptide derived from the 0^-chain of C3 causes an 
initial leukopaenia followed by leukocytosis (McColl et al, 
197&). This peptide, termed C3e has a molecular weight 10- 
12 kD and appears to be produced as a result of proteolytic 
cleavage of C3c by an unidentified plasma protease 
(Ghebrehiwet & Muller- Eberhard, 1979). In addition, C3e 
also stimulates the secretion of lysosomal enzymes from 
neutrophils (Ghebrehiwet, 198&).
C3d-k is another C3 fragment produced by the 
proteolysis of C3bi by kallikarein, which releases 
leukocytes from the bone marrow, and inhibits T-cell 
proliferative responses (Meuth et al, 1983)-
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1.15 SOLUBILIZATION OF IMMUNE PRECIPITATES
When antigen and antibody are mixed with buffer in a
test tube, precipitation occurs. The amount of precipitate
is dependent upon the proportions of antigen and antibody.
Maximal precipitation occurs when the ratio of antigen to
antibody is optimal, and this is defined as the equivalence
point. At this point all the antibody has been
precipitated. The amount of precipitate is reduced when
the proportion of antigen to antibody is increased
(antigen-excess). When the ratio of antigen to antibody is
decreased (antibody-excess) precipitation of antigen still
o
occurs. If immune precipitates are incubated at 37 C with
fresh serum, the amount of precipitate decreases. This
apparent loss of precipitation is not due to enzymatic
degradation of either antigen or antibody, but rather the
complex becomes smaller and more soluble (Czop &
Nussenzweig, 1975). This process, which has been termed
solubilization, was shown to be complement-dependent from
the observations that sera which had been decomplemented by
o
heat-inactivation (56 for 30 min.), by EDTA treatment, or 
by incubation with zymosan or cobra venom factor, did not 
exhibit this property (Miller & Nussenzweig, 1975). An 
absolute requirement for an intact alternative pathway was 
demonstrated by the observation that sera which had been 
depleted of factors D, B or P were unable to support 
solubilization unless the missing component was replaced 
(Takahashi et al, 1978). The importance of the alternative
pathway was re-emphasised when it was demonstrated that 
solubilization of immune complexes (IC) proceeded in the
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presence of the purified components 03. B, D, P, H and I 
(Fujita, Takata and Tamura, 1981).
The observation that solubilization did not occur in
the absence of either of the regulatory proteins H and I,
indicated the essential requirement for both of these
components. In the absence of either control proteins,
inappropriate fluid-phase turnover of the alternative
pathway occured, resulting in rapid depletion of C3.
Although solubilization displays an absolute requirement
for an intact alternative pathway, there is good evidence
that the classical pathway plays a non-essential role,
serving to accelerate and increase the efficiency of the
reaction. This conclusion is based upon the observations
that although solubilization occurred in C2- and 04-
deficient sera, there was a delay in the onset of the
process and the rate of solubilization was decreased (Czop
& Nussenzweig, 1975)- The reduced rate of solubilization
of complexes formed with the F(abf) fragments compared
2
with complexes formed with IgG antibody also indicates a 
role for the classical pathway (Czop & Nussenzweig, 1975)- 
As solubilization proceeds normally in C5-deficient or 
C6-deficient sera (Takahashi et al, 1976) but not in 03-
deficient sera (Czop & Nussenzweig, 1975). it can be 
concluded that 03. but not the terminal components, are 
essential for the reaction. Solubilized IC can be 
precipitated with antiserum to 03. showing that they 
contain bound 03 (Takahashi, Takahashi & Hirose, 1980). 
Analysis of 03 has revealed that it is covalently bound to 
both the antibody and antigen moieties (Takata, Tamura, and 
Fujita (1984). Solubilization proceeds through three
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distinct: stages. Firstly, C3b is deposited on the surface 
of the IC. Under normal circumstances, when the antibody 
in the IC is capable of binding and activating Cl, the 
initial deposition of C3b occurs very rapidly via the 
classical pathway (Takahashi et al, 1978). When the
complexed antibody is incapable of activating Cl, or if the 
serum is deficient in one or more of the classical pathway 
components, alternative pathway activation is responsible 
for the initial deposition of C3b. As this occurs more 
slowly, the solubilization process is prolonged (Takahashi 
et al, 1976).
Following the initial deposition of C3b on the IC the 
phase of amplification begins. The alternative pathway C3 
convertase, C3bBbP, is assembled on the IC and further C3 
cleavage ensures increased deposition of C3b on the IC.
When insoluble IC are incubated with serum for a limited 
period and then washed they remain insoluble, but when 
purified C3 is added solubilization occurs expeditiously 
(Takahashi, Tack & Nussenzweig, 1971). Thus, the 
incorporation of C3b into the antigen-antibody lattice is 
the critical event in the solubilization process, and 
kinetic studies have clearly demonstrated that it precedes 
solubilization (Takahashi, Tack & Nussenzweig, 1977; 
Takahashi et al, 1978).
The C3b which is deposited by the classical pathway is 
clearly insufficient to produce this effect, but for 
reasons which are as yet unclear. Perhaps the amount of 
C3b deposited by the classical pathway is insufficient in 
quantity or is too limited in distribution to achieve
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solubilization. The final phase of the solubilization 
process occurs after large quantities of C3b have been 
incorporated into the antigen-antibody lattice. This 
stage occurs in salt-free solution, in the absence of serum 
proteins and in the presence of chelating agents 
(Takahashi, Tack & Nussenzweig, 1971)• As enzymatic 
degradation of neither antigen nor antibody occurs, it is 
thought that solubilization takes place because C3b 
disrupts the antigen-antibody lattice. Additionally, it is 
thought that the interference with Fc-Fc interactions, 
which play a major role in immune precipitation (Nisonoff & 
Pressman, 1958), is a critical event in solubilization as 
the Fab fragment of antibodies directed against the Fc 
piece of the complexed antibody can solubilize immune 
precipitates.
The observation that insoluble IC formed with the low 
affinity antibody were more easily solubilized than those 
formed with high affinity antibody suggests that disruption 
of antigen-antibody bonds may also play a role in 
solubilization (Czop & Nussenzweig, 1975)* However, the 
evidence that antigen and antibody are dissociated is 
conflicting (Strassen & Beck, 1979)* Of course, even if 
dissociation of antigen and antibody does not occur, it is 
possible that disruption of antigen-antibody bonds may play 
a role in the re-arrangement of the IC by preventing the 
reassociation and cross-linking of antigen. It is also 
conceivable that the binding of C3b may also modify the 
overall solubility of IC, in addition to the possible 
actions described above.
Because solubilization is a general phenomenon which
31
occurs under any physiological conditions, with any class 
of antibody and any soluble antigen (Czop & Nussenzweig, 
1975)* it probably represents an important protective 
mechanism whereby large IC which are either formed or 
deposited in the tissues are removed. This suggestion has 
been supported by Bartolotti & Peters (1978)* who showed 
that decomplementation of rabbits with experimentally- 
induced serum sickness delayed the removal of IC from the 
kidney.
1.16 PREVENTION OF IMMUNE PRECIPITATION (PIP)
It is unlikely that IC are normally formed in vivo in 
the total absence of complement, thus the effect of 
complement on the early stages of formation of insoluble IC 
may be of greater biological significance than is 
solubilization (Schifferli, Bartolotti & Peters, 1980). 
Schifferli showed that IC formed at equivalence, or in 
antibody-excess in normal serum remained soluble for up to 
two hours. After this time IC formed at equivalence tended 
to precipitate, in contrast to those formed in antibody 
excess, which remained soluble. Heat-inactivated serum or 
EDTA-treated serum did not prevent immune precipitation, 
observations which implicated complement as being 
responsible for the effect. The finding that sera depleted 
of factors B, D, or P were able to prevent immune 
precipitation showed that the alternative pathway was not 
required (Schifferli, Bartolotti & Peters, 1980;
Schifferli, Woo & Peters, 1982). However, after an hour 
precipitation began to occur. IC formed in sera depleted
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of calcium ions by EGTA treatment showed an early phase of 
precipitation which was followed by a phase of 
resolubilization (Schifferli, Woo & Peters, 1982). As only 
the alternative pathway was able to function under these 
conditions, it can be concluded that the alternative 
pathway is concerned with maintaining IC in solution, 
whereas the classical pathway is important in preventing 
precipitation during the early stages of IC formation. As 
excessive immune precipitation occurred in sera deficient 
in Clq, Cll, C2 and C3 (Schifferli, Bartolotti & Peters, 
1980; Schifferli, Woo & Peters, 1932; Naama et al, 1983). 
but not in sera which lacked C5 or C7 (Naama et al, 1983),
the absolute necessity for the classical pathway components 
through C3 was established, and the lack of requirement for 
the terminal components beyond C3 was confirmed. Thus, as 
with solubilization, C3 activation and binding must be the 
critical step in the prevention of immune precipitation 
(PIP).
The precise role of the individual complement 
components and the relative roles of the classical and the 
alternative pathways in PIP have been defined by studying 
immune precipitation in the presence of purified complement 
components (Naama et al, 1984; Naama et al, 1985). The
rate of precipitation of IC formed in Cl was reduced, 
although the extent of precipitation was not altered (Naama 
et al, 1984). Thus, Cl forms the first line of defence 
against immune precipitation. Cl-inhibitor dissociates Cl, 
leaving Clq bound to the complexes. When Cl-inhibitor was 
mixed with Cl, complexes precipitated rapidly (Naama et al,
1984). It has been suggested that low frequency of immune
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complex disease in patients with Cl-inhibitor deficiency 
(who lack CH) is due to the unopposed protective effect of 
Cl (Schifferli, Steiger & Schapira, 1985).
Although CU and C2 on their own, or together, do not
influence the rate of precipitation of IC, when they are
mixed with Cl and C3 at the same concentrations present in
serum, immune precipitation is prevented. The terminal C5-
C9 components do not influence immune precipitation (Naama
et al, 198ll) . In the presence of the six alternative
pathway components (C3. B, D, P, H and I) an early phase of
rapid immune precipitation occurred which was followed by
resolubilization (Naama et al, 1 98 a). Thus, the findings
with complement-deficient sera and purified components
demonstrated the absolute requirement for C3 in the PIP.
The binding of C3b to IC is essential, and studies using 
125
[I]-C3 have shown that the molar ratio of C3 to IgG 
antibody in the IC is consistently 2:5 (Naama et al, 1985).
The molar ratio of C3b: IgG in solubilized IC is higher
(1:1) (Fujita, Takata & Tamura, 1981) which indicates that 
greater amounts of C3b are required to solubilize immune 
precipitates than to prevent precipitation of IC. The site 
of attachment of C3b to immune complexes has not been 
ascertained, but presumably some must bind to the Fc region 
of the antibody to prevent Fc-Fc interactions. As 
mentioned earlier, during solubilization some C3b binds to 
the antigen and may disrupt some antigen-antibody bonds. 
Although the binding of C3 to antigen during PIP has not 
been demonstrated, there is no reason to believe that it 
does not occur. Such binding would help prevent extensive
3^
lattice formation.
The outcome of the interaction of IC with complement 
is clearly influenced by properties of both antigen and 
antibody. Precipitation of IC formed with small protein 
antigens such as BSA was easily prevented, whereas IC 
formed with larger antigens, such as thyroglobulin, were 
relatively difficult to keep in solution (Whaley,1987)- 
The affinity of antibody did not appear to affect the 
ability of complement to prevent immune precipitation 
(Johnson, et al.,1987)* The nature of immunoglobulin 
isotype is critical in determining whether IC formed in 
serum will precipitate. Although IgGl and IgM monoclonal 
anti-DNP antibodies produce IC which are rendered soluble 
extremely easily, IC formed with IgA precipitate rapidly 
even when formed in whole serum (Johnson, et al.,1987)* 
Thus, properties of the antigens and antibodies presents in 
IC may play an important role in determining whether 
complexes become deposited within the tissues and produce 
immune complex disease.
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PROPERTIES OF COMPLEMENT-REACTED COMPLEXES
Sucrose density gradient studies of IC which have been 
solubilized by the action of complement and IC which have 
been prevented from precipitation by the action of 
complement, have demonstrated that they exhibit 
heterogeneity of size, with sedimentation coeffients 
ranging from 11S to 22S (Czop & Nussenzweig, 1975; Malasit, 
Bartolotti & Humphrey, 1983)-
In addition to C3. solubilized IC and IC prevented 
from precipitating by the action of complement contain Clq, 
Ctlt C&bp, C5 and factors B, P and H (Takahashi, Tack & 
Nussenzweig, 1977; Takahashi et al, 1978; Scharfstein et 
al, 1979; Campbell, Dodds & Porter, 1980; Naama et al,
1985)•
Solubilized IC are unable to activate the classical or 
alternative pathways and have been termed ’end-stage' IC 
(Takahashi, Tack & Nussenzweig, 1977; Takahashi &
Takahashi, 1981). However, complement-reacted IC can bind 
to staphylococcal protein A Sepharose (Takahashi & 
Takahashi, 1981). Solubilized IC can bind to erythrocyte 
CR1, but IC which have been formed in serum do not bind to 
this receptor terribly well (Schifferli & Peters, 1983). 
This difference can be explained on the basis that the 
number of CR1 receptors per erythrocyte is low (Fearon, 
1980), and as multipoint attachment of C3b to receptors is 
required for stable binding to occur (Arnaout et al, 1981), 
large numbers of C3b molecules must be present on IC. As 
indicated earlier, greater amounts of C3b are bound to 
solubilized IC than to those which have been prevented from
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precipitating. However, these results were obtained using 
BSA-anti-BSA IC and are not representative of all 
complexes. It is far more difficult to prevent the 
precipitation of IC formed with high molecular weight 
antigens such as thyroglobulin, although, when these IC are 
soluble they bind avidly to erythrocyte CR1 (Whaley,1987)• 
In this instance it is probable that more bound C3b is 
required to retain the IC in solution. The ability of 
complement reacted IC to bind to complement receptors is 
important. When the IC cannot be rendered sufficiently 
small and soluble by the action of complement, binding to 
erythrocyte CR1 must occur for the IC to be transported to 
the reticuloendothelial system (Cornacoff et al, 1983)*
The presence of C3b on IC also promotes their uptake and 
degradation by macrophages (Kdilstra, Van Es & Daha, 1979)*
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1.17 SOLUBILIZATION AND PREVENTION OF IMMUNE PRECIPITATION 
IN IMMUNE COMPLEX DISEASE
If the processing of IC by complement plays an 
important role in the protection of the individual against 
IC-mediated tissue injury, then breakdown of this mechanism 
should be evident in patients with immune complex disease. 
The most obvious example is the high incidence of immune 
complex disease in patients with inherited deficiencies of 
complement components. The most important observation is 
that immune complex diseases are principally associated 
with deficiencies of the classical pathway proteins, and 
patients who lack factors D or P do not appear to be unduly 
predisposed to the development of immune complex disease.
These experiments of nature illustrate the essential 
role of the classical complement pathway in defence against 
immune complex disease. By implication, PIP is more 
important than the solubilization of immune precipitates.
The majority of patients with immune complex diseases 
do not have inherited deficiencies of complement 
components, so other defects in the system must occur.
Acquired hypocomplementaemia occurs in patients with 
deficiencies of Cl-inhibitor, and factors H or I. The 
former patients have uncontrolled catabolism of CH and C2, 
with low levels of these components (Frank, Gelfand & 
Atkinson, 1976), and acquired C3 depletion occurs in 
patients with deficiency of H or I (Thompson, 1987)- 
Patients with Cl-inhibitor deficiency have a somewhat 
increased risk of developing SLE, but although Ctl levels 
are usually extremely low the incidence of immune complex 
disease is far lower than that observed in inherited Ctl
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deficiency. In the latter patients the presence of Cl- 
inhibitor accelerates the aggregation of IC as a result of 
Cl disassembly. In contrast, in Cl-inhibitor deficient 
patients the lower levels of Cl-inhibitor may allow greater 
expression of the protective influence of Cl (Schifferli, 
Steiger & Shapira, 1985)* Moreover, the presence of small 
amounts of Ctl in the circulation of these patients might 
also help prevent the assembly of large IC aggregates.
Acquired hypocomplementaemia due to circulating C3 
nephritic factor and the classical pathway convertase 
stabilizing factors are associated with pronounced 
hypocomplementaemia and immune complex disease (Daha,
1987). Hypocomplementaemia which occurs as a result of 
disease, may itself lead to further difficulty in handling 
IC. The prolonged low levels of CU which may occur prior 
to clinical evidence of increased disease activity in SLE 
patients (Ruddy et al, 1971) and the hyposynthesis of C3
which occcurs in SLE (Ruddy et al, 1975)# may contribute to
the difficulty in handling IC.
Recent investigations have shown that the sera of 
patients with a variety of immune complex diseases (Table 
1.6) contain a factor which inhibits complement-mediated 
PIP (Naama, Mitchell & Whaley, 1983J Kerr, Naama &
Whaley, 1986; Webb et al, 1986; Baatrup et al, 1983).
The presence of the inhibitory factor is associated 
with large PEG-precipitable IC. It is probable, therefore, 
that the factor which inhibits solubilization, and the 
factor which inhibits PIP are identical. The inhibitory 
factor appears to act by binding to IgG and preventing Cl
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binding (Niven & Whaley, 1966), and activation (Naama, 
Mitchell & Whaley, 1983)* Although purified monoclonal and 
polyclonal IgM-rheuraatoid factors inhibit complement- 
mediated prevention of immune precipitation and 
solubilization (Whaley et al, 1987; Balastrieri et al,
1984; Mitchell et al, 1984; O ’Sullivan, Amos & Williams,
1988), purified monoclonal IgM-myeloma proteins without 
rheumatoid factor are able to produce the same effects, 
although higher concentrations are required (Whaley et al, 
1987). Furthermore, rheumatoid factor anti-idiotype 
antibodies do not abrogate this inhibitory activity (Whaley 
et al, 1987), and serum concentrations of IgM rheumatoid 
factor did not correlate with levels of PIP inhibitory 
activity (Webb et al, 1986). Thus the precise role of IgM
rheumatoid factor in the inhibition of PIP was questioned.
When all our IgM rheumatoid factor preparations were 
examined by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, it was found that all the preparations 
contained a contaminant with a molecular weight of 60kD.
The possibility that this 60kD contaminant was responsible 
for inhibition of PIP was suggested. The purpose of this 
study was to isolate and characterise this 60kD "protein” , 
and to assess its role in the inhibition of PIP.
CHAPTER 2 
MATERIALS AND GENERAL METHODS
This chapter describes all the materials and general 
methods used.
2.1 MATERIALS
The following materials were obtained from the specified 
sources.
Pharmacia Ltd., Pharmacia House,
Midsummer Boulevard, Milton Keynes.
Sephadex G50
Sephadex G150
Sephacryl S-300 Super Fine High Resolution.
Cyanogen bromide (CN-Br) activated Sepharose U-B
Sepharose UB
Protein A-Sepharose ti-B
Con A-Sepharose HB
Heparin-Sepharose llB
Diethylaminoethyl (DEAE) Sephacel
Gel Bond
Sigma Chemical Co.Ltd., Poole, Dorset.
Bovine serum albumin (BSA)
Tween-2 0
N-Hydroxysuccinimido-Biotin.
Diaminobenzidine tetrahydrochloride 
o-phenyldiamine 
fe.-amino-n~caproic acid
Trypsin, chymotrypsin, elastase, pepsin, protease V8, and
H 2
Sigma Chemical (continued) 
neuraminidase.
Folin and Ciocalteu’s phenol reagent
High and low molecular weight markers for SDS-PAGE. 
Phenylmethylsulphonyl fluoride (PMSF) 
monethanolamine
Sodium dodecyl sulphate (Lauryl sulphate)
Ammonium persulphate
N, N, N f, N * —Tetramethylethylenediamine (TEMED)
Guanidine hydrochloride
Anisitol
Cyanogen Bromide.
Aldrich Chemical Co. Ltd., New Road,
Gillingham, Dorset.
Dimethyl sulphoxide
Benzamidine hydrochloride hydrate 
Trifluoromethylsulphonic anhydride.
Amicon Ltd., Upper Mill, Stonehouse, Glos.
YM10 and YM30 filtration membranes.
Scottish Antibody Production Unit,
Law Hospital, Carluke, Lanarkshire.
Normal Rabbit serum
Sheep anti-whole human serum
Sheep anti-human IgG
Sheep anti-human IgM
Sheep anti-human IgA
Donkey anti-rabbit IgG
Peroxidase conjugated donkey anti-rabbit IgG 
Sheep erythrocytes suspension
H 3
Regional Blood Transfusion Service, Law Hospital, Carluke, 
Lanarkshire.
Fresh frozen human plasma.
Atlantic Antibodies, ATAB, American Hospital supply Ltd., 
Didcot,Oxon.
IgG fraction of
Goat anti-human Clq
Goat anti-human Clr
Goat anti-human Cls
Goat anti-human Cl-inhibitor
Goat anti-human CU
Goat anti-human C3
Goat anti-human C5
Goat anti-human factor B
Goat anti-human properdin
Goat anti-human factor H
Sheep anti-human serum albumin.
Cappel, Dynatech Laboratories Ltd.,
Deux Road, Billingshurst,Sussex.
Sheep anti-human C6
Sheep anti-human C7
Sheep anti-human C8
Behring Diagnostics, Hoechst UK Ltd., Hounslow, 
Middlesex.
Sheep anti- human CU binding protein 
Sheep anti-human S-protein 
Sheep anti-human prealbumin 
Sheep anti-human transferrin.
lili
Bio-Rad Laboratories Ltd., Coxton Way,
Watford, Hertfordshire.
Silver staining kit
Biorex-70 100-200 mesh (sodium free)
Difco Laboratories Ltd., P.O.Box l4B, Central 
Avenue, East Molesley, Surrey.
Freund’s complete adjuvant
Freund’s incomplete adjuvant.
Amersham International PLC., Aylesbury,
Buckinghamshire, U.K.
C3a des Arg RIA kit
C&a des Arg RIA kit.
Sources for the following materials were:
Methanol: May and Baker Ltd., Liverpool Road, Manchester
Diethylaminoethyl (DE52): Whatman Ltd., Springfield Mill
Maidstone, Kent.
Ethanol: James Burrough, 60 Montford Place, London.
Anti-human C2: Seward Laboratory, Norse Road, Bedford.
Avidin-Peroxidase conjugate: Vector Laboratories Ltd.,
Bretton, Peterbourough.
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Kodak X.Omat XAR-5 films: Kodak, Hemel Hempstead, Herts.
BCA protein assay reagent: Pierce (UK) Ltd., Clifton Road,
Cambridge.
IgM anti-sheep erythrocytes: was a kind gift from
Dr R.A. Thompson,
Regional Immunology Dept.,
East Birmingham Hospital.
Human IgGl, IgG2, IgG3 and IgG^ J. subclass myeloma proteins:
were a kind gift from Dr.P.Bird, Immunology unit,
Pathology Department, Medical School, 
Newcastle upon Tyne.
H 6
2.2 pH AND CONDUCTIVITY MEASURMENT
pH : The pH of buffers and column fractions were measured
using a Pye-Unicam pH meter, model 292.
CONDUCTIVITY: The conductivity of buffers was measured at
0
C using a conductivity meter model CDM3.Radiometer, 
Copenhagen.
2.3 BUFFERS
Phosphate buffered saline (20 x PBS.) pH 7* ft 
320 g NaCl
13.6 g Potassium dihydrogen phosphate 
ft8.ft g di-Potassium hydrogen phosphate 
Made up to 21 with water.
Veronal buffered saline ( 5 x VBS ) pH 7-ft 
85 S NaCl
3.75 S Barbitone sodium 
5-75 S Barbituric acid
Dissolved in 1 1 hot water, then made up to 2 1.
+  +
GVB pH 7•^
200 ml 5 x VBS 
5 ml 0.03 M CaCl
2
10 ml 0.1 M MgCl
2
10 ml 10 % (w/v) gelatin 
Made up to 1 1 with water.
GVB pH 7•ft
200 ml 5 x VBS 
10 ml 10 % (w/v) gelatin 
Made up to 1 1.
ft7
Isotonic dextrose ( D5W ) pH 5.5 
50g D-glucose 
5ml 0.03 M CaCl
2
10ml 0.1 M MgCl
2
Made up to 11.
Isotonic 0.086 M EDTA pH 7.4
198ml of 0.3 NaOH was added to 500 ml of 
0.12 M EDTA to give a pH of 7*& . The volume 
was then made up to 1 1 with water.
0.0a M EDTA GVB
230 ml of isotonic 0 .086 M EDTA was made up to 
500 ml with GVB 
0.01 M EDTA GVB
57*5 nil of isotonic 0.086 M EDTA was made up to 
500 ml with GVB
D50S.
50g D-glucose 
5.95s NaCl
Made up to 100 ml with water.
+  +
Mannitol GVB
9ml 20% Mannitol plus 
3ml GVB
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2 .H PROTEIN MEASUREMENT
a- O. D
280
The absorbance of the samples were read at 280 nm using the 
sample buffer as a blank using a Shimadzu UV-120-02 
spectrophotometer.
b- Folin assay : (Lowry et al.,1951)
known concentrations of BSA were used as a standards.
Solution A: 2g Na2C03
20mg Na/K tartarate
made up to 100 ml with 0.1M NaOH.
Solution B: 0.15 % (w/v) CuS04.5H O
2
Solution C: 1 volume of solution B was mixed with 50
volumes of solution A on the day of use. 
Solution D: Commercial Folin and Ciocalteu’s phenol
reagent was diluted with an equal volume of 
water.
One hundred mictolitres (100 ^ 1) of standard dilutions
of BSA (5yug, lOjug, 2Ojug, ilOfig, 80yjg) or the test samples
were each added to a series of test tubes containing 2 ml
of solution C. After the addition of 200yul solution D,
the tubes contents were mixed and left to stand at room
temperature for 30 minutes. The absorbance of each tube was
read at 700 nm, and a standard curve (Fig 2.1) was
constructed by plotting the O.D values of each standard
700
dilution against the amount of BSA in that standard. The 
concentration of protein in the test samples were then read 
off from the standard curve.
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Figure Z t_L
Example of folin assay 
standard curve
Folin  assay standard curve
Abs 700nm
0.3H
80510 20
jjg  BSA
c BCA PROTEIN ASSAY REAGENT
BCA working reagent: 1 volume of reagent B was mixed with
50 volumes of reagent A. One hundred microlitres (lOC^ul)
of standard dilutions of BSA or lOC^ul of test sample were
each added to a series of test tubes containing 2ml of BCA
working reagent- The tube contents were mixed and 
o
incubated at 60 C for 30 minutes, after which the 
absorbance was read at 362 nm and a standard curve was 
constructed by plotting O.D for each standard against
562
the amount of protein contained in that standard (Fig 2.2).
The amount of protein in test samples were then read off
the standard curve.
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Kigvir.e ZjuL*
Example of BCA assay 
standard curve
BCA standard curve
Abs 562nm
1.2-,
5 10 20
BSA ^ ig
2 .5 IMMUNOELECTROPHORESIS
(Grabar & Williams, 1953)
Tank buffer-: 17 & Barbitone dissolved in 500 ml water
23-5 ml of 1 M HC1 to give a pH of 8.6,
and the final volume was made to 11.
Agarose solution : 3 S agarose dissolved in 200 ml hot buffer
containing 0.9 g sodium barbitone, 2.3 ml 
of 0.086 M EDTA pH 8.6.
10 x 10 cm Gel Bond membranes were cut, and 12.5 nil 
of melted agarose was poured onto the hydrophilic side of 
the membrane which had been placed on a level table. After 
cooling at room temperature, a series of wells (2 -U mm) and 
troughs were cut in the agarose using a template. The wells 
were filled with the antigen or test sample together with 
lul Bromophenol blue (0.1 w/v) as a tracer, and the
electrophoresis was performed for 2-3 hours at a constant
current setting of Ho mA.
The electrophoresis was terminated when the dye had 
migrated to the anodal end of the trough. After the troughs 
were filled with the appropriate antiserum, diffusion of 
antigen and antibody was allowed to occur for 2 U.-118 hours 
in a humid chamber at room temperature. The membranes were 
then washed for 48-72 hours in 0.9% (w/v) NaCl, dried and 
finally stained with 0.1% (w/v) Coomasie blue in 50% 
methanol, 10% acetic acid, and destained in the same 
solution without the dye.
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2.6 RADIAL IMMUNODIFFUSION
(Mancini, Carbonara & Heremans, 1965)
Agarose (Is) was dissolved in 100 ml isotonic VBS (pH
7*&) containing 0.01M EDTA by boiling- When fully
o
dissolved the agarose solution was cooled to 50 C in a 
water- bath and the appropriate volume of antiserum added 
(the diameter of the precipitin ring for the 100% standard 
should be between 5 and 7 mm). After mixing, 3-5 ml was 
pipetted into each of plastic petri dish (50 mm diameter), 
which had been placed on a level surface.
The plates were then allowed to set at room
o
temperature and stored inverted in a moist chamber at 2 C. 
For use, wells (2mm diameter) were cut in the agarose using 
a gel punch. Each well was filled with test sample and a 
series of three standards dilutions (1/1; 1/2; 1/ k ) were
included in each plate. The plates were left for 2k-k& 
hours in a moist box at room temperature after which the 
diameters of the precipitin rings were measured using a 
measuring magnifier.
A standard curve was constructed by plotting the 
square of the diameter of the precipitin ring for each 
standard against its protein concentration. The 
concentrations of the protein in the test samples were read 
from the standard curve. Test samples in which the protein 
concentration was too high to be read off the standard 
curve were diluted and re-tested.
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2.7 DOUBLE IMMUNODIFFUSION 
(Ouchterlony, 1958)
Agarose (1% w/v) was prepared as described in section 
2.6, but without the addition of antiserum. Gels were 
prepared on Gel Bond membranes as described in section 2.5- 
Wells (2-5mm diameter) were punched at variable distances 
from each other and adjacent wells were filled with antigen 
solutions and antisera. Diffusion was allowed to occur for 
2tl hours at room temperature in a moist chamber. The gels 
were then washed, stained and destained as described in 
section 2.5. (see specific sections in chapter 3 For 
details of each experiment).
2.8 SODIUM DODECYL SULPHATE-POLYACRYLAMIDE SLAB GEL 
ELECTROPHORESIS SDS-PAGE (Laemmli, 1970)
Protein samples were electrophoresed in different
percentage gels made up according to Table 2. 1
Stock solution % Gel
6% 7% 8% 9% 10% 11% 12% 15%
30% Acrylamide 
(ml)
10 10 10 10 10 10 10 10
Water(ml) 15 11 8 6 5 3 2.5 2
0.75 M Tris-HCl 
pH 8.8 (ml)
25 21. 5 19 17 15 1 tl 12.5 10
Ammonium per­
sulphate (mg)
50 U2 38 33 30 27 25 2ll
10% SDS (ml) 0 .5 0.Z13 0 .38 0. 33 0. 3 0. 27 0.25 0.
TEMED (ul) 25 21 19 16 15 14 13 12
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The stacking gel composition was as follows :
30% acrylamide 1. 8 ml
Water 13 ml
0.75 M Tris-HCl pH 6.8 3 ml
10 % SDS 0.18 ml
Ammonium persulphate 18 mg
TEMED 9 yul
The separation gel was poured immediately between 
glass plates (20 x 20 cm),separated by 1.0 mm spacers. 
Water was layered on top of the gel which was then left to 
set. After setting the water was poured off and the 
stacking gel was layered on top of the separating gel. A 
comb for forming wells at the top of the stacking gel was 
inserted and the gel was allowed to set for 2 hours at 
room temperature.
Tank buffer: 10ml 10% SDS
33ml 0.75M Tris.
1ft. 2g glycine
Made up to 11 with water.
Sample buffer: 3* 00ml 10% SDS
1.00ml glycerol
0.85ml 0.75M Tris-HCl, pH 6.8
0.50ml 2-mercaptoethanol
lOO^ul Bromophenol blue (0.01% w/v).
Samples containing 1 to 10 yug protein were diluted 
with an equal volume of sample buffer (with or without 
mercaptoethanol; i.e under reducing or non-reducing 
conditions), and placed in a boiling water bath for 5 min.
5ft
The mixture was then loaded on to the gel and the 
electrophoresis performed at kO mA for 2-3 hours until the 
tracking dye had reached the bottom of the gel. The gels 
were stained as in 2.9. 2.10, 2.11 or immunoblotted as in
2. 12.
2.9 COOMASIE BRILLIANT BLUE STAINING
The slab gels were stained for 30 minutes in 500 ml
of:
0.5s Coomasie Briliant Blue 
250ml Methanol 
50ml glacial acetic acid 
Made up to 500 ml with water.
Then the gels were destained in 10# methanol 5# acetic 
acid overnight, finally the gels were stored in water.
2.10 SILVER STAINING OF SLAB GELS
Using a silver staining kit, the gels were fixed for 
30 min in UOOml of U0% (v/v) methanol,10# (v/v) acetic 
acid, followed by another period in &00ml of 10# (v/v) 
ethanol, 5# (v/v) acetic acid. The gels were oxidised with 
200 ml oxidizer solution diluted 1:5 with water for 5 min, 
followed by 3 washes with water (500 ml each).
Two hundred millilitre (200ml) of silver reagent 
solution (diluted 1:5 in water) was added, and the gel left 
on a shaker for 20 min. Following a short wash in 500 ml 
water, the developer (32 g/1) was added and finally the 
developing reaction was stopped by the addition of 400ml of 
5# (v/v) acetic acid for 5 minutes.
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Usually polyacrylamide gels were photographed wet, 
but some of those presented in this thesis were 
photographed after drying.
For drying the gel was placed on a cellophane membrane 
and dried in a Bio-Rad gel drier until absolutely dry.
2.11 GLYCOPROTEIN STAINING (PAS STAIN, CLARKE, 1964)
The gel was placed in 11 of 7-5% (v/v) glacial acetic 
acid for one hour at room temperature, followed by
o
incubation in 500 ml 0.2% (w/v) periodic acid at 4 C for a
further hour. The gel was stained in 200ml Schiff's
o
reagent for 1 hour at 4 C, and finally destained in a
solution containig 50 ml IN HC1 and 5 S potassium
metabisulphite made up to 11 with water. The gels were
o
stored in 3% (v/v) acetic acid at 4 C.
2.12 PROTEIN TRANSFER BLOTTING (IMMUNOBLOTTING-WESTERN 
BLOTTING) (Towbin, Stahlin & Gordon, 1979)
Proteins were transferred from polyacrylamide slab 
gels to a nitrocellulose membrane at constant voltage of 16 
V for 18 hours in a Bio-Rad Trans-Blot apparatus. The 
buffer used in the electroblotting cell was 24 mM Tris, 192 
mM glycine (pH) containing 20 % (v/v) methanol.
2.13 IMMUNOSTAINING OF WESTERN BLOTS
The nitrocellulose membranes were incubated for 2 
hours at room temperature in blocking buffer (10 mM Tris- 
HCl, 0.15 M NaCl, pH 7-5, containing 2 % (w/v) BSA, and 
0.05% (v/v) Tween-20. The membranes were then incubated for 
two hours at room temperature with the IgG fraction of the
56
appropriate polyclonal antiserum at a concentration of 
between 10 ug/ml and 100 ug/ml in blocking buffer.
Following six 10 minute washes in 250 ml blocking buffer, 
the membranes were incubated with peroxidase-conjugated 
donkey anti-rabbit IgG in blocking buffer for another 2 
hours at room temperature. The membranes were then washed 
6 times as described above, before developing with a 
solution of 50 mg diaminobenzidine tetrahydrochloride in 
100 ml Tris-HCl (0.1M pH 7.6), containing 20 ul hydrogen 
peroxide (30 % v/v). The reaction was terminated by washing 
in water, and drying the membranes.
2.14 RADIOIODINATION OF PROTEINS
The following two methods were used for labelling 
125-
proteins with [I] for the work described in this
thesis.
Chlgyamine T. method (McConahev & Dixon. 1966)
One millilitre (1ml) of protein solution (1 mg/ml) in
PBS was mixed with lOul of chloramine-T solution (5 mg/ml)
125-
and 38 MBq of carrier-free [I]) for 60 seconds at room
temperature. The reaction was stopped by the addition of 50 
ul L-tyrosine (0.5 mg/ml in 0.1M NaOH) before the reactants 
were applied to a Sephadex G-50 column (0.5 x 8 cm) 
equilibrated in PBS, and a 0.5 ml fractions were collected. 
An aliquot (5 j^ul) of each fraction was counted in an 
automatic-gamma counter (Packard, Model 300C) to determine 
the radioactivity.
The peak of radiolabelled protein was pooled, and the 
acid-precipitable radioactivity was determined by adding 10
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yul of the radiolabelled protein pool to 200 yul of BSA (10% 
w/v), after which 1 ml of TCA (20% w/v) was added.
The contents of the tubes were then mixed and 
centrifuged at 10 000 g for 5 minutes. The supernatants 
were removed and the pellets were washed three times in 10%
TCA prior to counting. In addition fyul of the labelled 
preparation was counted to measure the total radioactivity 
in the preparation.
The percentage acid-precipitable radioactivity was 
calculated from the equation:
total cpm - precipitated cpm 
% Acid-precipitable = 1- ( ----------------------------------) x 100
125-[I]-Protein total cpm
The protein concentration of the radiolabelled 
preparations was determined by measuring the absorbance at 
280 nm (2.4).
2 . lUte Iodoaen method 1 Mar&KfeJLl. &  Eq.X.» 1 97A 1
A solution of 1,3.^ .6-tetrachloro-3^, 6^- 
diphenylglycoluril (Iodogen; 0.25mg/ml) in methylene 
chloride was prepared, and 50 yul was placed in a glass tube 
and evaporated under a stream of nitrogen in order to form 
a thin layer of Iodogen on the wall of the tube. The
125
protein (250yug/ml) in PBS, and 38 MBq carrier free [I]
were added, and the reaction was allowed to proceed at room 
temperature for 5 minutes with gentle mixing. The reaction 
was terminated by applying the reaction mixture to a 
Sephadex G-50 column (0.5x8cm) equilibrated in PBS or PBS 
containing 0.1% (w/v) gelatin. The protein was eluted with
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PBS and 0.5 ml fractions were collected. The fractions
were counted as in 2.14a and the peak of radiolabelled
protein was pooled.
Acid-precipitable radioactivity was measured as
described above. The protein concentration of proteins
labelled by this method was determined by O.D (Clq, IgM-
280
RF, IgG-RF) or by ELISA (PIP-inhibitor). Radiolabelled
o
proteins were stored at -2q C in aliquots.
2.15 STANDARDIZATION OF ERYTHROCYTE SUSPENSIONS
A sheep erythrocyte suspension wa.S washed three times 
in GVB until the supernatant was free of haemoglobin.
One hundred microlitres (100Jo 1) were lysed in 2.9 ml of 
water, and the O.D at 5^1 nm was determined. The 
suspension was standardized using the following formula:
Volume of E required = Initial volume x ___________
0.385*
9
* O.D O .385 at 5^ -1 nm equals 1 x 10 cells/ml.
These cells were used for the preparation of antibody
coated erythrocytes, EA (see chapter 5, section 5.1.18),
for the preparation of EAC4 or EAC1&2 haemolytic
intermediates, the cell suspension was adjusted to 
8
1x10 /ml, so in this case the optical density of the 1:30
lysate was read at kill nm. A reading of 0.327 corresponds
8
to a cell concentration of 1x10 /ml.
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2.16 SEPARATION OF HUMAN OR RABBIT SERUM
Blood was collected Into sterile universal glass
o
containers, and incubated at 37 C for 30 minutes, to allow
clotting to occur, followed by 30 minutes on ice to allow
clot retraction to occur. The blood was centrifuged at 2000 
o
g at 2 C for 10 minutes, and the serum was collected and
divided into aliquots. Human serum was stored at -70
o o
C, while the rabbit serum was heat-inactivated at 56 C
o
for 30 minutes prior to storage at - 20 C.
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CHAPTER 3
PURIFICATION AND PARTIAL CHARACTERISATION OF THE 
INHIBITOR OF PREVENTION OF IMMUNE PRECIPITATION 
(PIP— INHIBITOR) AND ANTISERUM PRODUCTION
INTRODUCTION
P r e v i o u s a t: t e m p t b :i. n t t"i i s 1 a b o r a t o r y t o p u. r i f y t h e 
PIP-inhibitor -from rheumatoid arthritis sera, usually 
resulted in preparations which contained mainly 
IgM. rheumatoi d factor (M.i tchel 1 et al . ? 1984) » Since normal 
human serum contained a small amount of PIP inhibitory 
activity, it was hypothesised that the PIP—inhibitor was a 
plasma protein which was present in normal serum but which 
was present in much higher concentrations in rheumatoid 
a r t h r i t is sera. 11 was t h e refore d e c i cl e d t o u s e n o r rn a 1 
human serum as starting material for its pur i f .i. cat i on „ The 
puri f i cat i on methods were or i gi na11y based on the 
observation made by Niven and Whaley (1986), that the FTP— 
inhibitor binds to the IgG moiety of the IC, and involved 
affinity chromatography on IgG-Sepharose, protein A- 
Sepharose and Con.A-Sepharose or heparin-Sepharose. Later, 
a method which avoided IgG-Sepharose affinity 
chromatography was developed. The purified PIF’-i nhi hi tor 
was used to immunise rabbits to produce a monospecific 
anti serum.
6 2
METHODS
3.1.1 PURIFICATION OF IgG FROM WHOLE SERUM 
(Whaley et al, 1983)
The IgG fraction of normal animal or human serum was
obtained by the addition of equal volume of saturated
o
ammonium sulphate drop-wise with stirring at 0 C. The
precipitate was collected by centrifugation (5000 g, for 
o
30 mins. at 2 C), dissolved in 5 X VBS and dialysed for 18
hours against 10 mM Tris-HCl (pH 8.0.). The dialysed
material was clarified by centrifugation (5000 g, for 30 
o
mins. at 2 C) and applied to a DE52 column equilibrated in
the same buffer. The column was then washed with buffer
and the exclusion peak of the column was pooled. Following
o
dialysis against PBS the preparation was stored at -20 C. 
The purity of the IgG was examined by SDS- PAGE run under 
reducing conditions in 10% gels and double diffusion in 
agarose gel against anti-whole serum and anti-IgG.
3-1.2 CONJUGATION OF IgG TO SEPHAROSE 4B 
(Goetzl & Metzger, 1970)
Five hundred millilitres (500 ml) Sepharose kB were
washed 3 times with an equal volume of deionised water,
followed each time by centrifugation (2000g for 5 mins. at 
o
H C). The washed Sepharose was kept on ice and added to 
a solution of Cyanogen bromide 500 g/51) in water with 
gentle stirring, and the pH was maintained around 11 by 
the addition of fl-N NaOH, until the pH was stable at 11.
The activated Sepharose was transferred to an ice-filled 
scintered-glass funnel attached to a vacuum-flask, and
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washed with 501 of ice-cold 0,1 M sodium carbonate buffer
(pH 8.2). The Sepharose was divided into 25 ml portions
and to each was added an equal volume of IgG in the same
buffer (ratio 10 mg protein: 1 ml Sepharose), and mixed
o
end-over-end at ^ C for 18 hrs. The supernatant was
o
removed after centrifugation (200 g for 5 mins. at 2 C),
and following the measurement of the protein concentration
(OD ) the conjugation efficiency was determined using 
280
the formula:
% protein bound =
O.D* of starting material - O.D of supernatant
  x 100
O.D Of starting material
* O.D 280 nm
The remaining active sites on the Sepharose were 
blocked by incubation with 1 M mono-ethanolamine (pH 8.0) 
for 2 hours at room temperature, followed by three washing 
cycles of alternating pH. Each cycle consisted of a wash 
with glycine-HCl buffer (pH 3*0), containing 0.5 M NaCl, 
followed by a wash with 0.1 M Tris-HCl (pH 8.0) containig 
0.5 M NaCl. The IgG-Sepharose was finally stored after 
the addition of sodium azide to a final concentration of 
0.02% (w/v).
The same method was used for the preparation of BSA- 
Sepharose but it was scaled down to accommmodate one tenth 
of the volumes Sepharose and BSA (50 ml each).
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3-1.3 RADIOLABELLING OF PROTEINS
Both BSA and the PIP-inhibitor were radioiodinated 
using the chloramine-T method for BSA and the solid-phase 
Iodogen method for the PIP-inhibitor (2.1&a; 2.1&b).
3 • 1. 4- EQUIVALENCE POINT FOR BSA AND ANTI-BSA
The point of equivalence of 125[I]-BSA and anti-BSA
was determined by use of a quantitative precipitin test,
where tubes were set up containing a constant amount of
anti-BSA in 10 yul with decreasing concentrations of 
125 + +
[I]-BSA (600 yjg/ml to 9. U yjg/ml) in 5 JJ1 GVB . The
+  +
total reaction volume was adjusted to 115 yul with GVB
o
After one hour incubation at 37 C, 50 yul aliquot was
removed and added to 1 ml ice-cold PBS, which was then
centrifuged at 8000 g for 10 minutes and 250yul of
supernatant was counted in a gamma counter. Control tubes 
125 + +
were made of [I]-BSA and GVB and processed in
identical fashion to the test tubes. Percent immuno-
precipitation was calculated using the following formula:-
% precipitation =
c.p.m buffer control - c.p.m. test
1 - (------------------------------------------) X 100
c.p.m. buffer control
Percentage precipitation was plotted against the
concentrations of BSA and the equivalence point and the
amounts of BSA at, four-times antigen and four-times
antibody excess were determined. The anti-rabbit BSA
antiserum used for the formation of the IC was Kindly
prepared by Mrs. A. Johnson. This antiserum was also used
to prepare immunoadsorbent purified IgG anti-BSA (see 4.1.8).
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3.1.5 ASSAY FOR INHIBITION OF PIP
Normal human serum (2.16) had previously been titrated
In the PIP assay In order to determine the dilution which
would inhibit precipitation of BSA-anti-BSA IC by between
70-90% (See 5- )• For measurement of inhibition of PIP 50
+  +
ul of serum diluted 1:U in GVB was mixed with 50 ul of
125
test sample or heat-inactivated serum, and []I-BSA (0.5
o
ug in 5yul) was added. The reaction mixture warmed to 37 C
and at time 0, 1 0 anti-BSA (diluted in GVB + + in order to
form IC at equivalence) was added and the incubation was
o
continued at 37 C. At timed intervals or after one hour,
an aliquot (50^ul) was removed and transferred to an
Eppendorf tube containing 1ml ice-cold PBS. Following
centrifugation for 5 min at 8000 g in a Beckman Microfuge
B, 250^ul of the supernatant was removed and the
radioactivity counted in an automatic gamma counter.
Control tubes included:
i) radioactivity precipitated by antibody alone:- 
+ + 125
100 jjl 1 GVB , 5 yul [I] -BSA, 10 yul anti-BSA.
ii) Maximum PIP by serum alone:-
+ + 125
50 GVB , 50 jal serum, 5 ^ 1  [I]-BSA, 10 jal anti-BSA.
iii) Total radioactivity input:-
125 +-*-
5 ^ ul [I]-BSA, 50yul heat-inactivated serum, 60 yjl GVB
The control tubes were processed in an identical 
fashion to the assay tubes. Results were calculated using 
the formula:
c.p.m test - c.p.m buffer
% Inhibition of PIP = l-(------------------------------- ) X 100.
c.p.m serum - c.p.m buffer
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To investigate the kinetics of the action of PIP- 
inhibitor on the inhibition of PIP, the same assay was used 
but the PIP-inhibitor was added before the formation of IC 
in serum, or at timed intervals after their formation.
3.1.6 ASSAY FOR INHIBITION OF SOLUBILIZATION
BSA-anti-BSA immune precipitates were formed at
125
equivalence by incubating 0.125 yug [I]-BSA and 10 ^ yul
+ + o
anti-BSA (1:8) in 25yjl GVB for 30 min at 37 C. 50 yul of
test sample (dialysed in VBS), and 50yjil normal serum were
added, and the Incubation allowed to proceed for timed
intervals or another hour. The soluble IC were separated
as described in 3.1.5.
Controls included: -
i) zero solubilisation:- 50 ^ul EDTA-serum in place of 
normal serum.
+ +
ii) Maximum possible solubilization:- 50yul GVB in place 
of test sample.
The results were expressed as % inhibition from the 
formula:
% Inhibition of solubilisation =
c.p.m Max. solubilisation - c.p.m test
(  .---------------------------) X 100
c.p.m Max. solubilisation - c.p.m zero control
3.1.7 COLUMN SCREENING PROCEDURE
The column fractions were screened for inhibition of PIP 
(3*1.5). protein concentration (2.4), pH and conductivity 
(2 .2 ).
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3-1.8 PURIFICATION OF THE PIP INHIBITOR (METHOD 1)
The method consisted of affinity chromatography of
normal serum on IgG-Sepharose, protein A-Sepharose and
Con.A-Sepharose affinity chromatography.
All procedures, unless otherwise stated, were 
o o
performed between 2 to ll C.
3-1-9 IgG-SEPHAROSE AFFINITY CHROMATOGRAPHY
o
One unit of fresh frozen plasma was thawed at 37 C,
o
recalcified by the addition of ll ml 1 M CaCl , cooled to ll
2
C and allowed to clot for 18 hrs. After separation of the 
fibrin clot, the serum was diluted with an equal volume of 
20 mM EDTA (pH 7 . H ) , and 100 ml was applied to an IgG- 
Sepharose column (2.6 x 60 cm) equilibrated in 10 mM Tris- 
HC1 buffer (pH 7•H ) , containing 10 mM EDTA and 75 mM NaCl, 
at a flow rate of 50 ml/hr. Fractions of 10 ml were 
collected.
The column was washed with the starting buffer until
the O.D of the effluent was less than 0.01 and then 
280
eluted sequentially with a column volume of each of the 
following buffers:-
10 mM Tris-HCl(pH 7-4) containing 10 mM EDTA and 0.15 M NaCl. 
10 mM Tris-HCl(pH 7•H) containing 10 mM EDTA and 0.5 M NaCl. 
2 M guanidine-hydrochloride.
The collected fractions were then dialysed against VBS 
for 18 hours, and screened as described in 3.1.7.
Fractions which inhibited PIP were pooled and subjected to 
protein A-Sepharose affinity chromatography.
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3-1.10 PROTEIN A-SEPHAROSE AFFINITY CHROMATOGRAPHY
The PIP inhibitor* pool (3-1.9) was applied to a
protein A-Sepharose column (1 x 20 cm) which had been
equilibrated in VBS. The column was washed with VBS at a
flow rate of 30 ml/hour until the O.D of the effluent
280
was less than 0.01. The bound proteins were then eluted 
with 0.1 M glycine-HCl buffer (pH 2.8) containing 0.5 M 
NaCl. The acid-eluted fractions were neutralised by the 
addition of 100 ul of 1 M Tris base and dialysed overnight 
against VBS. The column fractions were screened as 
described in 3.1.7, and the exclusion peak which contained 
most of the PIP inhibitory activity was pooled and 
subjected to Con.A-Sepharose affinity chromatography.
3.1.11 CON.A-SEPHAROSE AFFINITY CHROMATOGRAPHY
The protein A-Sepharose pool was applied to Con.A-
Sepharose (1 x 20 cm), equilibrated in VBS. After washing
with VBS, the column was eluted with 0.1 M glycine-HCl
buffer (pH 2.8) containing 0.5 M NaCl. The acid eluted
fractions were neutralised and processed as described in
3-1.10. The PIP inhibitory fractions were pooled,
concentrated by ultrafiltration using an amicon YM10
o
membrane and finally stored at - 70 C.
The purity of the PIP-inhibitor was confirmed by SDS- 
PAGE run under reducing and non-reducing conditions in 10% 
gels (2.8), with silver staining (2.10), and by double 
diffusion in agarose gels (2.7) against anti-whole human 
serum.
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3.1.12 PURIFICATION OF THE PIP-INHIBITOR (METHOD 2)
The method consisted of affinity chromatography of 
normal human serum on IgG-Sepharose, protein A-Sepharose, 
gel filtration and finally heparin-Sepharose affinity 
chromatography. At all stages of the preparation pools of 
PIP inhibitory materials were treated with 1 mM PMSF.
3.1.13 IgG—SEPHAROSE AFFINITY CHROMATOGRAPHY
Three units of fresh frozen plasma w m  clotted as 
described in 3.1.9. Benzamidine (10 mM), PMSF (ImM) and 
sodium azide (0.01% w/v) were added to the serum, and 500 
ml was applied to IgG-Sepharose column (5*2x60 cm) 
equilibrated in 10 mM Tris-HCl buffer (pH 7«&). containing
10 mM EDTA, 0.15 M NaCl, 10 mM benzamidine, 1 mM PMSF and
0.01% (w/v) sodium azide, at a flow rate of 50 ml/hr.
Fractions of 10 ml were collected. The column was washed
with one column volume of the starting buffer, followed by
several column volumes of 10 mM Tris-HCl buffer (pH 7. ll) ,
containing 10 mM EDTA, 1.0 M NaCl, 10 mM bezamidine, 1 mM
PMSF, and 0.01% (w/v) sodium azide, until the O.D of the
280
column effluent was less than 0.01. Finally, the column
was eluted with a column volume of 2 M guanidine-
hydrochloride. The fractions were dialysed against VBS at 
o
11 C for 18 hours, and screened as described in 3. 1.9. The 
fractions which inhibited PIP were pooled and subjected to 
protein A-Sepharose chromatography.
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3.1.14 PROTEIN A-SEPHAROSE CHROMATOGRAPHY
The same method described in 3-1.10 was used although
the Protein A-Sepharose column was larger (1 x 40 cm). The
fractions were screened as described in 3.1-7. and those
which inhibited PIP were pooled and concentrated by
o
ultrafiltration at 0 C using an Amicon YM10 membrane.
3.1.15 SEPHACRYL S300 HIGH RESOLUTION GEL FILTRATION 
CHROMATOGRAPHY
Five millilitres (5 ml) of the concentrated PIP
inhibitor pool (3.1*14) were applied to 2.6 x 90 cm column
of Sephacryl-S300 equilibrated in 10 mM Tris-HCl buffer (pH
7.4), containing 10 mM EDTA, 1 M NaCl, 3 mM benzamidine, 1
mM PMSF and 0.01% (w/v) sodium azide, at a flow rate of 15
ml/hr. Fractions of 2 ml were collected. The fractions
were dialysed against VBS and were screened as described in
3*1.7. The fractions which inhibited PIP were pooled and
dialysed against 50 mM Tris-HCl buffer (pH 7-5).
containing 2 mM CaCl , and 2 mM benzamidine. The procedure
2
was r e p e a t e d i i ,  the entire concentrated PIP-inhibitor 
pool from the protein-A Sepharose column had been 
processed.
3.1.16 HEPARIN-SEPHAROSE AFFINITY CHROMATOGRAPHY
The dialysed PIP-inhibitor pool (3.1.15) was
o
centrifuged (2000 g for 10 min at 4 C), to remove
insoluble material prior to being applied to a heparin- 
Sepharose column (1.5 x 20 cm) equilibrated in the 
dialysis buffer, at a flow rate of 25 ml/hr. Fractions of 5 
ml were collected. After washing the column with starting
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buffer, the bound proteins were eluted with a linear salt
gradient consistl^of 300 ml starting buffer and 300 ml
starting buffer containing 1 M NaCl. The fractions were
screened as described (3-1.7) and the purity of the PIP-
inhibitor was confirmed as described in 3.1.11. The PIP
inhibitor fractions were pooled and concentrated by
ultrafiltration using an Amicon YM10 membrane and stored in 
o
aliquots at -70 C.
3-1.17 PURIFICATION OF THE PIP-INHIBITOR (METHOD 3)
The third method of PIP-inhibitor purification 
involved ion-exchange chromatography on DEAE-Sephacel, 
Biorex-70, gel filtration on Sephacryl-S300 and heparin- 
Sepharose affinity chromatography.
3-1.18 DEAE-SEPHACEL ION-EXCHANGE CHROMATOGRAPHY
One litre (11) of normal human serum was prepared as
described in 3*1.10 and diluted with 10 mM sodium phosphate
(pH 8.0), containing 10 mM benzamidine, 3 mM EDTA, 25 mM
EACA, ImM PMSF and 0.01% (w/v) sodium azide, until the
o
conductivity was U mS at 0 C. The pH was then adjusted to 
8.0. The diluted serum (8.0 1) was applied to a DEAE- 
Sephacel column (5-6 x 90 cm) equilibrated in 10 mM sodium 
phosphate buffer (pH 8.0), containing 20 mM NaCl, 10 mM 
benzamidine, 5 mM EDTA, 25 mM EACA.l mM PMSF and 0.01%
(w/v) sodium azide, at a flow rate of 300 ml/hr. Fractions 
of 20 ml were collected. Once the starting material had 
been washed through with starting buffer, the column was 
eluted with a linear salt gradient consisting of 5 1
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starting buffer and 5 1 of starting buffer containing 0.5 
M NaCl. The column fractions were screened as described 
(3.1-7). Fractions which inhibited PIP were pooled, 
dialysed and applied to a Biorex-70 column.
3.1.19 BIOREX-70 CATION-EXCHANGE CHROMATOGRAPHY
The DEAE-Sephacel pool (3 .I.1 8 ) was dialysed against 
several changes of 10 mM sodium phosphate buffer (pH 7.0) 
containing 20 mM NaCl, 5 niM benzamidine, 5 mM EDTA, 25 mM 
EACA, 1 mM PMSF and 0.01% (w/v) sodium azide, and applied 
to a Biorex-70 column (2.6 x 90 cm) equilibrated in the 
same buffer. A flow rate of 25 ml/hr was used and 10 ml 
fractions were collected. Once the exclusion peak had been 
washed through the column, the bound proteins were eluted 
with a linear salt gradient consisting of 21 of starting 
buffer and 21 of starting buffer containing 0.7 M NaCl.
The fractions were screened as described (3.1.7), and those 
which inhibited PIP were pooled, concentrated by 
ultrafiltration using an Amicon YM10 membrane and applied 
to a Sephacryl-S300 column.
3-1.20 SEPHACRYL-S300 GEL FILTRATION CHROMATOGRAPHY
The same experimental details described in 3.1.15 were
followed. The PIP inhibitory fractions were pooled,
dialysed against 50 mM Tris-HCl buffer (pH 7-5). containing
2 mM CaCl and 2 mM benzamidine, and centrifuged (2000 g 
2 o
for 1 minutes at C). The supernatant was subjected to 
heparin-Sepharose affinity chromatography.
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3.1.21 HEPARIN—SEPHAROSE AFFINITY CHROMATOGRAPHY
The dialysed and centrifuged pool (3.1.20) was applied to
a heparin-Sepharose column (2 x 15 cm) equilibrated in 50
mM Tris-HCl (pH 7*5). containing 2mM CaCl and 2 mM
2
benzamidine at a flow rate of 25 ml/hr. After washing the
starting material in the column until the OD of the
280
effluent was less than 0.01, the bound proteins were eluted 
with 50 mM Tris-HCl buffer (pH 7-5) containing 10 mM EDTA, 
1M NaCl and 2mM benzamidine. The fractions were screened 
and the purity of the PIP-inhibitor was confirmed as 
described in 3.1.12.
3-1.22 PRODUCTION OF ANTISERUM TO THE PIP INHIBITOR
Thirty micrograms (30 ug) of the purified PIP- 
inhibitor (prepared by method 1) were emulsified in 0.5 ml 
of Freund’s complete adjuvant, and injected bilaterally 
into the popliteal lymph nodes of rabbits. Booster 
injections of 10 ug of the inhibitor emulsified in Freund’s 
incomplete adjuvant were given intraperitoneally on week ll 
and intramuscularly on weeks 6 and 8. The rabbits were bled 
on weeks 9 and 10, and finally exsanguinated on week 11.
The antiserum was tested for monospecificity by double 
diffusion in agarose gels and Immunoelectrophoresis (2.7) 
against normal human serum, and for specificity by using 
the same procedures against the purified PIP-inhibitor. 
Later antisera to the high molecular weight gp60 were 
produced using the same immunization schedule.
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3-1.2 3 PREPARATION OF F(ab*)2 FRAGMENTS FROM RABBIT IgG
The IgG Fraction of normal rabbit serum and the
antiserum to the PIP-inhibitor were purified as described
in 3.1.1. The IgG was dialysed against 0.1 M acetate
buffer (pH a.0). Porcine pepsin was added at an
enzyme:substrate ratio of 1:100, and the mixture was
o
incubated overnight at 37 C. The digest was then buffered
by the addition of solid Tris to pH 8.0, centrifuged (2000g
o
for 15 min. at 2 C), and the supernatant was dialysed
against PBS. The F(ab’) fragments were separated from
2
undigested IgG and pFc fragments by protein A-Sepharose
chromatography using 0.5 x 3 cm column equilibrated in PBS.
o
The exclusion peak was then collected and stored at -20 C.
The purity of the (Fab*) preparations was assessed by SDS-
2
PAGE run under reducing and non-reducing conditions in 10% 
gels.
3.1.2^ PREPARATION OF Fab FRAGMENTS FROM RABBIT IgG
IgG was purified from normal rabbit serum and the PIP-
inhibitor antiserum as described in 3.1.1. Ten ml of rabbit
IgG (lmg/ml) was dialysed against 0.5 M sodium phosphate
buffer (pH 8.0), containing 2 mM EDTA and 10 mM cysteine.
Papain was added to the IgG to give an enzyme:substrate
o
ratio of 1:100, and the mixture was incubated at 37 C for
18 hours. It was then centrifuged (2000 g for 10 minutes at 
o
2 C) and the supernatant was collected and dialysed against 
o
VBS at U C for a further 18 hours, prior to application to 
a 3 ml column of protein A-Sepharose equilibrated in VBS. 
The column was then washed with VBS and the exclusion peak
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which contained the Fab fragments was collected, while the
undigested IgG and the Fc fragments remained bound to the
column. After pooling, the exclusion peak was tested for
purity by SDS-PAGE run under reducing and non-reducing
conditions in 10% gels. The preparation was then stored in 
o
aliquots at -20 C.
3-1.25 BIOTIN CONJUGATION OF IgG ANTI-PIP INHIBITOR
The IgG fraction of antiserum to the PIP-inhibitor was
adjusted to a concentration of 5 mg/ml in PBS, and a biotin
solution (11 mg/0.5 ml dimethylformamide) was added. The
mixture was left to stand at room temperature for two
hours, followed by dialysis against five changes of 2 1 PBS
for 18 hours to remove the unconjugated biotin. Finally the
o
conjugate was stored at ii C with 0.01% thiomersal.
3.1.26 ENZYME-LINKED IMMUNOSORBENT ASSAY 
FOR PIP-INHIBITOR
The wells of high binding microtitre plates (Nunc)
were coated with 1 ug/ml F (a b ') anti-PIP-inhibitor in 10
2
mM carbonate/bicarbonate buffer (pH 9-6, 100 ul/well) for
o
18 hours at U C. The wells were washed five times with 
PBS-Tween (PBS containing 0.05% v/v Tween-20), and the 
unreacted sites blocked by incubation for 1 hour at room 
temperature with PBS-Tween containing BSA (0.1% w/v) (200 
ul/well). The wells were then washed five times with PBS- 
Tween, and incubated with known concentrations of purified 
PIP-inhibitor, or test samples, for one hour at room 
temperature. After washing five times the wells were 
incubated with a 1:1000 dilution of biotin-anti-PIP-
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inhibitor (100 ^ ul/well) for another one hour at room 
temperature. Following a further five washes, HRP-avidin 
at 1:1000 dilution (100 Ja 1/well) was added and the 
incubation continued for further hour at room temperature. 
Removal of unbound enzyme by washing five times in PBS- 
Tween was followed by the developing reaction in which 100 
ul of the developing reagent (25 ml 0.1 M citric acid and 
25 ml 0.2 M di-sodium hydrogen phosphate, containing 17 jal 
hydrogen peroxide and 17 ug O-phenyldiamine, pH 5.4) was 
added to each well. The reaction was terminated by the 
addition of 2 5 of 4 N sulphuric acid per well, and the 
colour intensity read using an automatic MR700 microplate 
ELISA reader at U-92 nm (Dynatech Laboratories Ltd.).
3-1.27 SUCROSE DENSITY GRADIENT CENTRIFUGATION
Sucrose solutions were made up in VBS. Discontinuous
gradients composed of 1 ml of 10%, 20%, 30%, and 40%, were
formed on ice in 13 x 51 mm polyallomer centrifuge tubes.
Five hundred microlitres (500 yil) of the sample was layered
carefully on the top of the gradient which was then
o
centrifuged at 105.000 g for 16 hrs at 4 C on a Beckman 
model L2-656 ultracentifuge. Fractions of 100 yal or 200 jil 
were collected from the base of the tube using a sucrose 
gradient fractionator. The IgM, IgG, Clq, C3 and albumin 
content of each fraction was measured by single radial 
diffusion (2.6), the content of PIP-inhibitor by ELISA and 
radioactivity using an automatic gamma counter.
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3-1.28 DETERMINATION OF THE TRUE MOLECULAR WEIGHT OF THE 
PIP-INHIBITOR
Five microgrames (5 ^ Mg) of PIP-inhibitor was
electrophoresed on a series of different percentage (6, 7,
8, 9« 10, 11 and 12.%) polyacrylamide gels (SDS-PAGE 2.8)
run under reducing conditions. The molecular weight of the
PIP-inhibitor was determined for each gel, and the true
molecular weight was calculated by plotting percentage
gel against the logarithm (log ) of the molecular weight
10
and extrapolating the line to 0% gel concentration.
3-1.29 NEURAMINIDASE TREATMENT OF THE PIP-INHIBITOR
A mixture of 0.5 rag PIP-inhibitor in 50 mM sodium
acetate buffer (pH 5-5). and 5^ g  neuraminidase, was 
o
incubated at 37 C for one hour. The mixture was examined 
by immunoelectrophoresis (2.5) and by using SDS-PAGE (2.8) 
run under reducing conditions in 10% gels.
3-1-30 CHEMICAL DEGLYCOSYLATION OF THE PIP-INHIBITOR 
(Edge et al. , 1981)
The PIP inhibitor was deglycosylated by the incubation
of 0.5 ml trifluoromethylsulphonic anhydride (TFMS),
containing 5% (v/v) anisole with 2 mg salt free lyophilised
PIP-inhibitor in two stoppered conical glass tubes. The
tubes were flushed with nitrogen, stoppered and sealed with
o
parafilm. The reactants were incubated at 0 C for 1 and 2
hours, after which times the reactions were terminated by
the addition of anhydrous sodium carbonate, with vortexing
to neutralise the acid. The reactants were then dialysed
o
against water at U C and the precipitated protein was
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lyophilised. The deglycosylated protein was examined by 
SDS-PAGE (2.8) nun under reducing conditions in 10% gels.
125
3.1.31 REDUCTION AND ALKYLATION OF [I]-PIP INHIBITOR
125
Two hundred and fifty microgratnes (250 yag) [I]-
PlP-inhibitor in 1 ml PBS, were incubated with 10 ja 1 of 0.1
M dithiothreitol for 30 minutes at room temperature,
followed by the addition of 100^ul ice-cold 0.015 M
iodoactamide. The reaction was allowed to proceed for 2 
o
hours at 0 C, after which the reduced and alkylated protein
o o
was dialysed against PBS at U C and stored at -20 C.
3-1.32 PROTEOLYTIC DIGESTION OF NATIVE AND REDUCED & ALKYLATED 
PIP-INHIBITOR
125
Native or reduced and alkylated [I]-PIP-inhibitor
were incubated with trypsin, chymotrypsin, V8 protease, and
elastase in PBS at enzyme substrate ratio of 1:10, 1:100,
1:1000 for the native, orl:10, 1:100, 1:1000, 1:10 000, and
o
1:100 000 for reduced and alkylated protein, at 37 C for 1 
and 2U hours. The digestions were terminated by the 
addition of Laemmli sample buffer (2.8), and analysed by 
SDS-PAGE (2.8) using 15% gels run under reducing 
conditions. The gels were then stained (2.9). dried, and 
the distribution of the radioactivity was analysed by 
autoradiography (Swanstrom & Shank, 1978).
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RESULTS
3-2.1 PURIFICATION OF THE PIP-INHIBITOR (METHOD 1)
During IgG-Sepharose chromatography of normal human 
serum, the PIP-inhibitory material was eluted from the 
column as a single peak, along with other IgG-binding 
proteins (Fig. 3.1), using 2 M guanidine-hydrochloride, and 
was not found elsewhere in the chromatogram. Previous 
attempts to elute the PIP-inhibitor with low pH buffer 
(glycine-HCl pH 3.0) succeeded in only eluting a small 
proportion of the PIP-inhibitor from the column. The PIP- 
inhibitory material from the IgG-Sepharose column (50 ml) 
had a total protein concentration of 0.91 mg/ml and 
p r o d u c e d % inhibition of PIP.
Protein A-Sepharose chromatography of this pool (Fig. 
3.2) resulted in most of the PIP inhibitory material being 
excluded from the column, while IgG, the main contaminant 
was bound. The exclusion peak, contained 280 yjg/ml of 
protein and showed H2% inhibition of PIP. This peak (6& 
ml) was applied to Con.A-Sepharose affinity chromatography 
(Fig. 3*3), which resulted in the PIP-inhibitor being 
confined to the first U0 fractions, which produced 25% 
inhibition of PIP.
On SDS-PAGE run under reducing and non-reducing 
conditions, the purified PIP-inhibitor showed a single band 
with a molecular weight of 60 kD (Fig. 3-&). The 
preparation also gave a single precipitin line when 
analysed against anti-whole human serum by double diffusion 
in agarose gel (Fig. 3*15) and immunoelectrophoresis (Fig. 
3-16) •
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FiKure
IgG-Sepharose chromatography of 
normal serum. Total protein ( — ) measured 
at 280 nm, inhibition of PIP (.•-— • ), 
conductivity ( A — A ). The points of 
application of 150, 500 mM NaCl and 2M guanidine
hydrochloride are shown by the arrows.

Figure. 3,2:
Protein A-Sepharose affinity chromatography 
of PIP-inhibitory peak from IgG-Sepharose column.
Total protein was measured at 280 nm ( ----  ),
inhibition of PIP (•— •) measured by the described 
assay in 3 .1 .5 .
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Con.A-Sepharose affinity 
chromatography of exclusion peak of 
protein A-Sepharose column. Total 
protein measured by absorbance at 
280 nm( — — — ), inhibition of PIP 
(•— •) by the described assay.
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.Figure 3 , 4 :
Silver* stained 10% SDS-PAGE. Lanes 1-7 run 
under reducing conditions, lanes 8 and 9 run under 
non-reducing conditions. Lanes were loaded as follows: 
(1) molecular weight markers; (2) normal human 
serum; (3) PIP inhibitory peak from IgG-Sepharose;
(4) exclusion peak of protein A-Sepharose;
(5) material bound to protein A-Sepharose;
|
(6) exclusion peak of Con.A-Sepharose; (7) bound
material to Con.A-Sepharose; (8) molecular weight
markers; (9) exclusion peak of Con.A-Sepharose. j 
The single band in lanes 6 and 9 has an apparent 
molecular weight of 60 kD.
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Figure 3jJLl.
7. 5# SDS-PAQE of purified gp60
(prepared by method l)(lane 1) and normal human 
serum (lane 2) stained with PAS.
1 2
As the PIP-inhibitor reacted positively in the PAS 
reaction (Fig. 3*5), it was considered to be glycoprotein. 
It was therefore called glycoprotein 60 (gp60), and this 
name will be used throughout the reminder of this thesis.
A purification summary of gp60 prepared by Method 1 is 
presented in Table 3.1. Using an ELISA procedure (3.1.26), 
the concentration of gp60 was measured in the starting 
material and in pools prepared at different stages of the 
purification procedure. It can be seen that the starting 
material contained 1.6 mg of gp60 (32 ^ ug/ml), while the 
purified protein preparation contained 783 J*S. a yield of 
U-9%* and the degree of purification was 1518-fold.
During subsequent investigations aimed at the 
characterisation of gp60, sucrose density gradient and gel- 
filtration chromatography (Sephacry1-S300) studies of 
purified gp60 and gp60 in whole human serum were performed. 
It was found that in normal human serum the majority of the 
gp60 sedimented immediately along with IgM (19S) in sucrose 
density gradient centrifugation and was eluted in a similar 
position to IgM on gel filtration chromatography. A minor 
proportion (approximately 5-10%) appeared to be of low 
molecular weight (see section 3.2.5*)• The purified gp60 
had the properties of the low molecular weight material on 
sucrose density gradient centrifugation and Sephacryl-S300 
gel filtration chromatography. The possibility that the 
low molecular weight material represented proteolytically 
cleaved gp60 was considered, so it was decided to repeat 
the gp60 preparation using protease inhibitors throughout 
the purification procedures.
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3-2.2 PURIFICATION OF gp60 (METHOD 2)
Method 1 of the gp60 purification procedure was scaled 
up to increase the yield of gp60 by using 500 ml of normal 
serum. As in method one, gp60 was eluted from IgG- 
Sepharose as a single peak (Fig. 3-6). which contained 1.6 
mg/ml total protein, 96 gp60 and showed 96%
inhibition of PIP.
IgG contaminants were removed by protein A-Sepharose 
chromatography, while most of the gp60 was confined to the 
exclusion peak, which contained 0.6/1 mg/ml total protein.
(160 ml) was concentrated by ultrafiltration to 10 ml which 
was divided into two 5 ml aliquots which were applied 
separately to a Sephacryl-S300 gel filtration column. Gp60 
co-eluted with IgM, C/tbp and fibronectin in the first 
protein peak (Fig. 3-7)* The combined gp60 pools from the 
two chromatograms contained 1.7 mg/ml total protein, 331
was subjected to heparin-Sepharose affinity chromatography, 
which successfully removed the major contaminants, IgM,
C&BP and fibronectin which were bound to the column while 
gp60 appeared in the exclusion peak (Fig. 3 -8 )• This
pooled exclusion peak contained 8.2 mg gp60 and inhibited 
PIP by 95%. The preparation gave a single band of 60 kD 
when analysed by SDS-PAGE run under reducing and non­
reducing conditions in 10% gels (Fig. 3- 9 ). and a single 
precipitin line against anti-whole human serum on double 
diffusion in agarose gel (Fig. 3-15 ) and on immuno- 
electrophoresis (Fig. 3-16).
gp60 and showed 85% inhibition of PIP. This pool
gp60 and produced 97% inhibition of PIP. This pool
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.Figure 3.6:
IgG-Sepharose affinity chromatography 
of normal serum (method 2). Total protein 
measured by absorbance at 280 nm ( ^ — •),
conductivity ( A  A), gp60 concentration
measured by ELISA (O— o).
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Fifture 3, *3 :
Sephacryl-S300 gel filtration of the 
exclusion peak of protein A-Sepharose.
Total protein ( ------ ) measured at
O. D and gp60 levels ( O —  Q> ) measured by ELISA. 
280
The arrows show the elution volume for IgM, Clq, 
IgG and albumin.
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Figure 3.8: Heparin-Sepharose chromatography
of Sephacryl-S300 gp60 pool. Total protein (• — •)
was measured by BCA assay, conductivity (Ak — '“A) 
o
at 0 C and gp60 by ELISA. The arrow show 
the application point of the gradient which 
consisted of 300 ml starting buffer and 300 ml 
starting buffer containing 0.75 FI NaCl.
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PjgUEg. 3,..9.:
10# SDS-PAGE for gp60 purified by method 2. 
Lanes 1 and 2 run under reducing conditions, 
lanes 3 and it run under non-reducing 
conditions. Lanes 1 and 3 were loaded with 
molecular weight markers, and lanes 2 and it 
were loaded with gp60 purified by method 2.

A purification summary for the purification of gp60 by 
Method 2 is presented in Table 3-2, where the starting 
material contained 16 mg of gp60 (32^ug/ml), while the 
purified preparation contained 8.2 mg, representing a yield 
of 51% and a degree of purification of 1956-fold.
3-2.3 PURIFICATION OF gp60 (METHOD 3)
As it was proposed to study the functional properties 
of gp60 particularly with respect to its binding to IgG and 
inhibition of PIP, the possibility was considered that the 
harsh conditions required for the elution of gp60 from IgG- 
Sepharose might reduce its functional activity. It was 
therefore decided to purify gp60 from whole serum using a 
procedure which avoided the initial step of binding to IgG- 
Sepharose.
During the DEAE-Sephacel anion exchange chromatography
10
(Fig. 3-qq )« most of the IgG was eliminated in the 
exclusion peak. Gp60 was eluted from the column with a
o
linear salt gradient at a conductivity of 8-16 mS (at 0 C). 
The gp60 pool was applied to Biorex-70 cation exchange 
chromatography (Fig. 3- 11)• which resulted in the removal 
of most of the proteins in the exclusion peak, while gp60 
was eluted by a linear salt gradient.
This pool was concentrated and subjected to gel 
filtration (Sephacryl-S300), which resulted in the co­
elution of gp60 with IgM, CbBP and fibronectin in first 
protein peak (Fig. 3-12^* This peak inhibited PIP by 89%. 
and contained 0.92 mg/ml total protein and 195yug/ml gp60. 
On the application of gp60 pool to heparin-Sepharose, all
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Figure 2LJLQ.'-
DEAE-Sephacel anion exchange chromatography of 
normal serum. Total protein ( • ) measured by BCA
assay, conductivity (#*.), gp60 ( 0 ) by ELISA. The
arrow shows the application point of the gradient 
which consisted of 51 starting buffer and 51 
starting buffer containing 0.5M NaCl. Gp60 was 
eluted at 8 mS.
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Figure 3 ,11:
Biorex-70 cation exchange chromatography of gp60 
pool from DEAE-Sephacel column. Total protein
( • ---•), conductivity (A.---A.), gp60 (O— o)
measured by ELISA. Gp60 was eluted with a gradient| 
of 11 starting buffer and 11 starting buffer 
containing 0.7 M NaCl.
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Figure 3*. 1.2:
Sephacryl-S300 gel filtration 
chromatography of gp60 peak from Biorex-70 
column. Total protein measured by BCA assay 
( ----  ), gp60 by ELISA (O--0).
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of the contaminants were bound to the column, while gp60 
(PIP inhibitory) activity was confined in the exclusion 
peak (Fig. 3-13)- This preparation was homogeneous when 
analysed by SDS-PAGE run under reducing and non-reducing 
conditions in a 7.3% gel, which showed a single band with a 
molecular weight of 60 kD (Fig.
The preparation was also tested against anti-whole 
human serum by double diffusion analysis in agarose gels, 
which resulted in the appearance of a single precipitin 
line (Fig. 3-1 3)•
A purification summary for gp60 preparared by method 3 
is presented in Table 3-3- The starting material contained 
19 mg gp60 (19 yug/ml), while the pure preparation contained 
7-2 mg gp60 representing a yield of 38 % and a degree of 
purification 3360-fold.
3-2.4 CHARACTERISATION OF gp60
The protein concentration of gp60 preparations were
determined by O.D , Folin assay and BCA assay (2.4). Both
280
O.D and Folin assay results agreed with each other,
280
while the BCA assay results gave a value which was one
sixth of the former two. The OD and Folin assays
280
measure the content of aromatic amino acids, particularly 
tyrosine and tryptophan , while the BSA assay, a modified 
Buiret technique, measures peptide bonds. This discrepancy 
suggested that gp60 possesses a high content of aromatic 
amino acids, which has been confirmed by Mr. Tony Willis 
(MRC Immunochemistry Unit, Oxford).
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Heparin-Sepharose chromatography of gp60 peak 
from Sephacryl-S300 column.
Total protein (•— •) measured by BCA assay, 
gp60 ( O — -0) by ELISA. The bound proteins 
were eluted with 1M NaCl.
Total p ro te in  mg/ml gp60jug/ml
(•— •) (O— O)
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Figure 3.14;
Silver stained 7*5# SDS-PAGE, lanes 1 and 2 run 
under reducing conditions, lanes 3 and 4 run 
under non-reducing conditions. Lanes 1 and 3 
were loaded with molecular weight marker, and 
lanes 2 and 4 were loaded with gp6o purified by 
method 3-

Figur.fi 3..15:
Double diffusion analysis in agarose gel of
gp60 purified by method 1 (well 1), gp60
purified by method 2 (well 2), gp60 purified by 
method 3 ( well 3) and normal human serum (well ft). 
Center well ( 5) contained antiserum to whole 
human serum. Anti-normal human serum produced a
line of complete identity between the three gp60
preparations and normal serum.
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On SDS-PAGE, the three preparations showed a single band 
with a molecular weight of 60kD when run under reducing and 
non-reducing conditions. Double diffusion analysis of the 
three preparations of gp60 against anti-whole human serum 
resulted in single precipitin lines with gave reactions of 
complete identity with each other. ( Fig. 3. -| 5 ) .
On Immunoelectrophoresis gp60 prepared by method 1
migrated as a prealbumin when tested against anti-whole
human serum while gp60 prepared by methods 2 and 3 gave a
single arc in the B /  ^  region (Fig. 3*^5 )•
2
3.2.5. SUCROSE DENSITY GRADIENT CENTRIFUGATION AND GEL 
FILTRATIION STUDIES
On sucrose density gradient of normal serum, it was 
found that the majority of gp60 had a 19 S sedimentation 
coefficient while approximately 5-10% sedimented with a 
coefficient of 2.9S (Fig. 3- -jq ) • Fractionation of normal 
serum on gel filtration (Sephacryl-S300) showed that most 
of gp60 which was present had a molecular weight of 1000 
kD, while a minor proportion (approximately 5-10%) eluted 
from the column with a molecular weight of 58 kD. Gp60 
(prepared by method 1) sedimented at 2.9S and on gel 
filtration chromatography it eluted with an apparant 
molecular weight of 58 kD. Gp60 prepared by methods 2 and 3 
showed a sedimintation coefficient of 19S and molecular 
weight of 1000 kD on sucrose density gradient and gel 
filtration chromatography respectively (Figs. 3*'18* 3*'is0*
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Immunoelectrophoresis of normal serum (wells 1 
and S’), purified gp60 polymer prepared by method 
2 ( well q.), purified gp6o monomer prepared by 
method 1 ( wellsJL^) . Antiserum to whole human 
serum is in troughs a and d, and anti-gp60 is in 
troughsk/C a n d A n o d e  to the left.

Figure 3.17:
Immunoelectrophoresis of normal serum (well 1) 
and purified gp60 polymer prepared by method 3 
(well 2). Antiserum to whole human serum is in 
troughs a and c and anti-gp60 in trough b. 
Anode is to the left.

Figure 3.18;
Sucrose density gradient centrifugation of 
normal serum ( •-•) , gp6o prepared by method 1
(A.— & ) and gp60 prepared by method 2 ( A. ^  ).
Gp60 concentrations in 250 ul fractions were 
measured by ELISA (3-1*26), while concentrations 
of IgM, Clq, C3» IgG and albumin were measured 
by single radial immuno-diffusion.
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Figure 3^ 13.-
Distribution of gp60 on Sephacryl-S300 gel
Filtration of normal serum (O— 0 ), gp60 prepared
by method 2 {k— k  ) and gp60 prepared by method 1
(A-A). Total protein ( — • ) was measured by
O.D nm and gp60 levels were measured by ELISA. 
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3.2.6 STUDIES OF gp60 AS A GLYCOPROTEIN
Gp6o (pr-epar-ed by method 3) was sensitive to 
neuraminidase treatment. The neuraminidase-treated gp60 
showed a reduction in its molecular weight from 60 to 52 kD 
when tested by SDS-PAGE run under reducing conditions,
(Fig. 3.20') It also showed a shift in it’s electrophoretic 
mobility from B2/ ^  to . These findings indicate that 
gp60 contains significant amounts of sialic acid 
(Fig. 3. 21*> •
On chemical deglycosylation by TFMS, gp60 showed a 
reduction in its molecular weight from 60 kD to ll8 kD when 
tested by SDS-PAGE under reducing conditions (Fig. 3*20-)*
The determination of the true molecular weight of gp60 
from different percentage gels (Fig. 3. 22)* showed a true 
molecular weight of &3 kD. Thus, 28% of the weight of gp60 
is carbohydrate.
3-2.7 LIMITED PROTEOLYSIS OF gp60
Gp60 was relatively resistant to proteolysis by trypsin 
(Fig. 3..3 ), chymotrypsin (Fig. 3 .2 4), V8 protease (Fig.
3• 25>) and elastase (Fig. 3-26 0. Cleavage only occured at 
high enzyme: protein ratio (1 :1 0, 1 :100) and required
relatively long incubation periods (1-24 hours). Reduction 
and alkylation of the molecule did not seem to affect it’s 
proteolytic cleavage to a great extent (Figs. 3*27* 3«28 *
3 .; 29*. 3.3 0).
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Figure 3 tlQ:
Comassie-blue stained 10% SDS-PAGE run under 
reducing conditions. Lanes were loaded 
as follows:-
Lane 1: Molecular weight markers.
Lane 2: Gp60 prepared by method 2.
Lane 3: Neuraminidase treated gp60 prepared by
method 2.
Lane tl: TFMS treated gp60 prepared by method 2.
The single bands in lanes 2, 3 and 4. has
an apparent molecular weights of 60 kD, 52 kD 
and 4.8 kD.

Figure 3-21:
Immunoelectrophoresis of normal serum (well 1), 
gp60 purified by method 2 (well 2) and 
neuraminidase treated gp6o (well 3). Antiserum 
to whole human serum is in troughs a and c, and 
anti-gp60 is in trough b. Anode to the left.

Figure 3 ,22.:
De-termination of the true molecular weight of 
gp60. The molecular weight of purified gp60 was 
determined by SDS-PAGE analysis using a series 
of different gel concentrations. The apparent 
molecular weight was plotted against the 
corresponding gel concentration. The true 
molecular of gp60 at 0% gel concentration was 
shown to be &3 kD.
% gel
10 H
43
30 60 100
kD
Figure 3.23:
Autoradiograph of SDS-PAGE of limited 
125
proteolysis of [I]-gp6o by trypsin run under
reducing conditions. The lanes were loaded as 
follows:
Lane C: control
Lanes 1 and U trypsin/gp60 (1/10 ratio)
Lanes 2 and 5 trypsin/gp60 (1/100 ratio)
Lanes 3 and 6 tr-ypsin/gp60 (1/1000 ratio)
Lanes 1, 2 and 3 were digested for 1 hour at
o
37 C
Lanes U , 5 and 6 were digested for 2U hrs at
o
37 C.
I\
1
Figure 3.,2A.:
125
Chymotrypsin limited proteolysis of [I]—
gp60. symbols and conditions are the same as 
figure 3.23.
c 1 2 3  C 4  5 6
Autoradiograph of SDS-PAGE of limited proteolysis 
125
of CI3—gp60 bv VS protease run under
reducing conditions. The lanes were? 1oaded as
fol1ows:
Lane Cs control L I .go 60
Lanes 1 and 4:: VS prote?ase/gp60 < 1 / 10 rat i o)
L a n e s- .ti. a n d 5 s V S p r o t e a s e / g p 6 0 < 1 / .1.00 r at i o )
Lanes, 3 and 6s VS prot.ease/gp60 (1/1000 rat i o>
Lanes 1 , 2 and 3 wee re digested for 1 hour at
o
37 C„
Lanes 4 
o
37 C»
, 5 and 6 we?re digested for 24 hrs at

Fi_qure
Autoradiograph of SD9-PABE of limited proteoly
125
of EI 3—gp60 by elastase run under reducing
conditions- The lanes were loaded as in figures

E-Lolle? E^SZj*.
Autoradiograph of SDS—PAGE of limited proteolysis.
1 3
of reduced and alkylated CI Ll-~gp60 by trypsin
run under reducinq condi t i o n s T h e  1 anes were loaded 
as tol1ows:
125
L a n e Cs E e d u c e d a n d a 1 k y 1 a t e d L I 1 g p 6 0„
Lanes 1 and 6:: trvpsin/gp60 (1/10 ratio)
Lanes 2 and 7s trypsin/gp60 (1/100 ratio)
Lanes 3 and 8s trypsin/gp&O (1/1000 ratio)
L a n e s 4 a n d 9 s t r y p s i n / g p60 (1 /10000 r a t i o )
L a r i & s 5 a n d 10; t r y p s i n / g p 6 0 <1/100  0 0 0  r a t i o )
Lanes 1, 2, 3, 4 and 5 were digested for .1. hr 
o
a t 3 7 u »
Lanes 6, 7-, 8, 9 arid 10 were digested for 24 hrs
o

Eisycii -I-i.2&i.
Autoradiograph of SDS--PAGE o-f limited proteolysis
. 125
o f reduced and a 1 ky 1 at ed i" I 3 — gp60 wi t h
chymotr ypsi n » 3" he lanes were loaded as in
•figure 3.2\*

Aut or ad i ograph o-f SDS-PAGb o f 1 i mi ted prot. eol y si s:,
.{ ■**! rrI uJ
of reduced and alkylated (III—gp60 with
VS prot ease. The 1 a nee were? 1 oaded as;, described

h i g u r e  3^.30;
Autoradiograp h o f S D S—P A G E o -f 1 i m i t e d p r o t. e d  .!.
125
of reduced and alkylated C13—gp60 by 
elastase. The lanes were? loaded as in figure

3-2.8 ANTISERUM PRODUCTION
On double diffusion against normal human serum, anti-gp60 
produced a single precipitin line which gave a reaction of 
complete identity with all three purified gp60 preparations 
(Fig. 3.3 3) -
On Immunoelectrophoresis of normal human serum, anti- 
gp60 produced a single precipitin arc which overlapped the 
3^2 and^regions (Fig. 3 . '1-6).
The specificity of the antiserum was further confirmed 
by immunoblotting analysis of normal human serum and 
purified gp60 (prepared by method 1) on 10% SDS-PAGE, in 
which the IgG fraction of the antiserum detected a single 
band with a molecular weight of 60 kD (Fig. 3.3 2)* This 
band was not seen when normal rabbit IgG was used.
Furthermore, the antiserum did not cross-react with 26 
antisera to different plasma proteins (Table 3*&) on double 
diffusion in agarose gels. The antiserum was also analysed 
by Dr Chester Alper, (Centre for Blood Research, Boston, 
Massachusettes, USA). The antiserum was shown to react
monospecifically with normal human serum, but the identity
\
of the protein which was detected by the antiserum could 
not be identified. A list of the 57 antisera to different 
human plasma protein antisera which did not cross-react 
with the anti-gp60 in Dr Alper's laboratory are shown in 
Table 3 .5.
3.2.9 Gp60 ELISA
The IgG fraction of the anti-gp60 antiserum was used 
for the development of an ELISA (3 .1 .2 6 ). The assay was
87
Figure 3-..31:
Double-diffusion of gp60 preparations in agarose 
gel. Gp60 purified by method 1 (well 1). gp60 
purified by method 2 (well 2), gp60 purified by 
method 3 ( well 3) and normal human serum (well 
tl) . Antiserum to gp60 (purified by method 1) Is 
in the central well (5).

Figure 3*32:
Anti-gp60 immunoblot of SDS-PAGE of normal 
human serum (lane 1), inhibitory peak from IgG- 
Sepharose column 3.1.U (lane 2), gp6o purified 
by method 1 (lane 3 * )• Lanes 1 - 3  run
under reducing conditions.

TABLE 3.4
Antisera which did not react with gp60
Anti-Prealbumin
Anti-tU acid glycoprotein
Anti-IgG
Anti-IgA
Anti-IgM
Anti-Transferrin
Anti-Albumin
Anti-Clq
Anti-Cls
Anti-C4
Anti-C2
Anti-C3
Anti-C5
Anti-C6
Anti-C7
Anti-C8
Anti-C9
Anti-Factor B
Anti-Factor H
Anti-Factor I
Anti-Cl-Inhibitor
Anti-C4 Binding Protein
Anti-S-protein
Anti-^2“9lycoProte:*-n 1
TABLE 3.5
List of antisera which did not cross-react with anti-gp60 
(tested in Dr. Alper's laboratory)
Anti-^ B lipoprotein
Anti-P Component of Amyloid
Anti-Thyroxine binding globulin
Anti-Prothombin
Anti-Haptoglobin
Anti-Cl inhibitor
Anti-Gc globulin
Anti-Hemopexin
Anti-IgD
Anti-Prealbumin
Anti-Transferr in
Anti-C4BP
Anti-C8 fl( / ^
Anti-C3
Anti-Fab k + light chains
Anti-IgG
Anti-IgA
Anti-IgM
Anti-Properd in
Anti-C4
Anti-Albumin
Anti-Orosomucoid
Ant i-0(J.-anti trypsin
Anti-IX^-Hs glycoprotein
Anti-J32-glycoprotein 1
Anti-Factor H
Anti-C-reactive protein
Anti-Ceruloplasmin
Anti-free lambda chains
Anti-free Kappa chains
Anti-IgE
Anti-factor B
Anti-C5
Anti-Clq
Anti-Clr
Anti-Cls
Anti-Factor Vlll-related antigen 
Anti-lactoferr in 
Anti-Plasminogen 
Anti-lysozyme
Anti-Pregnancy associated antigen
Anti-Human placental antigen
Anti-secretory IgA
Anti-Fibrinogen
Anti- 2^ Microglobulin
Anti-O^-fetoprotein
Anti-IgG Heavy chain
Anti-IgA
Anti-IgM "
Anti-IgD "
TABLE 3.5 (continued)
Anti-Gammaglobulins 
Anti-Thrombin III 
Anti- 1-ant ichymo trypsin
Anti- 2-macroglobulin 
Anti-Ferritin
Anti-IgE Heavy chain 
Anti-tissue A Component
reproducible and sufficiently sensitive to detect as little 
as 2.3 ng/ml gp60 without any interference from IgM-RF.
The standard curve was linear up to 600 ng/ml (Fig 3-3~3)- 
The intra-assay variation was determined by performing 
triplicate assays on each of six normal and six
rheumatoid arthritis sera and was shown to be + 2 .U% of the 
mean. The interassay variation was measured by repeating 
the assays on the same sera on three consecutive days and 
was shown to be + 5-6% of the mean (Table 3.6).
3 .2 .IO INHIBITION OF PIP
The addition of increasing quantities of gp60 
(prepared by method one) to normal serum produced a dose- 
dependent inhibition of PIP, which was maximal at a 
concentration of 100 ug/ml (Fig. 3*3 4). Gp6o also inhibited 
the ability of normal serum to solubilise preformed IC in 
a dose-dependent fashion (Fig. 3*34). The inclusion of Fab 
fragments of anti-gp60 in the reaction mixture abrogated 
the inhibitory effect of gp6o on PIP, while Fab fragments 
of normal rabbit IgG had no effect. Gp6o, purified without 
the IgG-Sepharose affinity chromatography (method 3)* was 
four-times as effective as those gp60 preparations 
prepared by IgG affinity chromatography (methods 1 and 2) 
in inhibiting PIP and solubilization (Fig.3.35). All the 
three preparations of gp60 were much more effective at 
inhibiting PIP than solubilization.
Gp60 was more effective at inhibiting PIP and 
solubilization of IC formed at four-times antibody-excess 
and at equivalence than those formed at four-times antigen-
Figure 3,33:
Gp60 ELISA standard curve.
A^g2nm
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Zigyna 3-34;
Effect of gp60 (prepared by method 1) on PIP (a) 
and solubilization (b). Maximum inhibition of 
PIP was achieved at a concentration of 100 ug/ral 
( • — ®). Fab fragments of anti-gp60 (1 mg/ml)
abolished the inhibitory effect of gp60 ( O  O)t
while Fab fragments of normal rabbit IgG had no 
effect ( k—  A. ) .
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Figure
Effect of different gp60 preparations on 
PIP (a) and solubilization (b).
Gp60 prepared by method 1 ( A  Jl )
Gp60 prepared by method 2 ( • ---  • )
Gp60 prepared by method 3 ( 0 —  0 )
\\
<0
o
excess (Fig.3.36).
Kinetic studies of the effect of gp60 (prepared by method 
1) on PIP and solubilisation indicated that for maximum 
inhibition to occur gp60 had to be present at the time of 
IC formation (Fig. 3*36 )• The percentage inhibition of PIP 
and solubilization decreased as the time between IC 
formation and the addition of gp60 to the serum increased.
In the inhibition of PIP system, gp6o did not cause the 
reprecipitation of IC which were already soluble.
3-2.ll EFFECT OF PROTEASE INHIBITORS ON GP60 ACTIVITY
The ability of gp60 to inhibit PIP and solubilisation
was not affected by it’s incubation with SBTI (1 mg/ml) or
o
PMSF (ImM) for 30 minutes at 37 C prior to it ’s use in PIP 
and solubilisation assays (Table 3«7).
3-2.l2 EFFECT OF gp60 ON COMPLEMENT
The addition of purified gp60 to normal serum did not 
reduce the haemolytic activities of Cll and C2 (5.1.10;
o
5.1.11) during an incubation period of 30 minutes at 37 C 
(Table 3.8).
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Fi gure 3.^6:
Kinetics of gp60 action on (a )PIP and (b) 
solubilization.
(a) Gp60 (100 ug/ml), prepared by method 1, was 
added to a PIP assay at the time of formation 
of IC and at timed intervals afterwards. The % 
soluble was measured after an incubation period 
of 60 minutes.
(b) The same concentration of the same gp60 
preparation was added to a solubilization assay 
at time 0 (the time of addition of the serum to 
the immune precipitate) or at timed intervals
afterwards. The % IC soluble after 60 minutes
o
at 37 C was measured. IC were formed at 
equivalence ( • — o ) or at four-times antibody
excess (O  —  Q  )> or at four-times antigen 
excess
Kinetics of action of 100 ug/ml gp60 (prepared 
by method 1) on PIP and solubilization of IC 
formed at four-times antibody excess (q  — o )« 
equivalence (• —  •) and four-times antigen 
excess. Gp60 was added at time 0 of IC formation 
and 50 ul aligoutes were removed at the shown 
time intervals.
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E-f-fect o-f gp60 on normal serum C4 and C2 levels
gp60 added 04 units/ml U2 units/ml
100 jaq/ml 22.400 2.390
50 j-iq/ml 24.7S0 2.660
25 jjq/ml 25.100 2. 120
12.5 ^jg/ml 23.560 2.650
Control 23.540 2.500
Gp60 was added to serum at the -final concentrations
o
shown prior to incubation at 37 C -for 30 minutes, 
after which levels o-f C4 and C2 were measured by 
haemolytic assays.
DISCUSSION
PURIFICATION OF gp60
Prior to the successful purification of gp60 from 
normal human serum, a number of attempts had been made to 
purify PIP-inhibitory material from rheumatoid arthritis 
serum. These preparations consisted mainly of IgM 
rheumatoid factor (IgM-RF) (Mitchell et al.,198&)* although 
on SDS-PAGE analysis these preparations also contained a 60 
kD band in addition to the 70 kD heavy chains and 25 kD 
light chains of IgM (Mitchell et a l u n p u b l i s h e d  
observations; Levine R.P personal communication). However, 
in addition to the report from Mitchell et al.(1984), two 
further papers (Balastrieri et al.; O ’Sullivan et al., 1988)
reported that IgM-RF inhibited PIP. Neither of these 
reports contained data on SDS-PAGE analysis of the IgM-RF 
preparations.
The observation from this laboratory that serum levels 
of IgM-RF did not correlate with levels of PIP-inhibitory 
activity (Webb et al, 1986) suggested that IgM-RF could at 
the most be responsible for only part of the PIP- 
inhibitory activity, and also suggested that a second 
factor (possibly the 60 kD protein seen on SDS-PAGE) played 
a role in the ability of rheumatoid arthritis sera to 
inhibit PIP. It was then decided to purify this factor 
from normal serum in order to avoid any problems with IgM- 
RF contamination. It was assumed that the low levels of 
PIP-inhibitory activity in normal sera were produced by the 
same factor as was present in R.A sera, but the serum
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concentrations of the factor* were much lower- in normal 
individuals.
Using three different protocols, glycoprotein 60 
(gp60) was purified on the basis of it ’s ability to inhibit 
PIP. The original protocol which involved sequential 
affinity chromatography on IgG-Sepharose, protein A- 
Sepharose and Con.A-Sepharose, resulted in an average yield 
of gp60 in five separate preparations of 119% (range 39%- 
52#), and the degree of purification was 1518-fold.
During subsequent studies on the characterisation of gp60 
it was noted that the apparent molecular weight of gp60 on 
sucrose density gradient centrifugation and gel filtration 
chromatography was much smaller than that of the mador 
portion of gp60 in whole serum (Figs 3 --jq » 3*'l9/)« It was
considered that proteolysis of gp60 during the purification 
procedure could be responsible for this discrepancy. 
Therefore, in subsequent purification procedures protease 
inhibitors were added to all buffers, and all protein pools 
were treated with PMSF. As a result of this modification 
high molecular weight gp60 was obtained using the second 
purification procedure, which differed from the first 
procedure not only in the use of protease inhibitors but 
also in requiring a gel filtration chromatography step to 
remove low molecular weight contaminants and a final 
chromatography on heparin-Sepharose to remove traces of 
IgM, C/J-BP and fibronectin which bind to IgG-Sepharose and 
exhibit similar behaviour on anion exchange and gel 
filtration chromatography. The tendency of gp60 to bind to 
Sephacryl S-300 under isotonic conditions was overcome by 
using 1 M NaCl in the elution buffer. In three
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preparations, the average yield of gp60 was 51% (range k 2% 
- 57%)* and the degree of purification was 1956-fold.
The third purification procedure was employed in order 
to have preparations of gp60 which had never been in 
contact with IgG-Sepharose. It was intended to study the 
binding of gp60 to complexed IgG, and the harsh conditions 
required for the elution of gp60 from IgG-Sepharose might 
have denatured the molecule irreversibly. Furthermore, it 
is conceivable that some gp60 might remain bound 
irreversibly to the affinity matrix. The final procedure 
involved anion exchange chromatography on DEAE-Sephacel, 
cation exchange chromatography on Biorex-70, gel filtration 
chromatography on Sephacryl-S300 followed by heparin- 
Sepharose chromatography. As in the second purification 
method, heparin-Sepharose chromatography was required to 
remove traces of IgM, C4BP and fibronectin. The average 
yield of gp60 from three preparations was 1X2% (range 38% - 
1x6%) $ and the degree of purification was 3360-fold. The 
criteria of purity were a single band on SDS-PAGE (Fig. 
3.14), a single precipitin line on double diffusion in 
agarose gel and Immunoelectrophoresis against antiserum to 
whole human serum. (Fig.3.17). Furthermore, rabbits 
immunised with purified gp60 produced a monospecific 
antiserum.
MOLECULAR WEIGHT OF gp60
On SDS-PAGE analysis gp60 appeared as a single band of 
60 kD under both reducing and non-reducing conditions (Fig.
3. 1 4 •
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Sucrose density gradient studies of whole human serum 
showed that the majority of gp60 sedimented with a 
coefficient of 19 Svedberg units (19 S), with a minor 
proportion sedimenting with a coefficient of 2.9 S. (Fig.
3*.18)* Likwise on gel filtration chromatography most of 
the gp6o in serum was eluted in a volume which corresponded 
to a molecular weight of 1000 kD with a minor proportion 
having an apparent molecular weight of 58 kD (Fig. 3.19 ).
Gp60 which had been purified by the first procedure 
had the same sedimentation and gel filtration 
characteristics as the minor serum component, hence the 
possibility that gp60 had been proteolytically digested 
during purification was considered. The incorporation of 
protease inhibitors into the subsequent purification 
procedures resulted in gp60 preparation which had 
sedimentation and gel filtration characteristics of the 
larger molecular weight fraction of serum gp60, which 
appeared to confirm this possibility. However, as gp60 
purified by all three procedures appeared as a single band 
on SDS-PAGE run under reducing and non-reducing conditions, 
it is probable that the high molecular weight form of gp60 
represents a polymer of the smaller molecular weight
material, which is probably gp60 monomer.
The larger and smaller molecular weight forms of gp60
gave a reaction of complete identity on double diffusion in
agarose gel using antisera raised against both the purified 
high molecular weight and low molecular weight 
preparations. Thus, there do not appear to be any major 
antigenic differences between the high and low molecular 
weight forms of gp60.
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Using a molecular- weight lOOOkD for- the polymer- and 60 
kD for the polymer and 60 kD for the monomer it would 
appear that the polymeric form of gp60 is made up of 16 
monomeric subunits. However, it is difficult to explain why 
gp60 dissociated into the smaller molecular weight form 
when purified in the absence of protease inhibitors. The 
purified protein was relatively resistant to proteolysis as 
judged by SDS-PAGE analysis. However, it must be 
emphasised that serum proteases were not studied. 
Furthermore, a single proteolytic cleavage which resulted 
in dissociation of the larger form into the monomeric 
subunits may not have been detected by this technique. 
Although the hypothesis that serum gp60 comprises a 
polymer, which is assembled from a number of monomeric 
subunits, has not yet been proven, for the sake of 
simplicity in the remainder of the thesis, the larger 
molecular weight form will be called gp60 polymer and the 
smaller molecular weight form called gp60 monomer.
GLYCOPROTEIN NATURE OF gp60
Although gp60 is relatively resistant to proteolysis 
as shown by the high enzyme:substarate ratios (1:10;1:100 
for trypsin chyraotrypsin, elastase and V8 protease) and the 
long incubation periods (1-24 hours) required for 
digestion, these data confirm the protein nature of gp60. 
Interestingly, reduction and alkylation of gp60 did not 
increase its sensitivity to proteolytic enzymes to any 
great extent. The observation that the gp60 band in 
polyacrylamide gels stained in the PAS reaction indicated
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that the molecule contained carbohydrate and hence was a 
glycoprotein with an apparent molecular weight of 60 kD. It 
was therefore called glycoprotein 60 (gp60). Gp60 was 
shown to be sensitive to neuraminidase by the more cathodal 
migration on Immunoelectrophoresis of the neuraminidase 
digested preparation compared with untreated gp60 (Fig.
3.2,1). This result was confirmed by the observation that 
©n SDS-PAGE analysis the apparent molecular weight of 
neuraminidase treated gp60 was reduced to 52 kD. Removal 
of all the carbohydrate with TFMS reduced the apparent 
molecular weight of gp60 to 48 kD on SDS-PAGE. This result 
was supported by the results of measuring the apparent 
molecular weight of gp60 by SDS-PAGE using a series of gels 
of different polyacrylamide content. This experiment gave 
a real molecular weight for gp60 of 43 kD.
OTHER CHARACTERISTICS OF gp60
On isoelectric focusing, gp60 in whole serum and both 
the polymeric and monomeric forms of purified gp60 had iso­
electric points of 5*1-5*3* On Immunoelectrophoresis the 
polymeric form of gp60 had p2./ ^  globulin mobility, while 
the monomeric form migrated as a pre-albumin. The large 
molecular weight of gp60 polymer makes it difficult for the 
molecule to migrate through the agarose gel so the 
precipitin arc appears at the boundary zone between the B2
When serum was electrophoresed in agarose gel and the 
gel sliced and the gp60 eluted from the slices, gp60 ( 
measured by ELISA) was found principally in the 
globulin boundary zone, but a significant amount was also
and the globulin fractions.
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found in the pre-albumin region (Fig. 3-37). This confirms 
the result of the sucrose density gradient centrifugation 
and the gel filtration studies which demonstrated that a 
proportion of serum gp60 was in the monomeric form.
The inhibitory action of gp60 on PIP was not due to 
serine protease activity as SBTI and PMSF treated gp60 was 
still able to inhibit PIP.
The protein content of purified gp60 preparations was
measured by O.D , Folin assay and by the BCA technique 
280
which is a modified Biuret assay. The former procedures 
which detect aromatic amino acids gave values six times 
higher than those of the BCA technique, which measures 
peptide bonds. This discrepancy could be accounted for by a
high aromatic amino acid content of gp60. Although we have
not yet obtained a complete amino acid analysis, 
preliminary data do suggest that gp6o has an extremly high
tryptophane content (Willis A et al, unpublished
observations). Thus for all the data reported in this
thesis, the protein content of purified gp60 preparations
was based on results of the BCA procedure.
Gp60 INHIBITS PIP AND SOLUBILISATIION
Both monomeric and polymeric forms of gp60 were able
to inhibit PIP and solubilisation. These effects did not 
occur in the presence of Fab fragments of anti-gp60, 
although Fab fragments of normal rabbit IgG did not affect 
these activities of gp60. The monomeric form of gp60 and 
the polymeric form which had been purified by IgG-Sepharose 
affinity chromatography were almost equally effective at
96
Figure 3•37- 
Immunoelectrophoresis of normal human srum 
(well 1), anti-whole human serum is in trough 
and anti-gp60 is in trough b.
An identical part of the gel was cut into 2.0
o
slices, which was eluted for &8 hours at li C 
PBS. Gp60 concentration in the eluate was 
measured by ELISA.
a
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inhibiting PIP and solubilisation. In contrast, polymeric 
gp60 which had been purified by method 3 (i.e no IgG- 
Sepharose affinity chromatography step) was four-times more 
effective at inhibiting PIP and solubilisation as the other 
two preparations (Fig. 3*35)* This finding suggests that 
either the conditions involved in the elution of gp60 from 
IgG-Sepharose denatured the molecule, or less probably, 
high affinity gp60 is not eluted from this affinity matrix. 
Gp60 was less effective at inhibiting PIP and 
solubilisation for IC formed in antigen-excess. The 
significance of this finding is unknown, however IC formed 
in antigen excess are more soluble and less likely to 
produce tissue injury than those formed at equivalence or 
in antibody excess (Theofilopoulos & Dixon, 1980). It is 
also unusual for IC to be formed at antigen excess in-vivo. 
Furthermore, IC formed in antigen-excess do not activate 
complement as well as those formed at equivalence or in 
antibody excess (Theofilopoulos & Dixon,1979)- Thus, if 
gp60 inhibits PIP by interfering with the ability of 
complement to retain in solution IC formed at equivalence 
or in antibody-excess, a significant pathogenetic role for 
gp6o could be postulated.
The dose response curves showed that gp60 was more 
effective at inhibiting PIP than solubilisation. As the 
amount of IC used in the solubilisation assays was only 
one quarter of that used in PIP assays, the relative 
resistance of solubilisation to the inhibitory action of 
Sp60 is further emphasised. PIP is absolutely dependent 
upon the classical pathway (Schifferli et al., 198I; Naama
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et al.,1983) and while solubilization is absolutely 
dependent on the alternative pathway (Czop & Nussenzweig, 
1976), the process is more effective in the presence of 
classical pathway activation (Czop & Nussenzweig, 1976)*
As gp60 binds to IgG-Sepharose, and as the ability of 
rheumatoid arthritis sera to inhibit PIP correlated with 
their ability to inhibit Clq binding to IC (Niven &
Whaley, 1986), and to inhibit CU consumption by IC (Naama 
et al, 198il), it was likley that gp60 bound to the Fc piece
of IgG and inhibited classical pathway activation. This 
would explain the relative sensitivity of PIP to the action 
of gp60.
The studies of the kinetics of the action of gp60 
on PIP and solubilisation showed that for maximum effect 
gp60 had to be present at the time of formation of the IC. 
After IC had been rendered soluble by complement, gp60 did 
not cause IC to precipitate. Thus, gp60 acts on IC before 
complement activation occurs, and does not act on 
complement-reacted IC. Thus, these data support the 
earlier argument that gp60 binds to IC by the IgG antibody 
moiety and then interferes with complement activation.
PRODUCTION OF ANTISERUM TO gp60 AND ESTABLISHING ELISA
The rabbit antisera produced against gp60 were shown 
to be monospecific by double diffusion in agarose gels and 
immuno-electrophoresis against normal human serum (Fig.
3.1 6). The specificity of the first antiserum was 
demonstrated by the ability of Fab fragments of the IgG 
fraction of the antiserum to inhibit the action of gp60 on 
PIP and solubilisation (Fig. 3-3*^0 • All antisera
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precipitated with purified gp60 on double diffusion in
agarose gels and on Immunoelectrophoresis.
The identity of the protein recognised by the antisera
was tested in this laboratory (Table 3-4) and in the
laboratory of Dr Chester Alper (Table 3*5) • The
serum protein detected by anti-gp60 was not detected by
monospecific antisera to 57 known plasma proteins (Table
3-5)- Thus gp6o appears to be a previously undescribed
plasma protein.
The gp60 antiserum was used to establish an ELISA
procedure to measure gp60 levels in biological fluids.
F(ab’) fragments were used to coat the wells of microtitre 
2
plates in order to prevent IgM-RF interfering with the
assay by binding to the Fc piece of the intact antibody.
The probe used to detect bound gp60 was intact IgG which
had been labelled with biotin. The intact IgG was used as
it was felt unnecessary to use F(ab’) fragments at this
2
stage as IgM-RF would not have bound to the wells, and so 
would not be a source of interference. The assay was 
sensitive over a wide range of concentrations, the dose- 
response curve being linear from 2.3 ng/ml to 600 ng/ml.
The assay was reproducible as shown by the low interassay 
and intra-assay variations (Table 3*6).
The assay was used succssfully to measure gp60 in 
serum fractions from sucrose density gradient and gel 
filtration chromatography, and revealed the presence of the 
polymeric form of gp60 in whole serum. It was later used to 
measure gp60 concentrations of purified preparations used 
in the experiments described in chapters ll and 5 and in
99
whole serum (see chapter 5)*
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CHAPTER FOUR 
BINDING OF GP6Q TO IMMUNOGLOBULINS
101
INTRODUCTION
The initial step in gp60 purification, affinity- 
chromatography on IgG-Sepharose, indicated that binding of 
gp60 to IgG probably played an important role in its 
ability to inhibit PIP. In this chapter I describe studies 
in which the binding of gp60 to different immunoglobulin 
isotypes and the localisation of the gp60 binding site on 
IgG was investigated. The binding affinity of gp60 for IgG 
in solid-phase IC was measured, and the interactions of 
gp60, Clq, IgM-RF, IgG—RF and Staphylococcal protein-A are 
reported.
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METHODS
ft.1.1 Gp60 PREPARATIONS
Gp60 was purified by the three procedures described in 
chapter three. The protein concentration of the purified 
preparations was determined by ELISA (3*1.26).
ft. 1.2 PURIFICATION OF HUMAN Clq 
(Tenner, Lesavre & Cooper,1981)
Serum from one unit of fresh frozen plasma was 
prepared as described in 3-1-9. and 5ml of 0.2M EDTA (pH 
7.5) was added to make the final concentration 5iwM. The 
serum was then applied to a 2.6 x 20 cm Biorex-70 column 
equilibrated in 50 mM sodium phosphate buffer (pH 7-3) 
containing 2 mM EDTA and 82 mM NaCl. After washing the 
column with 2 1 of equilibrating buffer, until the O. D
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of the column effluent was less than 0.01, the column was 
eluted with a linear salt gradient composed of 300 ml 
starting buffer, and 300 ml starting buffer containing 0.3M 
NaCl. The column was screened as in 3.1.7, and fractions 
containing Clq were detected by radial immunodiffusion 
(2.7).
The Clq pool was concentrated by ammonium sulphate
o
precipitation and then centrifuged (8000 g at 2 C for 30
minutes). The precipitate was dissolved in 10 ml5xVBS and
o
dialysed overnight at ft C against PBS. Finally, the Clq 
preparation was passed over a column (1 ml) of protein A- 
Sepharose to remove any IgG contaminants. The purity of 
the Clq preparation was tested by SDS-PAGE run under 
reducing and non-reducing conditions on a 5 % gel
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o
and then stored at - 70 C.
a. 1.3 HUMAN IgG SUBCLASS MYELOMA PROTEINS
Human IgGl, IgG2, IgG3. and IgG4 were imraunoaffinity 
purified from the sera of myeloma patients by the method of 
Bird et al, 1984. IgGl, IgG2, and IgG3 were each free 
from contamination with other isotypes, but IgG4 contained 
traces of IgG3 as assessed by haemagglutination inhibition 
assays.
4. 1. 4 PREPARATION OF Fc FRAGMENTS FROM HUMAN IgG
Human IgG was purified from normal serum and digested
with pepsin as described previously (3 .1 .1 ; 3 -1 .2 3 ).
Following dialysis against VBS the digest was passed over a
column (1.0x20 cm) of protein A-Sepharose which was washed
in VBS until the O.D of the effluent was less than 0.01.
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The bound IgG was then eluted with 0. 1 M glycine-HCl(pH 3-0 ) 
and dialysed against PBS. Five millilitres (5ml) were 
gel filtered on a Sephacryl-S300 column equilibrated in PBS 
at a flow rate of 15 ml/hr, and 2 ml fractions were collected.
The fractions were screened as in 3.1.7 , and tested by 
SDS-PAGE run under reducing and non-reducing conditions in 
10# gel.
4. 1.5 PURIFICATION OF HUMAN IgM PARAPROTEIN
Two millilitres (2ml) of IgM myeloma serum were
o
dialysed overnight at 4 C against 10 mM sodium phosphate
buffer (pH 7 .0 ). The euglobulin precipitate was recovered
o
by centrifugation (8000 g for 15 minutes at 4 C), and
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dissolved in 1 ml 5xVBS prior to dialysis against 2 1 PBS. 
The solution was then absorbed with 100 ul of packed 
protein A-Sepharose for one hour at room temperature and 
the supernatant was collected. The purity of the 
preparation was tested by double diffusion in agarose gel 
against both anti-whole human serum and anti-IgM, and also 
by SDS-PAGE run under reducing and non-reducing conditions 
in a 10# gel.
4.1.6 PURIFICATION OF HUMAN IgA PARAPROTEIN
The euglobulin precipitate of 2 ml IgA myeloma serum 
was formed and collected as in 4.1.5- The precipitate was 
dissolved in 1 ml 5xVBS and then dialysed against 10 mM 
Tris-HCl (pH 8.0) prior to absorption onto DE52 (100 ul of 
50# suspension in 10 mM Tris-HCl, pH 8.0). The supernatant 
was discarded, and after washing the matrix several times 
with starting buffer, the IgA was eluted by adding 1 ml of 
starting buffer containing 0-5 M NaCl to the ion exchange 
pellet. IgA purity was confirmed by double diffusion in 
agarose gel against anti-whole human serum and anti-IgA, 
and by SDS-PAGE run under reducing and non-reducing 
conditions in a 10 # gel.
4.1.7 PREPARATION OF IgM AND IgG RHEUMATOID FACTORS 
(Mitchell et al, 1984)
Rheumatoid arthritis serum (20 ml) was applied to an 
IgG-Sepharose column (2.5x15 cm) equilibrated in 10 mM 
Tris-HCl buffer (pH 8.0) containing 10 mM EDTA and 0.15 M 
NaCl at a flow rate of 20 ml/hr. After washing the column 
with several column volumes of the starting buffer, IgM-RF
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and IgG-RF were eluted with 0.1 M sodium acetate buffer (pH
il.O) containing 0.5 M NaCl. The two rheumatoid factors
were separated on Sephacryl-S300 column ( 2.6x90 cm)
equilibrated in 0.1 M sodium acetate ( pH il.O) containing
0.5 M NaCl, at a flow rate of 15 ml/hr and 2 ml fractions
were collected. IgM-RF was confined to the first protein
peak, whereas IgG-RF was present in the second peak. The
fractions containing IgM-RF were pooled, dialysed against
o
PBS and stored at ll C, while those which contained IgG-RF
were digested with pepsin and the F(abT)2 fragments were
purified as described in 3-1.23. The purified F(ab*)2
o
fragments were dialysed against PBS and stored at -20 C. 
.1.8 PREPARATION OF IMMUNOADSORBENT-PURIFIED IgG ANTI-BSA
Twenty millilitres (20ml) of rabbit anti-BSA were
applied to a BSA-Sepharose column (1.5 x 10 cm)
equilibrated in PBS. After washing the column extensively
with PBS until the O.D of the effluent was less than
280
0.01, the bound proteins were eluted with 0.1M glycine-HCl 
(pH 3.0) containing 0.5 M NaCl and antibody containing 
fractions were neutralised with 100 ul of 1M Tris. After 
pooling the anti-BSA was further purified by DE52 
chromatography as described in tl. 1.6.
H.1.9 RADIOLABELLING OF PROTEINS
125
IgG anti-BSA was labelled using [I] by the
chloramine-T method, while gp60, Clq, IgM-RF and IgG-RF 
were radiolabelled by the solld-phase Iodogen method
106
(2.1/1).
The specific radioactivities were; gp60 prepared by 
9
method 1 (3.&X10 cpm/ug), gp60 prepared by method 2 
8 8 
(9*6x10 cpm/ug), gp60 prepared by method 3(1.2x10
7 6
cpm/ug), Clq (l.ZlxlO cpm/ug), IgM-RF (6.1x10 cpm/ug),
7 8
F(abf ) IgG-RF (1x10 cpm/ug), and IgG anti-BSA (*J..2xlO 
2
cpm/ug).
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a. 1.10 BINDING OF PROTEINS TO MICROTITRE WELLS
Disposable U-shaped wells (Remova wells, Dynatech Labs 
Ltd.) were coated with 100 ul of the appropriate protein 
solution (0.1-10 ug/ml) diluted in 10 mM
carbonate/bicarbonate buffer pH 9-6 during an overnight 
o
incubation at H C.
a.1.11 PREPARATION OF SOLID-PHASE IMMUNE COMPLEXES (IC)
BSA-coated wells (1 ug/ml) were washed five times
with PBS-Tween (PBS containing 0.05% (v/v) Tween-20), and
the unreacted sites were blocked with 0.1 % (w/v) gelatin
in PBS (250 ul/well) except for those wells to be used for
Clq binding assays in which case 0.1% (w/v) casein was used
125
to reduce the background binding. The [I]-labelled or
non-radiolabelled IgG-anti-BSA (0.1-0.5 ug) in 100 ul of 
PBS-Tween were added to each well. After one hour 
incubation at room temperature, the wells were emptied by 
aspiration and washed five times with PBS-Tween, prior to 
counting the radioactivity, or being used for the binding 
study. This method allowed the determination of the number 
of molecules of IgG bound to each well. For each 
concentration of IgG used, the variation in antibody 
binding between wells was + li. 0% of the mean. This 
variation was consistent throughout the series of 
experiments.
Extensive washing of the wells did not remove bound
antibody under these conditions. In the experiments
described, the number of bound IgG molecules ranged from 
10 12 
2.8 x 10 to 6. it x 10 per well.
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4.1.12 Gp60 BINDING TO IMMUNOGLOBULIN ISOTYPES, IgG SUBCLASSES 
AND FRAGMENTS
After the wells were coated with IgM, IgA, IgG, or
it’s F(ab’) , Fab or Fc fragments, IgG subclasses, Clq,
2
IgM-RF or F (ab ’) fragments of IgG—RF, and blocked as
2 125
described in 4.1.11, 0.5 - 42 ng [I]-gp60 (in 100 ul
PBS-Tween) were added to each well. After incubation for 1
hour at room temperature, and washing five times with PBS-
Tween, the bound radioactivity was counted. Background
binding was determined using uncoated but blocked wells,
which were processed in the same way as the wells to which
the specific protein had been bound.
4.1.13 BINDING OF RADIOLABELLED PROTEINS TO SOLID-PHASE-IC
125 125
The binding of [I]-gp60 (0.5-42 ng), [I]-Clq
125 125
(12-385 ng), [I]—IgM—RF (6.9-120 ug) and [I]-
F(ab’) IgG-RF (6.25- 200 ng) in PBS-Tween (100 ul) to 
2
wells containing 1-8 ng IgG IC was studied. After 
incubation of one hour at room temperature, and washing 
five times with PBS-Tween, the bound radioactivity was 
determined. Non-specific binding was calculated using BSA- 
coated wells without IgG anti-BSA.
4.1.14 COMPETITION INHIBITION STUDIES
Non-radiolabelled Clq, Staphylococcus protein A,
IgM.RF or F(ab’) IgG-RF at concentrations of 25. 50, and
2
100 ng/100 ul of PBS-Tween, were incubated with 100 ul of 
125
[I]-gp60 (1.3-42 ng) in wells containing 7.7 ng bound 
IgG IC (4.1.11) for one hour at room temperature, followed 
by washing five times with PBS-Tween and counting the bound
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radioactivity.
In another* series of experiments, 4.2, and 16.6
ng/lOO ul of non-radiolabelled gp60 were incubated with 
125 125
[I]—Clq (12-385 ng), [I]-IgM-RF (6.9-120 ug), or
125
[I]-F(ab*) IgG-RF (6.25-200 ng) in wells containing the 
2
same amount of IgG-IC, and the binding studies were 
performed as described above.
Controls for non-specific binding using BSA-coated 
wells but without IgG anti-BSA were included. Control 
values were substracted from experimental results.
4.1.15 NUMERICAL CALCULATIONS
The gamma counter background was substracted from 
all c.p.m values. The triplicate values obtained for bound 
c.p.m. were averaged and the standard errors calculated.
Any single value differ'^ by more than 5% of the mean of 
the three values was excluded from the calculation. When 
two values differed by more than 5% of the mean of the 
triplicate measurments, the experiment was repeated.
All the experiments described were repeated on at least 
three occasions. The specific binding values were obtained 
by substracting the non-specific binding values from the 
total binding values over a range of input values.
In all experiments the radioactivity due to non-specific 
binding was less than 5# of the specific binding counts. 
Using the specific binding values at a given input, Scatchard, 
double-reciprocal, and Hill plots were drawn to calculate 
the affinity constants and to determine the number of 
binding sites on the IgG-IC using linear regression analysis.
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The molecular weights used for the calculations were:
gp60-60 kD., Clq—410 kD., IgM-RF-960 kD., and IgG-RF
F (ab * ) 100 kD.
2
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RESULTS
4.2.1 BINDING OF gp60 TO IMMUNOGLOBULIN ISOTYPES
125
There was no significant binding of [I]-gp60
prepared by method 1 to wells coated with IgM or IgA (Fig.
125
4.1), in contrast [I]-gp60 was able to bind to IgG, the
amount of binding being dependent upon the amount of IgG
125
bound to each well, and upon the amount of [I]-gp60
added to each well (Fig. 4.1).
125
Kinetic studies of [I]-gp60 binding to IgG-coated
wells was rapid with 90-95% of maximum binding occurring 
within 10 minutes (Fig.4.1).
4.2.2 CHARACTERISTICS OF gp60 (PREPARED BY METHOD 1) 
BINDING TO IgG
125
In order to study [I]-gp60 binding to IgG-IC,
BSA/anti-BSA solid-phase IC w »olS formed using
immunoadsorbent purified IgG anti-BSA, where the number of
molecules of IgG per well was determined. The addition of
125
increasing amounts of [I]-gp60 to solid-phase IC was
associated with increasing binding to the wells in which 
10
3. 4 x 10 molecules of IgG w w .  bound per well (Fig. 4.2). 
125
When bound [I]-gp60 was plotted on the ordinate against
125
free [I]-gp60 on the abscissa, the dose-response curve
was concave towards the abscissa (Fig. 4.2) indicating that
the binding was saturable, and at saturation there was 6.8 
9 125
x 10 molecules of [I]-gp6o bound per well. At
saturation 1 molecule of gp60 was bound for every 5
available IgG molecules. In this experiment only 0.034%
125
of the offered -[I]-gp60 was bound, but this increased
112
Figur.a L l-L '
125
Binding of [I]-gp60 (monomer) to
immunoglobulin isotypes.
a) Wells were coated with 10 ng IgG (0 —  O),
5 ng IgG (& &), 1 ng IgG (d — Q ) , 10 ng IgM
(■ —  • ) or 10 ng IgA ( 4 —  4  ) . Different amounts
125
of [I]-gp60 ( 1.3-20 ng) were added/well.
125
b) Kinetics of [I]-gp60 binding to solid-
phase IgG. Wells were coated with 5 ng IgG, 20 
125
ng [I)-gp60 was added to each well at time 0,
and aspirated at times shown on the abscissa.
gp
60
 
BO
UN
D 
gp
60
 
BO
UN
D
(cp
m 
x 
10
'3
) 
(cp
m 
x 
10
*3
)
- 3
</>
o £ <■> 3 Z
z
Figure 1L-Z:
125
Direct plot of [I]-gp60 monomer binding to
10
solid-phase BSA-IgG-anti-BSA IC. 3-^-xlO
molecules of IgG were bound per well. Bound 
125
[I]-gp60 on ordinate plotted against Free
125
[I]-gp60 on abscissa. Only 0.03&% of offered
125
[I]-gp60 was bound.
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to 1.2% when the number1 of molecules of IgG per well was
12
increased to 5.7 x 10
To determine the affinity of gp60 binding to solid-
phase IgG-IC, the data were analysed by Scatchard and
double-reciprocal plots. Scatchard plot analysis in which
125
the ratio of the number of molecules of [I]-gp6o bound /
125
the number of free [I]-gp60 molecules was plotted
125
against the number of [I]-£P60 molecules bound per
molecule of IgG, revealed a single regression line,
indicating the presence of only a single class of binding
sites for gp60 on the IgG molecule. The intercept on the
abscissa indicated that at saturation 0.213 molecules of
gp60 was bound per IgG molecule, giving ratio of 1
molecule of gp60 to 5 molecules IgG (Fig. 4.3).The binding
8
affinity of gp60 for IgG which was calculated as 9 . & x 10
1/mol. In double-reciprocal plot analysis (Fig. k.U) where
125
1/B (the reciprocal of moles of bound [I]-gp60 was
plotted against 1/F (the reciprocal of moles of free 
125
[I]-gp60), showed that the intercept on the ordinate
which is the reciprocal of maximum attainable molar
125 11
concentration of bound [I]-£P60 was 0.23 x 10 1/mol.
The affinity constant was calculated from the slope of the
line which was equal to 1/nK. In this case the affinity
8
constant was calculated to be 9 -& x 10 1/mol.
From Hill plot analysis (Hill, 1910) of the same
data (Fig. *1.5), the Hill coefficient was equal to 0.992,
125
indicating the non-cooperativity of the binding of [I]-
gp60 to IgG solid-phase IC. These results were 
reproducible, as in a total of nine experiments, the mean
113
Figure *l ■ 3:
Scatchard plot analysis of data shown in figure 
*1.2 .
125
B/F, number of molecules [I)-£p60
125
bound/number of molecules of [I]-gp60 free.
The intercept on the abscissa shows the number
125
of molecules of [I]-£p60 bound per IgG
molecule (0.213). The slope of the line
125
represents the affinity constant of [I]-£p60
binding to IgG-IC which was calculated as 
8
9-8x10 1/mol.
.CM
CM
“ O
OCM
Mo
lec
ul
es
 
in
hi
bi
to
r 
bo
un
d 
pe
r 
IgG
 
m
ol
ec
ul
e
F i g u r e  .ft,.A ■
125
Double reciprocal plot analysis of [I]-gp60
binding to IgG-IC.
125
1/B: reciprocal of moles of [I]-gp60 bound
125
1/F: reciprocal of moles of [I]-gp60 free
n: maximum attainable molar concentration of
125
bound [I]-gp60.
The slope of the graph equals the reciprocal
of the affinity constant x n. The affinity
3
constant was calculated as 9.36x10 1/mol.
I/B
(I.mol- l x10-11)
4.0
2,5 -
0.8 -
l/n= 0.23x10
3.30
Figure jlt 5:
125
Hill plot analysis of [I]-gp60
monomer to IgG-IC.
125
B: number of moles [I]-gp60 bound/1
125
F: number of moles [I]-ep60 free/1
C: Hill constant (a measure of the slope of the
graph) which was calculated to be 0 .992.
Log( fT=B *
1*2
-1 0
-1.7
c=0.992
'— 10
8
affinity constant K was calculated to be 9-4-8 x 10 1/mol
8
(range 6.6 to 11.2 x 10 1/mol) and the mean Hill 
coeffecient was 1.01 (range 0.91 ~ 1.12).
4.2.3 COMPARISON OF THE BINDING OF DIFFERENT gp60 PREPARATIONS 
TO IgG
125
The binding to IgG of [I]-gp60 prepared by each of
the three methods was compared. Different concentrations 
125
of the [I]-gp6o preparations were added to a series of
microtitre wells containing solid-phase IgG-IC (4.1.11)
with a known amount of bound IgG (8 ng/well). Direct plots
and Scatchard plots showed that the characterstics of
monomer binding (gp60 prepared by method 1) were similar to
those determined previously (4.2.2), the affinity constant 
8 125
being 6.1x10 1/mol with one molecule of [I]-gp60 bound
per 5 molecules of IgG (Fig. 4.6). For the calculations
involving the monomer, a molecular weight of 60 kD was
assumed, while for those involving the binding of the
polymer, the molecular weight was taken as IOOO kD. The
125
binding characteristics of [I]-gp60 prepared by method 2
9
showed higher affinity (1.7x10 1/mol) with one molecule of 
125
[I]-gp60 binding for every 24 molecules of IgG (Fig.
4.7).
125
When the binding of [I]-gp60 (prepared by method 3)
125
was studied, it was found that one molecule of [I]-gp60
bound per 26 molecules of IgG, and the affinity constant 
9
was 3-7x10 1/mol (Fig.4.8). Each experiment in which the
125
binding of the different [I]-gp60 preparations to a
fixed amount of bound IgG anti-BSA was determined, was 
repeated on three separate occasions. On each occasion
114
Figure 4,x, 6.:
125
Binding of [I]-gp60 monomer to IgG-IC
125
a) Direct plot of the number of moles [I] —
gp60 bound plotted against the number of moles of 
125
[I]-gp60 free.
b) Scatchard plot analysis of the data shown in
(a). The affinity constant was found to be 
8
6.1x10 1/mol and the number of moles of gp60 
monomer bound per IgG mol at saturation was 
0 . 2 6.
Bound (mol/1 x 1Cp°)
2.0
1 .0 -
1.0
Free (mol/1 x 10°)
2.0
B/F (10“ 
2 .0-1
1.0 -
0.2
Molecules of gp60 bound per IgG molecule
Figure jL_Z:
125
Binding of [I]-ep60 polymer
(prepared by method 2) to IgG-IC.
a) Direct binding
b) Scatchard plot analysis of the data in (a).
125
The affinity constant of [I]-gp60 to IgG % IC
9
was found to be 1.7x10 1/mol and the number of 
125
molecules of [I]-gp60 polymer bound per
molecule of IgG was 0.0^1.
Bound (mol/1 x 1 0 11)
2.5 5
B/F ( x 1 0 '7) Free (fn0l/1 x1° 9)
5.0 -i
2.5-
0.025 0.05
Molecules of gp60 bound per molecule of IgG
Figure H .g
125
Binding of [I]-gp60 polymer prepared by
method 3 to IgG-IC.
a) Direct binding plot
b) Scatchard plot analysis of the data in (a)
The affinity constant was calculated as 
9
3.7x10 1/mol, and the number of molecules of 
125
[I]-gp60 polymer prepared by method 3 per IgG 
molecule was found to be 0 .0 3 9-
Bound (mol/1 x 1011)
2.0
.0
3.0 6.5
Free (mol/1 x1010)B/F (x 10
10
K = 3.7 x10^1/mol 
n = 0.039
0.025 0.05
Molecules gp60 bound per IgG molecule
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similar results were obtained (see Table 4.1).
The binding studies were performed using four
different amounts of bound IgG anti-BSA (lng, 8ng, 32ng and
64ng bound IgG anti-BSA per well), and each set of
experiments was repeated on three separate occasions. The
results which are shown in Table 4.1 gave similar
affinities to those in the experiments described. As
saturation was not achieved when 64 ng IgG anti-BSA were
bound per well, the ratio of molecules of gp60 bound per
molecule of IgG could not be calculated. However, for the
three lower amounts of bound IgG the molar ratios of 
125
[I]-gp60 bound per IgG were similar to those calculated 
in the first series of experiments.
4.2.4 LOCALISATION OF THE gp60 BINDING SITE ON IgG
The binding site for gp60 on the IgG molecule was
localised from direct binding and competition inhibition
studies with F(ab’) , Fab and Fc fragments of normal human 
125 2
IgG. [I]-gp60 showed dose-dependent binding to solid-
phase Fc, but there was no binding to Fab and very little
binding of F(abf) . These results were confirmed by
2
showing that Fc fragments were able to inhibit the binding 
125
of [I]-gp60 to solid-phase IgG-IC in a dose-dependent
fashion, while Fab and F(ab') fragments had no effect
2
(Fig. 4.9).
4.2.5 EFFECT OF IgG SUBCLASSES ON gp60 BINDING
In competition inhibition assays, IgGl and IgG3 were
more effective than IgG2 and IgG4 in reducing the binding 
125 125
of [I]-gp60 to solid-phase IgG-IC (Fig. 4.10). [I]-
115
Figure 4,9 :
125
Binding of [I]-gp60 monomer to IgG fragments.
125
a) Inhibition of [I]-gp60 binding to solid-
phase IC by differnt amounts of Fc ( • — • ), Fab
( 0 --- 0 ) and F(ab') (A— k) .
225
b) Direct binding of [I]-gp60 to wells coated
with 10 ng Fc (•— •), 10 ng Fab ( o —  0) and 10
ng F(ab') ( k— & ) .
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125
Binding of [I]-gp60 to IgG subclasses^# —
125
a ) Direct binding. Different amounts of [13 —
gp60 were added to microtitre wells coated with 
10 ng IgGl IgG2 (O-Tl), IgG3 ( O —  O) and
IgG4 (£-£).
125
b) Inhibition of [I]-gp60 binding to solid-
phase IgG-IC by, 10 ng IgGl (&-&), IgG2 (n — U),
IgG3( 0 —  0 ) and IgG4 (£ —  ^ ) were added
simultaneously with different concentrations of 
125
[I]-gp60 (2. 6-^-0 ng) to microtitre wells 
coated with BSA-anti-BSA IgG solid-phase 
complexes.
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gp60 bound more effectively to solid-phase IgGl and IgG3
than to the IgG2 and IgG*l subclasses (Fig. ll. 10) . Scatchard
125
plot analysis of the direct binding of [I]-gp60 to
solid-phase IgG subclass proteins, showed that
affinity of gp60 for each subclass was as follows: IgGl,
8 8 8 
5-2 x 10 1/mol; IgG2, 2.3 x 10 1/mol; IgG3, 5-5 x 10
8
1/mol; and IgG*l, 1.1 x 10 1/mol.
U.2.6 EFFECT OF Gp60 ON Clq BINDING
Unlabelled gp60 (4 - 32 ng) produced dose-dependent
125
inhibition of the binding of [I]-Clq (200 ng) to solid-
phase IgG but did not affect its binding to solid-phase IgM
125
(Fig. 4.11). Inhibition of [I]-Clq binding to solid-
phase IgG was also seen in the converse experiment in which
a single dose of gp60 (32 ng) was incubated with different 
125
amounts of [I]-Clq (25-200 ng).
In a second series of experiments, the effect of
different amounts of unlabelled gp60 ( 4. 2, 8.4 and 16.8
125
ng) on the binding of [I]-Clq to solid-phase BSA/anti-
BSA IgG-IC was studied. Again gp60 caused dose-dependent
125
inhibition of the binding of [I]-Clq to IgG.
Scatchard plot analysis of these studies showed that
with increasing concentration of gp60. the apparent
affinity of Clq to IgG-IC was reduced, but the number of
binding sites was unaltered (Fig. 4.12). The affinity
constant of Clq binding to solid-phase IgG-IC was
8
calculated to be 1.1 x 10 1/mol, and in the presence of
7
*1.2, 8.4. and 16.8 ng gp60 it was reduced to 9x10 1/mol,
7 7
6.9x10 1/mol and 5.6x10 1/mol respectively. In the
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125
Effect of gp60 on [I]-Clq binding to solid
phase IgG or IgM.
a) Unlabelled gp60 (4-32 ng) was added
125
simultaneously wi thtt-f ixed dose of [I]-Clq
(200 ng) to microtitre wells precoated with 10 
ng IgG (# —  • ) or IgM ( 4 ) .
b) Unlabelled gp60 (32 ng) was added with
125
different amounts of [I]-Clq ( 12.5-200 ng)
to microtitre wells precoated with 10 ng IgG (p-0)» 
125
[I]—Clq binding alone ( • — •).
c) Unlabelled gp60 was added with different
125
amounts of [I]-Clq (12.5-200 ng) to
microtitre wells precoated with 10 ng IgM (O'-*3)* 
125
[I]-Clq binding alone ( 4 —  k ) .
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125
Effect of gp60 on the binding of [I]-Clq to
solid-phase IC.
a) Direct binding of different amounts of 
125
[I ]—Clq (25-200 ng) to solid-phase BSA anti- 
BSA IgG (•— •) and in the presnce of unlabelled 
gp60 4.2 ng —  ^ ), 8. 4 n g ( «  —  m  ) and 16.8 ng
( ♦  —  * >•
b) Scatchard plot analysis of data in (a).
125
The affinity constant of [I]-Clq to IgG-IC
8
(• — •) was calculated as 1.1x10 1/mol and in the
presence of 4. 2 ng gp60 —  A.), 8.4 ng gp60
(■I —  H )  and 16.4 ng gp60 ( ^  ^  ) it was
7 7 7
reduced to 9x10 , 6.9x10 and 5.6x10 1/mol
125
respectively. The number of molecules of [I]-
Clq bound per IgG molecule did not change in the 
presence of gp60.
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converse experiment unlabelled Clq produced dose-
125
dependent inhibition of [I]-gp60 binding to solid-phase 
IgG-IC.
Analysis of these data by Scatchard plot showed that
the affinity constant of gp60 in the absence of Clq was 
8
7-5x10 1/mol, while in the presence of 2 5 * 50 and 100 ng
8 8 
Clq it was reduced to 2-5 x 10 1/mol, 1-7 x 10 1/mol 
7
and 9-2x10 1/mol respectively.
125
[I]-gp60 did not bind to solid-phase Clq or to the
125
solid-phase F(abf) fragments of Clq antiserum. [I]-Clq
125 2
and [I] F(abf) anti-Clq did not bind to solid-phase
2
gp<50.
ft.2.7 EFFECT OF gp60 ON THE BINDING OF RHEUMATOID FACTOR 
TO IgG
In a set of experiments designed to investigate the
effect of gp60 on rheumatoid factor binding to IgG,
unlabelled gp60 monomer produced dose-dependent inhibition
125
of the binding of both [I]-IgM.RF (Fig.ft.13). and
125
[I ] - F( ab * ) IgG-RF to solid-phase IgG-IC (Fig. ft.lft).
2
Scatchard plot analysis showed an affinity constant for
6
IgM.RF as 5 x 10 1/mol which was reduced in the presence
6 5
of it. 2, 8. it and 16.8 ng gp60 to 1.8x10 , 9.8x10 , and
5
5.7x10 l/mol respectively. The affinity constant of
6
F(ab*) IgG-RF was found to be in the order of 2.1x10
2 5 5 5
l/mol, and was reduced to 5-5x10 , 3-9x10 and 2.6x10
l/mol respectively in the presence of gp60 at the same
concentrations. In the converse experiments both IgM-RF
125
and F(ab’) IgG-RF were able to inhibit the binding of 
2
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Figure
125
Effect of unlabelled gp60 on [I]-IgM-RF
binding to solid-phase IgG-IC.
125
a) Direct binding plot of [I]-IgM-RF alone
(• —  • ) and in the presence of 16.8 ng (£ —  ,
8.ft ng (a — O ) and ft.2 ng (k —  A ) unlabelled gp60.
b) Scatchard plot analysis of data in (a).
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125
Effect of gp60 on the binding of [IJ-FCab*)
2
IgG-RF to solid-phase IgG-IC.
125
a) Direct plot of [I] F(ab') IgG-RF to
2
solid-phase IC alone (•— •), and in the 
presence of 16.8 ng (^ —  ^ )* S. ll ng (CU— d )  and 
it. 2 ng ( A — -A.) unlabelled gp60.
b) Scatchard plot of data in (a).
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[I]-gp60 to solid-phase IgG-IC in a dose-dependent fashion.
25 125
Both [I]—IgM—RF and [I]-F(abf)
2 125
IgG.RF did not bind to solid-phase gp60, and [I]-gp60
monomer did not bind to solid-phase IgM-RF or F(ab’) IgG-
2
RF.
4.2. 8 EFFECT OF STAPHYLOCOCCUS AUREUS PROTEIN A ON BINDING OF 
gp60 TO IgG
Staphylococcus protein A produced dose-dependent
125
inhibition of the binding of [I]-£p60 to solid-phase
IgG-IC.
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DISCUSSION
The initial step of the gp60 purification procedure, 
affinity chromatography on IgG-Sepharose, indicated that 
the action of gp60 was most probably mediated by its 
binding to the antibody moiety of IC. Direct binding 
studies showed that gp60 binds to IgG but not to the IgM or 
IgA isotypes.
125
By studying the binding of [I]-£p60 to solid-phase
Fc, Fab and F(abf) fragments of IgG, and by investigating
2
the ability of these different fragments to inhibit the 
125
binding of [I]-gp60 to solid-phase BSA/anti-BSA IgG-IC,
it was clearly shown that the binding site for gp60 is
located on the Fc piece of IgG. Further evidence to
support this conclusion was provided by the experiments in
which it was shown that Clq, IgM-RF, F(ab*) IgG-RF and
2
Staphylococcus protein A were able to inhibit the binding 
125
of [I]-gp60 to solid-phase IC. All four of these
proteins have been shown to bind to the Fc piece of IgG.
Clq binds to CH2 domain, IgM-RF and IgG-RF binds to either 
the CH2 or CH3 domains, while Staphylococcus protein A 
binds to both (Burton,1985)• These results emphasise the 
need to study the interactions of IgG, gp60 and these other 
Fc binding proteinsin-vivo.
125
The selective binding of [I]-gp60 to the IgG
subclass myeloma proteins IgGl and IgG3 is further evidence 
that the binding site for gpfiO is located on the Fc piece 
of IgG. These two subclasses of IgG bind Clq, IgM-RF and 
IgG-RF better than IgG2 or IgGil (Burton, 1985)- IgG/J. is 
thought not to bind to Clq or Fc receptors because the
119
conformation of the intact molecule prevents access of these 
proteins to the Fc piece (Burton,1985), although the 
isolated Fc fragment of IgGtl can bind Clq (Isenman, 
Dorrington & Painter, 1975)- The finding that gp60 showed 
some binding to IgGft in these experiments is probably 
explained by the residual contamination of IgG& with IgG3 
(Bird. P., Personal communication).
125
The studies of the binding of [I]-gp60 to solid-
phase IgG anti-BSA IC containing a known amount of IgG
bound per well allowed important parameters of the
interaction between gp60 and IgG to be determined. The
affinity of the interaction between gp60 monomer and IgG
was determined from Scatchard plots and double reciprocal
plots, both of which gave similar results with a mean
8 8
affinity of 9.Zl8xlO l/mol (range 6.6-11.2x10 l/mol).
This value was lower than that obtained for the two
polymeric forms of gp60, that prepared by method 2 had a
9 9
mean value of 1.7x10 l/mol (range 1.1-2.3x10 l/mol),
while that prepared by method 3 was even higher, mean 
9 9
3-7x10 (range 2.3-5-1x10 l/mol). The higher affinity
constants for the polymeric forms can be explained on the
basis of the increased number of binding sites for IgG per
molecule of polymer compared with the monomer.
The significantly higher binding affinity for IgG of
125 125
[I]-gp60 prepared by method 3 compared with [I]-gp60
prepared by method 2 is most likely due to partial
denaturation of gp60 during its elution from IgG-Sepharose
by 2M guanidine hydrochloride. The alternative explanation
that a high affinity fraction of gp60 remained bound to the
IgG-Sepharose is improbable.
120
At saturation with monomeric gp60 only 0.2 molecules 
of gp60 were bound for each molecule of IgG in the solid- 
phase IC. As a similar result was obtained when different 
amounts of IgG were bound to the wells, it is unlikely that 
steric hindrance accounts for the observation that 
saturation of gp60 binding to IgG is achieved only when one 
fifth of the available IgG binding sites are occupied.
It could be argued that rabbit Clq or other IgG 
binding proteins were co-purified with the specific 
antibody. However, this is unlikely as the
purification procedure involved affinity chromatography on 
BSA-Sepharose followed by protein A-Sepharose 
chromatography, and Clq could possibly bind to IgG in both 
procedures (particularly the former), analysis of the 
antibody by SDS-PAGE did not reveal any obvious 
contaminants. It is therefore likely that only 20# of the 
rabbit IgG anti-BSA molecules are capable of binding gp60.
The possible explanations for this include:-
1) Damage to 80# of the molecules during purification.
2) Following binding of antibody to antigen the 
conformation of 80# of the antibody molecules may 
prevent gp60 binding.
3) The 20# of rabbit IgG molecules represents the 
only subclass or a mixture of subclasses of IgG 
which can bind gp60.
Damage to 80# of the IgG molecules could occur during
the purification procedure as an acid elution step
(glycine-HCl, pH 3-0) was used for the purification of the 
antibody. However, I consider this degree of damage to be 
unlikely, as it would have been described by authors
121
studying Clq binding or Cl activation, or IgG-Fc receptor 
interactions.
It has been suggested that the angle of the Fab arms
o o
of IgG can vary between 0 and 180 (Valentine and Green,
1967)- Those molecules in which the angle was less than 
o
60 could not fix complement, while those in which the
o o
angle was between 90 and 180 possessed complement fixing
ability (Hyslop et al, 1970). These data show that in 
addition to aggregation for the complement activation to 
occur, and by implication the binding of Cl to IC, IgG 
molecules must acquire a specific configuration that is 
determined by the angle of the Fab arms. If the 
configuration is important for Cl binding, it could be 
equally important for the binding of gp60 to IgG, as gp60 
and Clq competitively inhibit the binding of each other. 
Thus it could be argued that only 20% of the IgG anti-BSA 
in the solid-phase IC were in suitable configuration for 
gp60 binding to occur. The observation that at saturation 
the molar ratios of gp60 to IgG were independent of the 
number of bound IgG molecules argues against this 
explanation. In the experiments in which these molar 
ratios could be calculated, the amount of IgG bound per 
well varied from 1-32 ng. It is probable that over this 
range the angle of the Fab arms would have altered 
significantly and a change in the molar ratio of gp60 to 
IgG would have been observed.
Evidence to support the third possibility comes from 
experiments of Doekes et al (1985). who showed that both 
aggregated and monomeric human IgG was between two and five
122
times as effective as the rabbit IgG equivalents in terms 
of binding human Cl. Although these authors did not 
perform solid-phase studies, their data supported the view 
that only a proportion of rabbit IgG molecules can bind Cl. 
If this is the case, then it is possible that only a 
proportion of rabbit IgG molecules will bind gp60. Other 
evidence to support the third explanation has been provided 
by Hughes-Jones and Gardner (1978), who showed that in 
fluid-phase DNP-rabbit anti-DNP IC system only one molecule 
of Clq bound for every 10-1/J. molecules of IgG. On 
balance, the third possibility appears to provide the most 
reasonable explanation for my findings.
The binding studies with both preparations of 
polymeric gp60 showed that at saturation the molar ratios of 
gp60 to IgG were similar (mean 1:2U for preparation 2 and 
mean 1:26 for preparation 3)- The ratio was slightly higher 
for the lowest amount of bound IgG (1:27 and 1:30 
respectively).
These ratios were derived by using a molecular weight 
of 1000 kD for gp60, are higher than might be expected from 
the binding data for monomeric gp60 (1:5). assuming that 
polymeric gp60 is composed of 16 monomeric subunits. The 
most probable explanation is that only a minority of the 
available binding sites on gp60 have been bound to IgG in 
these experiments.
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The finding that the affinity constant of [I]-gp6o
to polyclonal IgG was higher than for its binding to IgGl 
or IgG3, is probably explained on the basis of species and 
technical differences of the assays used. For the studies 
of the interaction of gp60 with polyclonal IgG, rabbit
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antibody was used in the form of an IC so that all the
sites were presented for optimal interaction with Fc
binding proteins. In contrast, in the studies with
immunoglobulin subclasses, human myeloma proteins bound
directly to the wells were used. This binding is entirely
random so it is probable that some Fc pieces were able to
bind to gp60 while others may have been unable to do so. Of
those molecules which were able to bind gp60, it is likely
that the orientation of some was such that the affinity of
the interaction was reduced.
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The failure of [I]-gp60 to bind to solid-phase Clq
125
and [I]-Clq to bind to solid-phase gp60 confirms that
gp60 acts on the IgG antibody moiety of IC and not on the
Cl component of complement. Its failure to bind to solid-
phase F(ab’) fragments of IgG anti-Clq and the failure of 
125 2
[I]-F(ab*) anti-Clq to bind to solid phase gp60 shows 
2
that it is not an altered form of Clq. The lack of binding
of gp60 to IgM-RF or F(ab') fragments of IgG-RF and the 
125 2 125
failure of [I]-IgM-RF and [I]-F(abf) IgG-RF to bind
2
to solid-phase gp60 show that gp6o is not an altered
fragment of the IgG heavy chain, as such a fragment would
probably be detected by these autoantibodies, which react
with IgG (Carson, 198/1).
The affinity of Clq for IgG was calculated to be
8
between 1.1 and 3.1x10 l/mol which is in agreement with 
results of other authors (Hughes-Jones and Gardner, 1978), 
and is close to that calculated for monomeric gp60, but 
significantly lower than that calculated for polymeric gp60 
which had been prepared by method 3- The mean
12/1
concentration of gp60 and Clq in normal serum are us/ml
(see chapter 5) and 75 ug/ml (Tenner, Lesavre & Cooper, 
1981) respectively. Thus their relative molar 
concentrations must be similar as their molecular weights 
are 1000 kD and U10 kD respectively.
If this is the case, it is difficult to understand how 
complement activation occurs, as the high affinity of gp60 
for IgG would prevent Cl binding and activation to IgG 
containing IC. Perhaps the presence of IgM in the IC would 
allow complement activation to occur. Alternatively, gp60 
activity in vivo may be regulated by another plasma 
constituent.
The studies on the interaction of gp60 and Clq with 
IgG suggest that once IgG antibody binds to antigen, the 
progression to a large tissue damaging lattice could well 
depend on the relative serum concentrations of gp60 and 
Clq. Relatively high levels of gp60 would favour 
precipitation, while relatively low levels (with respect to 
Clq) would favour PIP and the retention of IC in solution 
in a non-phlogistic form. Thus the outcome of the 
interaction of IgG antibody with antigen, with respect to 
whether the IC would remain soluble or form an insoluble 
lattice, could well depend upon the relative plasma 
concentrations of Clq and gp60 and their relationship to 
inhibition of PIP.
CHAPTER 5
THE EFFECT OF GP60 ON THE ACTIVATION 
OF THE CLASSICAL PATHWAY OF COMPLEMENT
126
INTRODUCTION
In the previous chapter it was shown that gp60 bound
to the Fc piece of IgG but not to the IgA or IgM isotypes.
Furthermore, it was shown that gp60 competitively inhibited 
the binding of Clq to IgG. PIP is dependent upon an intact 
classical pathway (Schifferli et al, 1982; Naama et al, 
198/t). The important events are the binding of the Cl 
macromolecule to IC, which slows the rate of immune 
precipitation (Shifferli & Peters, 1983: Naama et al,
198U), subsequent Cl activation, binding of C/lb to IC, C3 
convertase formation followed by C3 activation and binding 
of C3b to IC (Naama et al, 198ZI; 198 5). The binding of C3b
is thought to prevent the Fc-Fc interactions which
facilitate immune precipitation (Moller, 1979; Moller & 
Steensgaard, 1979).
In this chapter experiments designed to investigate 
the effect of gp60 on classical pathway activation are 
reported. The results of these experiments show that gp60 
prevents Cl activation, as a consequence of which C3 
convertase formation is limited and C3 activation is 
reduced.
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METHODS
5.1.1 SERUM SAMPLES
Venous blood was collected from 12 normal healthy 
laboratory personnel (6 males and 6 females) and 21 
patients (9 male and 12 female) with definite or classical 
rheumatoid arthritis (Ropes et al, 1959). The serum was
collected and stored as described in 2.16.
5.1.2 MEASUREMENT OF Cls-Cl-INHIBITOR COMPLEX BY ELISA
fraction of anti-Cls in 10 mM carbonate/bicarbonate buffer
pH 9*6 (100 yil/well) overnight at U. C. The first two rows
inhibitor. The wells were washed five times in PBS-Tween 
(PBS containing 0.05% v/v Tween-20), and blocked with 
gelatin (0.1% w/v in PBS) for one hour at room temperature. 
After another five washes in PBS-Tween, doubling 
dilutions of a Cl-inhibitor standard in PBS-EDTA-Tween 
(PBS-Tween containing 10 mM EDTA) were added to the first 
two rows of wells, while the diluted test samples in PBS- 
EDTA-Tween were added to the rest of the wells. After 
incubation for one hour at room temperature, the wells were 
washed five times in PBS-Tween, and 1/1000 dilution of IgG 
biotin-conjugated anti-Cl-inhibitor was added. The 
incubation was allowed to proceed at room temperature for 
a further hour, after which the wells were washed again 
five times in PBS-Tween, and a 1/1000 dilution of avidin- 
HRP in PBS-EDTA-Tween was added. After one hour at room
(Nilsson and Bock, 1985)
Microtitre plates were coated with 5 JL»e/ml IgG
o
of the plate were coated with IgG anti-Cl-
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temperature, the wells were washed as described earlier, 
and developed using the same conditions described in 
3 -1.26.
A standard curve was plotted using the absorbance 
values of the standard dilutions against their Cl-inhibitor 
concentrations. The concentrations of Cls-Cl-inhibitor 
complex in the test samples were determined by 
interpolation from the standard curve, and results were 
expressed as jjlz Cl-inhibi tor/ml. In all experiments a 
positive control of IC-activated serum was included.
5-1.3 MEASUREMENT OF C3-PROPERDIN COMPLEX BY ELISA 
(Mayes et al, 198*0
The same procedure to that described in 5*1.2 was used 
to coat wells with anti-properdin antibodies and biotin- 
conjugated anti-C3 was used as the detecting antibody. The 
sequence of incubation and washing steps was identical to 
that used in the Cls-Cl inhibitor assay. In this case the 
standard curve was prepared in wells coated with anti-C3 
antibody, and the results were expressed as ^ig C3/ml.
5.1.*l MEASUREMENT OF C5b-9 COMPLEXES BY ELISA 
(G&wryl et al, 1986)
The same procedure to that described in 5.1.2 was used 
to coat wells with anti-C9 antibody, and biotin-conjugated 
anti-C5 was used as the detecting antibody. The sequence 
of incubation and washing steps was identical to that used 
in the Cls-Cl inhibitor assay. In this case the standard 
curve was prepared in wells coated with anti-C5 antibody, 
and the results were expressed as yug C5/ml.
1 2 9
5.1.5 C3a AND CH& MEASUREMENT BY RADIOIMMUNOASSAY
C3a and C/la were measured using commercially
available radioimmunoassay kits. The test samples and
standards were diluted in 0.15M NaCl and 100jal of each
diluted sample or standard was transferred to a series of
tubes (12x75mm). An equal volume of the precipitating
reagent was added to each tube, and after mixing, the tubes
were allowed to stand at room temperature for one hour.
The precipitate (containing native C3 and C/l) was separated
o
by centrifugation (2000 g for 15 minutes at 2 C) , and 100
u^l of supernatant was transferred to a second tube
containing 50 jxl assay buffer, followed by the addition of 
125 125
50 jal [I]-C3a or [I]-C/la, and 50 jxl antiserum to C3a
or C/la. The tubes were incubated for 30 minutes at room
temperature, and then 5 0 of the secondary antibody were
added. After mixing, the tubes were incubated at room
temperature for 30 minutes before 2 ml isotonic saline was
added to each tube. Following centrifugation (2000 g for 10 
o
minutes at /I C), the supernatant was aspirated and the 
tubes were inverted over a Whatm.an filter paper until they 
were dry. The radioactivity of the pellets was counted in 
an automatic gamma counter.
Controls included:
125 125
1) Total input (50 jjlI buffer, 50 jx 1 [I]-C3a or 50 ^ul
[I]-C/la,
2) Non-specific binding without first antibody (50 ul
125 125
buffer, lOO^jul saline and 50 jxl [I]-C3a or 50 Jxl [13 —
C&a, 50 jxl second antibody).
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3) Zero standard (50 yul buffer, 50 yul saline, 50 yul 
125 125
[I]-C3a or 50 yul [I]-C/la, 50 yul anti C3& or anti
C/la, 50 yul secondary antibody).
A series of standards of known C3& or C/la
concentrations was included in each run.
Each assay was performed in duplicate and the
results were calculated by averaging the c.p.m. for each
replicate and substracting the average non-specific binding
from all the tubes except total input.
The percentage of bound isotope for each sample or
standard was calculated using the formula:
% bound/Zero standard =
Standard or test c.p.m. - Background c.p.m.
Zero standard c.p.m. - Background c.p.m.
A standard curve was plotted on log-logit graph paper,
using the percent bound/zero standard as a function of the
logit and one as a function of the logarithm concentrations
of C/la des Arg. or C3a des Arg. The concentration of
anaphylatoxins in the samples were determined directly from
the standard curve.
5.1.6 PREPARATION OF ANTIBODY-SENSITISED SHEEP 
ERYTHROCYTES (EA)
Sheep erythrocyte suspension was standardised as 
described in 2.15* The standardised cell suspension was 
mixed with an equal volume of antiserum (IgG or IgM 
antibody) to sheep erythrocytes (diluted to the maximum
sub-agglutinating dose) in 0.01M EDTA-GVB , and incubated
o
in a shaking water bath at 37 C for 30 minutes. The EAs 
were then pelleted by centrifugation (2000 g for 5 minutes
1 3 1
o —
at ll C), washed three times in 0.01M EDTA-GVB and
-4- +
resuspended to the original volume in GVB . The EA
o
preparation was stored at k C until used.
5.1.7 PREPARATION OF EAC1
(Ruddy & Austen, 1967)
EAs were washed three times in GVB , and resuspended 
8 -+- -+• 
to 1x10 cell/ml in DGVB (2.16). The EA suspension (5
ml) was incubated with an equal volume of Cl (IOO units/ml 
+ + o
in DGVB ) for 15 minutes in a shaking water bath at 37 C.
The EAC1 cells were pelleted by centrifugation (2000 g for 
o
5 minutes at U C), and resuspended to the original volume 
+  +
in DGVB . EAC1 preparations were used immediately in the 
measurement of Cil haemolytic activity.
5.1.8 PREPARATION OF RAT—SERUM—EDTA (C-RAT)
Rat serum was obtained as described in 2.16, and 
diluted 1/30 in kO mM EDTA-GVB . The diluted serum was 
kept on ice and used immediately.
5.1.9 PREPARATION OF EACH
Frozen EACft were kindly supplied by Dr. E. Holme. An
aliquot of frozen EACH in a 15 ml Falcon tube was thawed at 
o
37 C in a shaking water bath using the following
procedure: Two hundred and thirty microlitres (230 ul) D50S
was added to the cells drop-wise with shaking and incubated
o + +
for 5 minutes at 37 C. Mannitol-GVB was added drop-wise
with shaking in three stages involving the addition of 1 , 2
and 8 ml respectively. Between each stage the cells were
o
incubated for 2 minutes at 37 C. After the third addition
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of mannitol-GVB , the cells were transferred to a 50 ml
o + +
Falcon tube and incubated for 5 minutes at 37 C. DGVB
was then added drop-wise with shaking in four stages with
incubation periods of five minutes between each stage. In
the first stage 5 ml DGVB were added, whereas in the
subsequent three stages the volume was 10 ml. After the
+  +
final addition of DGVB , the cells were incubated for 10 
o
minutes at 37 C and then centrifuged (2000 g for 5 minutes 
o -+• +
at 2 C), washed three times in DGVB and the cell count
8
adjusted to 1x10 /ml in DGVB as described in 2.15 
5-1.10 CH HAEMOLYTIC ASSAY (Whaley, 1985)
Test sera were serially diluted in DGVB (1/10000,
1/20000, 1/&0000,1/80000). One hundred microlitre (100 yul)
<yv\
of each dilution was incubated with equal volume of EAC1 at 
o
37 C for 15 minutes, followed by the addition of 100 jj.1
+ +
guniea pig C2 (50 units/ml in DGVB ), and the incubation 
o
continued at 30 C for another 15 minutes to form EAC1/12.
After the addition of 300 ^ ul C-rat to each tube, and a
o
further incubation at 37 C for one hour, the reaction was 
terminated by the addition of 2 ml ice-cold saline to each 
tube.
o
Following centrifugation (2000 g for 5 minutes at 2 C) 
to pellet unlysed cells, the optical density of the 
supernatants was measured at Hill nm. Controls of the assay 
included:
+  -»-
1) Cell blank (500 ^ »1 DGVB , 100 yul EAC1)
+  +
2) Reagent blank (100 jil DGVB , 100 yul EAC1, 100 yil C2,
300 yul C-rat)
3) 100% lysis ( same as reagent blank but with the
substitution of water for saline at the end of the assay).
The control tubes were processed in an identical 
manner to test tubes. The results were calculated using 
the formula:
O.D sample - O.D reagent blank.
% lysis  -----------------------------------------x 100
O.D 100% lysis - O.D reagent blank.
The number of haemolytic sites (Z) were calculated using
the equation Z = In (1 - y) where y = the preparation of
cells lysed.
The concentration of units of ca haemolytic activity 
was calculated as described (Whaley, 1985)- Results of 
complement activation assays were expressed as % C& 
consumption which was taken as % of haemolytic units which 
were consumed.
5.1.11 C2 HAEMOLYTIC ASSAY (Whaley, 1985)
Samples were serially diluted ( 1/1000 to 1/32000) in 
+ + o
DGVB , and a 100 yjl was warmed to 30 C in a water bath. At
timed intervals, a 100 yu 1 of EAC1 tl cells were added, and
incubated for 2 minutes (T-max time), followed by the
addition of 300yjl C-rat, after which the tubes were
o
transferred to a 37 C water bath in which the incubation
was allowed to proceed for one hour. The reaction was
terminated by the addition of 2 ml saline to each tube and
o
centrifugation (2000 g at U C for 10 minutes), after which 
the O. D at kill nm of the supernatant was measured. Control 
for the assay included:
1. Cell blank (&00 jal GVB , 100 yu1 EACia
2. Reagent blank (100 yul DGVB , 100 yul EACia, 300 yul C-rat)
13a
3. 100% lysis (Same as reagent blank but with the
substitution of water for saline at the end of the assay.) 
The control tubes were processed in an identical 
fashion to the test tubes. The results were calculated as 
for the ca assay.
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5.1.12 ANTISERA
The IgG fractlon^of anti-gp60 or of normal rabbit
(3-1.1) were papain digested as described earlier (3- 1.2ft)
o
and the Fab fragments were stored at at -20 C. 
Immunoadsorbent purified IgG anti-BSA was prepared as 
described in ft.1.8.
5-1.13 RADIOLABELLING OF BSA
125
[I]-BSA was prepared as described in 2 .1ft.
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5.1.1ft EFFECT OF EXOGENOUS GP60 ON IC—MEDIATED
COMPLEMENT ACTIVATION
BSA-anti-BSA IC were formed at equivalence, four-times
antibody excess and four-times antigen excess in normal 
o
serum at 37 C to which increasing amounts of gp60 had been
added. The extent of complement activation was measured at
different time intervals up to one hour. The reaction
■+• +
mixture contained 50 ul normal serum, 50 yul GVB , 10 yul
+ +
gp60 (0-15 yug/10yhl GVB ) and 20 yul immunoadsorbent 
purified IgG-anti-BSA (700ytig/ml) . At zero time sufficient 
BSA in 10yul VBS was added to achieve the desired antigen- 
antibody ratio.
Control tubes contained:
1. Serum with gp60 alone
2. Serum with BSA alone
3. Serum with anti-BSA alone
ft. Complete reaction mixture containing 20 mM EDTA.
The volume of the reaction mixture was adjusted to 150
o
yul with VBS, prior to its incubation at 37 C. At pre­
determined time intervals, 2 5 yul aliquots were removed and 
diluted in 100 yul ice-cold VBS containing 20 mM EDTA, and
after centrifugation (8000 g for 5 minutes in a Beckman
o
Microfuge), the supernatants were stored at -70 C until 
tested for complement activation.
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5-1.15 EFFECT OF ENDOGENOUS GP60 ON COMPLEMENT ACTIVATION
The role of the endogenous gp6o on complement 
activation was studied by examining the effect of Fab 
fragments of anti-gp60 on the PIP assay, total haemolytic 
complement activity and its effect on IC-mediated 
complement activation.
5.1.16 EFFECT OF Fab ANTI—GP60 ON PIP
125
[I]-BSA-anti-BSA IC were formed at equivalence in
12 normal and 12 rheumatoid arthritis sera using undiluted
sera in the protocol described in 3.1.5- Purified gp60 was
omitted from the reaction mixture, but Fab fragments of
IgG anti-gp60 or normal rabbit IgG were added to each tube
(1/J.O yig/ml final concentrat ion) . After incubation for one 
o
hour at 37 C, 50 yul of the reaction mixture was added to 1 
ml ice-cold VBS containing 20 mM EDTA in a Microcap tube, 
which was then centrifuged (Beckman Microfuge for 5 minutes 
at 8000 g at room temperature).
An aliquot of the supernatant (250yul) was removed for 
counting soluble radioactivity. Controls included:
1) Total radioactivity input
2) Complete reaction mixture containing 20 mM EDTA.
3) Reaction mixture without Fab fragments.
The percentage of IC remaining soluble was calculated 
for each serum sample.
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5.1.17 EFFECT OF Fab ANTI-GP60 ON INHIBITION OF PIP
The capacity of the same sera as those used In the PIP
assay (5.1.16) to Inhibit PIP was tested after heat-
o
inactivation (56 C for 30 minutes) using the procedure 
described in 3.1.5- The assay was performed in the absence 
and presence of Fab fragments of IgG anti-gp60, or of normal 
rabbit IgG (1&0 yu g/ml final concentration).
5-1-18 EFFECT OF Fab-ANTI GP60 ON TOTAL 
COMPLEMENT HAEMOLYTIC ACTIVITY
Sheep erythrocytes were coated with either IgG or IgM
using the procedure described in 5*2.6.
-+- +
Sera were diluted 1/30 in GVB , and increasing
volumes of diluted serum (150yul to ZlOOyil using 50yul
increments) were added to a triplicate series of test tubes.
One hundred microlitres (100 yul) of GVB containing Fab
anti-gp60 or normal rabbit IgG Fab (each at a final
concentration of 100 yig/ml in the reaction mixture) were
added to the first two series of tubes. The volume of all
three sets of tubes was adjusted to 500 yul by the addition 
+ + 8 
of GVB and then 3 0 0 EA (IgG) or EA (IgM) (5x10 /ml 
+ +
GVB were added to each tube. Control tubes included:
1. Cell blank - 500 yul GVB + 300 yul EA
2. 100% lysis - same as cell blank but cells lysed in 2
ml water at the end of the experiment
o
The tubes were then incubated at 37 C for 30 minutes
and the reaction was stopped by the addition of 2 ml
isotonic saline. The tubes were centrifuged (2000 g for 5
0
minutes at 2 C) and the proportion of cells which had been
1 3 9
lysed was determined after reading the OD at 5^1 nm, using
the following formula:
O.D test- OD cell blank
Y = ----------------------------------------------
OD 100 % lysis- OD cell blank
CH50 levels were calculated by plotting Y/l-Y against serum 
dilution, and determining the serum dilution at which Y/l-Y 
equals one (i.e 50% lysis), using the formula :
CH50 units/ml = X x initial serum dilution.
Where X = volume of diluted serum giving a value of 
Y/l-Y of one.
5.1-19 EFFECT OF Fab ANTI—GP60 ON IC—MEDIATED COMPLEMENT 
ACTIVATION
The same protocol described in k.l.lli was used with the 
following exceptions.
1) Exogenous gp6o was omitted from the reaction mixture.
2) Fab fragments of IgG anti-gp60 or of normal rabbit IgG 
were added to the reaction mixtures at a final 
concentration of 1H0 yug/ml.
5 .1.20 MEASURMENT OF GP60 LEVELS IN NORMAL AND 
RHEUMATOID ARTHRITIS SERA
Serum levels of gp60 were determined using the ELISA 
protocol described in 3.1*16. Serum samples were diluted 
1/100 in PBS-Tween.
m o
RESULTS
5.2.1 EFFECT OF EXOGENOUS GP60 ON COMPLEMENT ACTIVATION
Gp60 produced dose- dependent inhibition of IC- 
mediated complement activation as measured by Cls- 
Clinhibitor complex formation (Fig. 5 .la;5-2), Ck and C2 
consumption (Figs. 5.1c), Clla (Fig. 5.1b) and C3& (Fig 
5 . Id) generation, Cil and C2 consumption, (Fig 5- lc) , and 
the formation of the C3-properdin complex (Fig 5-le;5.3) and 
C5b-9 complexes (Fig 5 . If;5 .4). The concentrations of the gp60 
added to the reaction mixtures (12.5-100 ug/ral) correlated 
inversely with the concentrations of Cls-Cl-inhibitor 
complex (r = -0.997), CUa (r = -O.99 9), C3a (r = -0.958), 
C3-properdin complex (r= -0 .9 6 7), and C5b-9 complex (r=
-0 .9 8 2 ) generated, and with CU (r= -0.973) and C2 (r= - 
0 .9 6 5 ) consumption using IC formed at equivelance. Similar 
correlations were obtained when IC were formed in four- 
times antigen excess or four-times antibody excess (Table 
5.1).
5.2.2 EFFECT OF ENDOGENOUS GP60 ON COMPLEMENT ACTIVATION
a) PIP
The mean PIP level in 12 normal sera was 86 (standard 
vw\(\C.V
deviation ±5%). in the presence of Fab fragments of anti- 
gp60 rose to 96% (±3-9) (Fig 5-5), while in the 12 
rheumatoid arthritis sera the mean level was 50% (+ 6.8), 
which a rose to 8*1% (+. 9-6) upon the addition of Fab 
fragments of anti-gp60. Fab fragments of normal rabbit 
IgG had no effect on PIP when added to either normal or 
rheumatoid arthritis sera.
l&l
Figure 5.1:
Effect of exogenous gp60 on IC-mediated 
complement activation. Gp60 (0-100 ug/ml) was 
added at time 0 of IC formation in normal serum.
a) Effect on Cls-Cl-inhibitor complexes formation
b) Effect of gp60 on C/la generation by IC
c) Effect of gp60 on C2 haemolyticConsumption by IC
d) Effect of gp60 on C3a generation by IC
f) Effect of gp6o on the formation of C3/P complexes
by IC
g) Effect of gp6o on the formation of C5b-9 
complexes by IC.
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Figure 5, .2:
Effect of sp60 preparations on Cl activation. 
Gp60 (0-100 ug/ml) prepared by method 1 ( A — A). 
2 (• —  •) or 3 ( 0 — 0 )was added at time 0 of IC 
formation in normal serum. The extent of Cl 
activation was measured by Cls-Cl-inhibitor 
ELISA.
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Figure 5.«_3:
Effect of gp60 preparation on IC-medaited 
formation of C3-Properdin complexes.
Gp60 (0-100 us/ml) prepared by method 1 ( A — &), 
prepared by method 2 ( • — •• ) and gp60 prepared 
by method 3 (o —  0) was added at time 0 of IC 
formation in normal serum and the formation of 
C3-Properdin complexes was measured by C3/P 
ELISA.
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•formation by IC. Gp60 <0-100 ug/ml ) prepared by 
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In neither the normal nor the rheumatoid arthritis 
sera studied did the levels of PIP correlate with gp60 
concentrations.
Heat-inactivated normal sera were able to inhibit PIP 
to a small extent with a meam value of 9 *8% ( + 3 -8 ), while 
rheumatoid arthritis sera contained much higher levels of 
PIP inhibitory activity (mean 45% + 21.il). In the presence 
of Fab fragments of anti-gp60, these values were reduced to 
3-7% (±2.7%), and 28.5% (*21.4%) respectively (Fig 5-5b).
The levels of PIP inhibitory activity in rheumatoid 
arthritis sera correlated with gp60 levels ( r=0.94), but 
only a weak correlation was seen with the normal sera (Fig 
5-6).
b) HAEMOLYTIC COMPLEMENT LEVELS
The mean CH50 level in normal sera was 168 units/ml 
(±37) when measured with EAIgG and 137 (± 33) with EA IgM.
In the presence of Fab fragments of anti-gp60, the former 
rose to 238 ( + 58 ), while the latter was unchanged (Table 
5-2). Similarly, the mean CH50 level determined with EA IgG 
in the rheumatoid arthritis sera was increased from 202 
units/ml (±77) to 307 (+144) in the presence of Fab anti- 
gp60# while the EA IgM CH50 levels remained unchanged at 
214 (±115)- Fab fragments of normal rabbit IgG had no 
effect on the CH50 as^ay.
C) IC—MEDIATED COMPLEMENT ACTIVATION
IC produced increased complement activation in serato 
which Fab anti-gp60 had been added as witnessed by the 
increased levels of Cls-Cl inhibitor, C3-properdin and C5b-
1 4 2
Figure 5.5:
Effect of endogenous gp60 on PIP and inhibition 
of PIP.
a) % PIP of 12 normal ( 0  ) and 10 rheumatoid 
arthritis sera (A ) before and after the addition of 
Fab fragments of anti-gp60 to a final concentration 
of 140 ug/ml.
b) % inhibition of PIP produced by 12 normal ( O  ), 
and 10 rheumatoid arthritis sera ( A. ), before
or after the addition of Fab fragments of anti- 
gp60 to a final concentration of lUO ug/ml in 
the reaction mixture.
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Figure 3.,A-
Relationship between gp60 levels in normal ( O ) 
and rheumatoid arthritis ( IL ) sera and their 
ability to inhibit PIP.
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9 complexes (Fig 5-7). while normal rabbit Fab fragments 
had no effect on IC-mediated complement activation (Fig. 
5.7).
The addition of Fab fragments of ant±-gp60 and of 
normal rabbit IgG to normal serum in the absence of IC did 
not produce complement activation.
Figure 5.7.:
Effect of endogenous gp60 on IC-mediated
complement activation. Cls-Cl-inhibitor, 03-
Properdin and C5b-9 complex formation was
measured after incubation of serum in absence
( §§L ) or presence of Fab fragments of anti-gp60
( CH ) or> normal rabbit IgG ( £7] ) .
BSA-anti-BSA IC were formed in the serum at time
0 and the levels of activation products were
o
measured after 60 minutes at 37 C.
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DISCUSSION
The observation that the binding site for gp60 was
localised on the Fc piece of IgG, suggested the possibility
that gp60 might inhibit PIP by preventing the binding of Cl
to IC with a reduction in classical pathway activation.
The first step in the activation of the classical pathway
is the binding of Cl to IgG or IgM by means of the Clq
subcomponent (Reid & Porter,1981). In the previous chapter
it was shown that in a solid-phase system, gp60 competitively
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inhibited the binding of [I]-Clq to IgG, but not to IgM. 
These data not only confirmed that the binding site for 
gp60 is only present on IgG, but also suggested that 
binding of gp60 to IgG could prevent the binding and 
activation of Cl by IgG-containing IC. This possibility 
was also suggested by the results of previous studies in 
which it was noted that 1) rheumatoid arthritis sera 
contained a factor which inhibited the binding of Clq to 
IC, and that serum levels of this activity correlated with 
their ability to inhibit PIP (Niven & Whaley,1986), 2)
Levels of PIP inhibitory activity in rheumatoid arthritis 
sera correlated inversely with the extent of Cll turnover 
(Naama et al, 1983)-
The effects of exogenous gp60 on complement activation 
were studied in a fluid-phase system in which IC were 
formed in normal human serum. Gp60 produced dose-dependent 
inhibition of Cl activation as shown by decreased formation 
of Cls-Cl-inhibitor, which in turn was associated with 
reduced activation of CU and C2 as shown by reduced 
generation of Ctla and reduced Cll and C2 consumption. Thus
formation of the classical pathway C3 convertase (C4b2a) 
would have been reduced by gp60, which could account for 
the dose-dependent inhibition of C3 activation, as shown by 
reduced C3a generation. As a result of the reduction in 
C3 activation, less C3b would be available to bind to IC.
As the covalent binding of C3b to IC is the essential step 
in PIP (Naama et al, 1985) the inhibition of PIP produced 
by gp60 can be readily explained.
The mean concentration of gp60 in 10 normal sera was 
34 ^ Jg/ml (+5-2 ), while increased levels were found in 
9 RA sera (mean 97 ^ Jg/ml + 43).
The presence of gp60 in normal serum suggests that it 
may regulate complement activation in-vivo. Evidence for 
such a regulatory role was obtained from three sets of 
experiments. In the first it was found PIP was increased 
and inhibition of PIP was almost abolished when Fab 
fragments of anti-gp60 were added to normal sera. However, 
in rheumatoid arthritis sera, although Fab fragments of 
anti-gp60 increased the levels of PIP, they did not return 
to normal, and levels of PIP inhibitory activity were only 
reduced by 40-50%. It is possible that the amount of Fab 
anti-gp60 (l^O^jg/ml) added to these rheumatoid arthritis 
sera may have been insufficient to neutralise all the gp6o 
activity, particularly as levels were markedly elevated in 
some. This is unlikely to be the case as the same amount of 
Fab anti-gp60 was able to neutralise the inhibitory 
activity of 12.5 of purified gp60 in a PIP assay. Thus 
the failure to neutralise all the inhibitory activity in 
rheumatoid arthritis sera with Fab anti-gp60 argues that 
gp60 may not be the only factor involved in inhibition of
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PIP in these sera. Indeed, Mitchell et si, 198^1; 
Balastrieri et al, 1984 and O ’Sullivan et al, 1988 have 
shown that purified IgM-RF will also inhibit PIP. In 
addition partially solubilised IC are also thought to play 
a similar role in systemic lupus erythematosus sera 
(Baatrup et al, 1983)-
The relative roles of gp60, IgM-RF and possibly other 
factors in the inhibition of PIP require further study. 
However, the close correlation of serum levels of gp60 and 
the ability of rheumatoid arthritis sera to inhibit PIP 
supports the notion that gp60 plays a role in this 
activity.
In contrast to the situation in rheumatoid arthritis 
sera, the observation that Fab anti-gp60 almost completely 
abrogated the ability of normal sera to produce limited 
inhibition of PIP suggests that gp60 is entirely 
responsible for these low levels of inhibitory activity.
In the second series of experiments it was shown that 
the addition of Fab anti-gp60 to normal and rheumatoid 
arthritis sera increased the levels of total haemolytic 
complement activity when EAIgG were used. In contrast no 
effect was seen when EAIgM were used as the target cells. 
These results also confirm the specificity of gp60 to IgG. 
Finally, when Fab anti-gp6o was added to normal serum, IC 
produced increased complement activation.
Taken together these findings demonstrate that gp60 
plays a regulatory role in the activation of the classical 
pathway by IgG- containing IC. This regulatory role 
differs from that of Cl-inhibitor as neutralisation of gp60
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activity by Fab anti-gp60 did not result in spontaneous Cl 
activation which is observed when Cl-inhibitor activity is 
neutralised in this way (Gronski et al. , 1986). The
biological significance of this regulatory role of gp60 on 
complement activation remains unclear, and further 
investigations are required.
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CHAPTER SIX 
FINAL DISCUSSION
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The formation of, or the deposition of antigen- 
antibody complexes (IC) in the tissues is considered to be 
an important mechanism of tissue injury (Theofilopouls & 
Dixon,1979)•
It is well known that when IC are formed around 
equivalence or in antibody-excess in buffer, they tend to 
precipitate. However, IC formed in the presence of normal 
serum remain small and soluble. The ability of normal 
serum to prevent immune precipitation is mediated by the 
complement system (Schifferli et al, 1980). The use of
purified complement components has shown that the 
classical pathway of complement is responsible for this 
activity (Naama et al, 198/1), while the alternative
pathway serves simply to provide a backup support system 
(Naama et al, 198/I; 1985)- The final and critical step in
complement-mediated prevention of immune precipitation 
(PIP), appears to be the binding of C3b to IC to prevent 
the formation of large insoluble immune precipitates (Naama 
et al, 1985)-
The sera of patients with rheumatoid arthritis who are 
sero-positive for IgM-RF are unable to retain IC in 
solution because they contain an inhibitor of PIP (Naama, 
Mitchell & Whaley, 1983)- During attempts to purify the 
PIP-inhibitory material from rheumatoid arthritis sera 
using IgG-Sepharose affinity chromatography followed by gel 
filtration chromatography, the PIP-inhibitory activity co­
eluted with IgM-RF (Mitchell et al. ,198/1). However, IgM-RF 
levels did not correlate with the PIP-inhibitory activity 
present in these sera, which suggested that IgM-RF could, 
at the most, be only partly responsible for their PIP-
1 Zi-9
Inhibitory activity. As normal human serum was shown to 
contain a low level of PIP-inhibitory activity, it was 
suggested that inhibition of PIP might be due to a plasma 
protein which was present in normal serum and that 
increased levels were found in rheumatoid arthritis sera.
The main object of these studies was to purify and 
characterise this PIP-inhibitor, and define its mode of 
action on the complement system.
The first objective was achieved as described in 
detail in chapter three. The protein isolated had a 
molecular weight of 60 kD on SDS-PAGE run under reducing 
and non-reducing conditions', and because it stained 
positively in the PAS reaction it was called 
glycoprotein 60 (gp60).
When prepared by method one, gp60 had sedimentation 
and gel filtration characteristics which were identical 
with a minor fraction of the gp60 which was present in 
whole serum, in which the characteristics of the majority 
of the gp60 were similar to those of IgM (19S sedimentation 
coefficient; 1000 kD on gel filtration). When gp60 was 
isolated in the presence of protease inhibitors, the 
purified protein shared the same sedimentation and gel 
filtration characteristics as the larger molecular weight 
component in whole serum.
As both the high molecular weight and low molecular 
weight forms of gp60 appears as a single polypeptide chain 
on SDS-PAGE run under either reducing or non-reducing 
conditions it is probable that the high molecular weight 
gp60 is a polymer of the low molecular weight form, which
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probably represents the monomer. The number of monomeric
subunits which make up the polymer, assuming molecular
weights of 60 kD and 1000 kD fox- the monomer and polymer
respectively, must be 16-17 which is extremely high. For
instance, the C3t» receptor (CR1) has a molecular weight of
200 kD on SDS-PAGE but on gel filtration chromatography it
6
is eluted with an apparent molecular weight of 1.2x10 
(Fearon,1979). which means that 6 subunits make up the 
polymer. Likewise, C&BP is made up of 6 identical subunits 
(Dhalback & Stenflo,1981). It is possible that the 
estimate of 1000 kD for the molecular weight of the polymer 
is inaccurate. It could also be argued that the high 
molecular weight of gp60 in serum could be due to the 
complexing of gp60 with another serum constituent, such as 
IgG. The observation that purified gp60 (purified by 
methods 2 and 3) had a similar molecular weight to serum 
gp60 suggests that the second explanation is not the case. 
Although the polymeric form of gp60 sedimented along with 
IgM on sucrose density gradient centrifugation, and co­
eluted with IgM on gel filtration chromatography, C/IBP 
(molecular weight 590 kD) and fibronectin (molecular weight 
MlO kD) also sediment close to IgM on sucrose density 
gradient centrifugation and co-elute with IgM on Sephacryl 
S-300 gel filtration chromatography. Thus the molecular 
weight of polymeric gp60 may be considerably less than 1000 
kD, which would mean that the number of monomeric subunits 
required to form the polymer would be less than the 
previous estimate.
The observation that gp60 polymer migrated at the B / ^
2
globulin boundary on immunoelectrophoresis, while C&BP
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migrates as a B -globulin suggests that polymeric gp60 has 
1
a higher molecular weight than CilBP. The low isoelectric 
point of gp60 (5-1-5*3) and the prealbumin mobility of the 
monomer suggest that the differences in electrophoretic 
mobility between gp60 and CilBP are not due to charge 
differences, unless the isoelectric point of CUBP is lower 
than that of gp60. There do not appear to be any data 
published on the isoelectric point of C/J-BP.
From the above discussion it is clear that the 
molecular relationship between gp60 polymer and gp60 
monomer is a problem which requires further investigation. 
Approaches which could be used to solve this problem are 
electronmicroscopy, x-ray crystallography or neutron 
scattering studies, all of which may yield valuable 
information about the size, shape and subunit structure of 
plasma proteins. In the past they have been used 
successfully to study the structure of complement proteins. 
The molecular weight of the polymer could be determined by 
studying various physical properties such as the osmotic 
pressure of gp60 in solution or the ability of gp60 to 
lower the freezing point of water.
Although gp60 (prepared by all the methods) was 
relatively resistant to proteolysis, the conversion of 
polymer to monomer when protease inhibitors were not 
included in the purification procedure was reproducible. 
Thus it appears that limited proteolysis of the polymer by 
a plasma/ serum protease accounts for the transformation 
from the polymeric to the monomeric form. The positive 
staining of gp60 in the PAS reaction and the
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sensitivity of the molecule to proteases, showed that gp60 
was a glycoprotein.
The true molecular weight of gp60, as determined by 
the Ferguson technique (Ferguson, 196/1), was /13 kD which is 
in rough agreement with the results of chemical 
deglycosylation with trifluoromethylsulphonic anhydride. 
Thus approximately 28% of the gp60 molecule consists of 
carbohydrate. As neuraminidase treatment reduced the 
molecular weight of gp60 to 52 kD, it is probable that 
approximately 40% of the carbohydrate on gp60 is sialic 
acid. The relative high carbohydrate content of gp60 is 
not unusual for a plasma protein; approximately 30% of the 
molecular? weight of Cl-inhibitor consists of carbohydrate 
(Harrison,1983)• The function of the carbohydrate 
constituents of glycoproteins is generally unknown. There 
is evidence that they may be involved in protein catabolism 
(Hughes,1976). However, if one removes sialic acid from the 
glycoproteins of the complement system there is no loss of 
functional activity. Thus, although studies of the possible 
functional role of the carbohydrate component of gp60 
should be undertaken, they unlikely to yield much useful 
information.
Gp60 was purified from normal serum on the basis of 
its ability to inhibit PIP. The purified protein was 
shown to inhibit both PIP and solubilisation, although it 
was more effective at inhibiting PIP. This is probably 
related to its ability to bind to the Fc piece of IgG and 
inhibit activation of the classical pathway, which is 
essential for PIP but non-essentail for solubilisation.
Gp60 was more effective at inhibiting PIP and
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solubilisation when IC were formed at equivalance or in 
antibody-excess, compared with those formed in antigen- 
excess. The explanation for this observation is not 
immediately apparent, but could be related to the intrinsic 
solubility of IC formed in antigen-excess, or could be due 
to a failure of gp60 to bind effectively to fluid-phase IC 
formed in antigen-excess. Certainly complement activation 
is achieved more efficiently by IC formed in antibody- 
excess or at equivalence, than by those formed in antigen 
excess (Osler& Heidelberger,19&8). Thus if the binding of 
Cl is less efficient in antigen-excess and as I have shown 
that gp60 and Cl compete with each other in terms of 
binding to IgG, it could expected that gp60 will bind less 
effectively to IC formed in antigen-excess. Future studies 
into the mechanism of inhibition of PIP by gp60 should 
investigate the binding of gp60 to soluble IC formed at 
different antigen-antibody ratios.
The solid-phase studies showed that gp60 bound to 
IgG but not to the IgM or IgA isotypes. Using defined 
fragments of IgG, the binding site for gp60 was shown to be 
located on the Fc piece. This conclusion was supported by 
assays which showed that other Fc binding proteins could 
competitively inhibit the binding of gp60 to IgG. The 
precise binding site for gp60 on IgG has yet to be 
determined. The data presented in this thesis show that it 
could involve either the CH2 or CH3 domain, or both. The 
binding site for Clq is located within the CH2 domain 
(Colomb & Porter, 1975). while the epitopes recognised by 
RF may be located on either the CH2 or CH3 domains
154
(Jefferis, 19^0), and Staphylococcus protein A binds to 
both the CH2 and CH3 domains (Deisenhofer,198 1).
Experiments performed by Dr. G .P.Sandilands of this 
department show that EA(IgG) incubated with gp60 do not 
bind to the Fc receptors of lymphocytes monocytes or 
polymorphonuclear leukocytes, which recognise either the 
CH2 or CH3 domains of IgG.
Clq, gp60, RFs and Staphylococcus protein A are 
large molecules, so their binding to one site on the Fc 
piece of IgG might be expected to interfere with the 
binding of other proteins to the IgG Fc piece, despite the 
fact that they may not share the same binding site. More 
accurate localisation of the gp60 binding site on the IgG 
Fc piece could be achieved by studying the effect of 
synthetic peptides, which correspond to different regions 
of the Fc piece, on the binding of gp60 to IgG 
(Lukas,Munoz&Erickson,198I ). Alternatively, the effect of 
chemical modification of amino acid residues in the Fc 
piece on the binding to gp60 could be studied.
As the molar concentration of IgG in whole serum is
-6
high (6.7x10 mol/1), and as it does not appear that gp60
circulates bound to IgG, one must conclude that gp60 can 
only bind to IgG once it has become aggregated in the form 
of an IC. The problem underlying the recognition by gp60 of 
IgG aggregated in IC must be similar to those facing Clq or 
Fc receptors, which have been the subject of great
debate (reviewed by Burton, 1985)- The discussion of the
mechanism of recognition of aggregated IgG cannot be 
continued without reference to the IgG subclass specificity 
of gp60 binding. As the primary amino acid structures of
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the CH2 and CH3 domains of the four different IgG subclasses 
are remarkably constant, it is unlikely that differences in 
the amino acid sequences account for the subclass 
differences in the binding of gp60, Clq and RFs to IgG. The 
possibility that hidden binding sites are exposed in the 
IgG heavy chain following antigen-binding has been 
suggested, but available data do not support this concept 
(reviewed by Burton,1985)* However, in the case of Clq, 
there is no doubt that it binds extremly efficiently to 
IgG antibody on the surface of erythrocytes (Isenman, 
Dorington & Painter, 1975)* If the binding site was 
available on monomeric IgG, there would be sufficient 
fluid-phase monomeric IgG available to prevent any Clq 
binding. Thus a conformational change in IgG antibody must 
occur following its binding to antigen. The hinge region 
plays a key role in this process. The hinge regions of 
IgGl and particularly IgG3 are large and allow the Fab 
arms great flexibility so that on binding to antigen, the 
binding domains for Clq and Fc receptors on the Fc piece 
became accessible. This has been used to explain why the 
IgGl and IgG3 subclasses activate Cl and bind to Fc 
receptors far more effectively than IgG2 and IgG& which 
have much smaller and less flexible hinge regions 
(Burton,1985)•
The recognition of aggregated IgG, and the subclass
W
specificity of the binding of gp60 can probably explained 
in the same way. It would be of interest to study the 
binding of gp60 to IgG molecules which have deletions in 
their hinge regions (Dorrington & Klein, 1982). These
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molecules bind to Clq and Fc receptors far less 
effectively than normal IgG molecules.
The studies of the role of gp60 in complement 
activation showed that the addition of purified gp60 to 
whole serum reduced complement activation by IC. This 
observation raised the possibility that gp60 already 
present in serum might regulate the activation of 
complement. This possibility was investigated by 
neutralisation of serum gp6o activity by the addition of 
Fab anti-gp60 to the serum. Using this procedure it was 
shown that neutralisation of serum gp60 activity resulted 
in 1) increased levels of haemolytic complement using EA(IgG) 
targets, 2) increased level of complement activation 
products following the formation of IC in whole serum, and 
3) increased levels of PIP activity in normal serum.
These findings show that serum gp60 does regulate 
complement activation, although the biological importance 
of this role is by no means clear.
When IC are formed in-vivo they will contain 
circulating antibodies of all isotypes. Thus, although 
gp60 binds to IgG and inhibits complement activation, it 
will not prevent complement activation by IgM antibody.
Thus, how gp60 affects complement activation by IC 
containing both IgG and IgM antibodies requires 
investigation, as does the fate of such IC following 
complement activation. The availability of murine anti-DNP 
monoclonal antibodies of different isotypes (Johnson et al, 
1988) will allow these problems to be investigated.
The failure of Fab anti-gp60 to neutralise completely 
all the PIP-inhibitory activity in rheumatoid arthritis
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sera suggests that gp60 may not be the only constituent of 
these sera which inhibits PIP- Earlier studies (Mitchell 
et al, 198&; Balastrieri et al, 198*1; O ’Sullivan et al,
1988} showed that IgM-RF did inhibit PIP. Although most 
IgM-RF preparations contain variable amounts of gp60, it is 
possible that IgM-RF does inhibit PIP. The high 
correlation between inhibition of PIP and the gp60 
concentrations in rheumatoid arthritis sera which was found 
in this study, stands in contrast to the poor correlation 
which was found between inhibition of PIP and IgM-RF levels 
found in a previous study (Webb et al, 1986). Thus the
relative importance of gp60 and IgM-RF in the inhibition of 
PIP requires further study.
The final aspects of gp60 which requires discussion
is the identity of the molecule. Using serological
techniques it has been shown that gp60 has not been
recognised previously as a plasma protein. This may seem
difficult to believe as the concentration of gp60 in normal
serum is approximately 30 ug/ml. However, on account of
this relatively low concentration, together with its
electrophoretic mobility (gp60 migrates in the B - $
2
boundary zone along with a large number of other plasma 
proteins, some of which are present in far higher 
concentrations) may account for the failure to detect gp60 
previously. It should also be pointed out that it is 
difficult to detect C2, a protein of similar serum 
concentration on immunoelectrophoresis of whole serum using 
anti whole serum as the developing antibody. C2 was 
detected on the basis of its biological activity.
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The observation that gp60 is an Fc binding protein 
and that the binding site is expressed preferentially on 
the IgGl and IgG3 subclasses indicates that gp6o has 
characteristics in common with leucocyte Fc receptors 
(Burton, 1985* Anderson & Loon^, 1986). There appear to be 
at least three distinct classes of human leucocytes Fc 
receptors, FCRI, FCRII, and a low-affinity receptor termed 
FCRlo (Anderson & Loon^, 1986). This classification is based 
on immuno-reactivity with defined monoclonal antibodies, 
mobility on SDS-PAGE and distribution on different 
populations of leucocytes. The molecular weight of FCRlo- 
70 kD (Anderson & Loon£)£ 1986 ) , is closest to that of gp60. 
It has been shown previously that normal serum contains a 
factor which is able to reconstitute Fc receptor activity 
on peripheral blood lymphocytes, which during incubation 
with IC have lost their surface Fc receptors (Reid et 
al, 1983j Sandilands, Peel & MacSween, 198**). Fc 
receptors have also been detected in normal mouse serum 
(Khyat et al, 198*1; Pure et al, 198*1). The observation 
that the fluid-phase murine lymphocyte Fc receptor inhibits 
complement activation by the classical pathway (Fridman, 
Nelson & Liabeuf, 197**; Molenaar et al, 1977). also 
supports the notion that gp60 may be an Fc receptor.
The next step in solving many of the outstanding 
problems of gp60 is to determine its amino acid sequence. 
Sequence data could then be analysed by computer and 
homologies with other proteins identified. Attempts at 
determining the amino acid sequence of gp60 have so far 
been unsuccessful. The protein appears to be relatively 
resistant to proteolysis. In the absence of amino acid
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sequence, screening of cDNA libraries for cDNA clones 
coding for gp60 must depend on the use of expression 
libraries. Such studies are presently underway.
Hopefully they will help shed some light on the biological 
role of gp60 in normal individuals and its role in the 
pathogenesis of immune complex disease.
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